

STIC-Biotech/ChemLib

154743

11/12/05

From: Bunner, Bridget
Sent: Friday, May 27, 2005 10:09 AM
To: STIC-Biotech/ChemLib
Subject: sequence search

Hi! I'd like to request a sequence search for case 10/777,524:

1. the amino acid sequence of SEQ ID NO: 2

Thanks!

Bridget Bunner

Art Unit 1647
Rem 4C65
(571) 272-0881
mailbox 4C70

RECEIVED
MAY 27 2005
STIC

STAFF USE ONLY

Searcher: _____
Searcher Phone: 2- _____
Date Searcher Picked up: _____
Date Completed: _____
Searcher Prep/Rev. Time: _____
Online Time: _____

Type of Search

NA#: _____ AA#: _____
Interference: _____ SPDI: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure#: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable

STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other(Specify): _____

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 1, 2005, 22:01:20 ; Search time 40 Seconds
(without alignments)
728.842 Million cell updates/sec

Title: US-10-777-524-2
Perfect score: 1591

Sequence: 1 MGRPLLPPLPPLPPLPPLQ.....PSHRLKSPQNETLYSVLKA 303

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	144.5	9.1	823	2	S48394
2	123.5	7.8	1114	2	T49517
3	118.5	7.4	509	2	JC5288
4	116	7.3	392	2	B44194
5	116	7.3	417	2	A44194
6	115.5	7.3	513	2	JC5289
7	114	7.2	392	1	RWHUPD
8	114	7.2	417	1	RWHUPA
9	112.5	7.1	403	2	I52590
10	110	6.9	235	2	S25758
11	110	6.9	847	2	JH0371
12	109.5	6.9	233	2	S25747
13	108.5	6.8	230	2	S45449
14	108.5	6.8	235	2	S14675
15	108.5	6.8	862	2	I49583
16	108.5	6.8	868	2	A46512
17	108	6.8	236	2	S25746
18	108	6.8	1694	2	S50065
19	106	6.7	647	2	A35648
20	106	6.7	710	2	A99486
21	105.5	6.6	235	2	S25750
22	104.5	6.6	214	2	PC4156
23	104	6.5	231	2	S25751
24	104	6.5	798	2	T34248
25	103	6.5	446	2	T45525
26	103	6.5	469	2	S37483
27	102.5	6.4	407	2	T08732
28	102	6.4	572	2	B46529
29	101	6.3	118	2	E27889

30	101	6.3	790	2	T34293	hypothetical prote
31	100.5	6.3	151	2	T46626	rearranged T-cell
32	100.5	6.3	152	2	B26471	Ig heavy chain pre
33	100	6.3	365	2	A47636	MHC class I histoc
34	100	6.3	365	2	I83063	All.2 - human
35	100	6.3	365	2	I37478	MHC class I histoc
36	99.5	6.3	413	2	T04520	hypothetical prote
37	99	6.2	210	2	S25657	T-cell surface gly
38	99	6.2	231	2	S25728	Ig lambda chain -
39	99	6.2	232	2	S25756	Ig lambda chain -
40	98	6.2	217	2	JE0246	Ig lambda chain NI
41	98	6.2	235	2	S25759	Ig lambda chain -
42	97	6.1	142	2	A28344	Voreb protein prec
43	97	6.1	229	2	A20969	Ig kappa chain pre
44	97	6.1	365	2	I16961	MHC class I protei
45	97	6.1	1272	2	S26180	neurofascin - chlc

ALIGNMENTS

RESULT 1

S48394 probable membrane protein YJL140W - Yeast (Saccharomyces cerevisiae)

C:Species: Saccharomyces cerevisiae

C>Date: 02-Dec-1994 #sequence_revision 02-Dec-1994 #text_change 09-Jul-2004

C:Accession: S48394; S50276

R:Churcher, C. submitted to the EMBL Data Library, September 1994

A:Reference number: S48310

A:Accession: S48394

A:Molecule type: DNA

A:Residues: 1-823 <CHU>

A:Cross-references: UNIPROT:P38928; GB:Z47047; EMBL:Z38059; NID:9603997; PID:9763206; MI

R:Torpey, L.E.; Gibbs, P.E.M.; Nelson, J.; Lawrence, C.W. Yeast 10, 1503-1509, 1994

A>Title: Cloning and sequence of REV7, a gene whose function is required for DNA damage-

A:Reference number: S50275; MUID:95176709; PMID:7871890

A:Accession: S50276

A>Status: nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 80-823 <TOR>

A:Cross-references: EMBL:U07228; NID:9460247; PID:NAA67919.1; PID:9460249

A>Note: the nucleotide sequence was submitted to the EMBL Data Library, March 1994

C:Genetics: A:Gene: SGD:SR04

A:Cross-references: SGD:S0001402; MIPS:YJL140W

A:Map position: 9L

C:Superfamily: Saccharomyces cerevisiae probable membrane protein YJL140W

C:Keywords: transmembrane protein

F:6-22/Domain: transmembrane #status predicted <TM1>

F:511-527/Domain: transmembrane #status predicted <TM2>

Query Match 9.1%; Score 144.5; DB 2; Length 823;
Best local similarity 24.7%; Pred. No. 0.0026;
Matches 72; Conservative 45; Mismatches 96; Indels 79; Gaps 16;

QY	25	TGSGPSYLYGV-TQPKLASM--GGSVEIPFSFYPMELATADV-----RISMR	73
DB	308	SGSVDELKGNMNPANVSISYDTYGDV-----IYFVEVSTPDLFAISLNPINATR	362
QY	74	GHPGQSFSTRPSPSIHKDYNR---LFLN-----WTEQKS-----GFLRIS	113
DB	363	GEWFSYFL---PSQFTDYNTVSLFTNSSQDHPMKQSSNLTLAGEVPPKPDFLS	418
QY	114	-----NLQKQDSVYFCRVELDTRSSGROQMSIEGTGLSTQAVTTTTPRPSMTTWR	168
DB	419	LGLANQSSQDELXFNIGMSKITHSNHANTSTRSS---HHSSTSSYTSSTYAK	475
QY	169	LSSTT---TTTGLRVTOGKRSDSMHISLETAVGAVAVTV-LQIMIGLIC-LRRMR	223
DB	476	ISSTSAATSSAPALPAANKTSSHN---KKAVALACGVALPLGVIIVALICPLFMR	532

RESULT 5

A44194

poliovirus receptor (clone AGM-alpha-1) - green monkey

CISpecies: Cercopithecus aethiops (green monkey, grivet)

CDate: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004

CAccession: A44194

R.Kojima, S., Ise, I., Sato, Y., Yonekawa, H., Gotoh, O., Nomoto, A.

J. Virol. 66, 7059-7066, 1992

Article: A second gene for the African green monkey poliovirus receptor that has no putative reference number: A44194; MUID:9305651; PMID:1331508

A:Accession: A44194

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-417 <KOI>

A:Cross-references: UNIPROT:P32506; GB:S48777

C:Superfamily: poliovirus receptor; Immunoglobulin homology

C:Keywords: transmembrane protein

F:259-314/Domain: Immunoglobulin homology <IMM>

Query Match 7.3%; Score 116; DB 2; Length 417;

Best Local Similarity 21.2%; Pred. No. 0.18;

Matches 77; Conservative 42; Mismatches 110; Indels 134; Gaps 16;

QY 4 PLLPLPLPLPPAPLPPSGSGSPSYLYGVTPKHLASMGSGVEIPFSFYPMELAT 63

DB 11 PLLTLLELSWPP-----FGTGDII--VOAPYVPGFLGDSVTLPCYLQVGMEE 59

QY 64 APDVASIRRGHFGHQS-----FYSTRPPSIHKDVNRLFNMTEGQSGF----- 109

DB 60 HVS-QLTMSR--HGESSMAVPHOTGP-----NYSEPKLEVAARLGTGL 103

QY 110 ---LRISNLQKQDQSYFC-----RYELDRSSGQWQSGIEGKLSI 149

DB 104 RDAELRMGLGVEDEGNATCLEFTVPQGSRSVDIMLRVLAKPQWAEVQKQLGKRPV 163

QY 150 TQAVTTTQRSSMTTKR-----LSSTTTTGARVYQGRKSDS----- 189

DB 164 ARCVSTGSRPAHI--TWHSDLGGMPTSGAPFLSGIVTYSIMILVPSSQVDGKSVTC 221

QY 190 --WHISLETVAVNAVTVLGLIMILGILCLRMRKQGRKATTPARBEFQWTEPEYE 247

DB 222 KVEHSEPFKPOLLYTNLTV-----YPEVISISGYD 252

QY 248 N---INNEGQNT-DPKLNPKDGIIVASLALSSSTSPRAPPSH-----RPLKSPQ 293

DB 253 NNWYLSQNEATLTCDBARSNPEPTGYW-----STTWGRLPPFAVAGAGQLIRPVDKPI 306

QY 294 NET 296

DB 307 NTT 309

RESULT 6

JC5289

SHP substructure-1 protein, 513 - mouse

CISpecies: Mus musculus (house mouse)

CDate: 16-Apr-1997 #sequence_revision 09-May-1997 #text_change 09-Jul-2004

CAccession: JC5289

R.Yamano, T., Matczak, T., Amano, K., Matsumoto, Y., Takahashi, N., Ochi, F., Fujioaka, Y., et al.

Biochem. Biophys. Res. Commun. 231, 61-67, 1997

Article: Mouse and human SHP-1: Molecular cloning of cDNAs and chromosomal localization

A:Reference number: JC5287; MUID:97223399; PMID:9070220

A:Contents: Bzrain

A:Accession: JC5289

A:Molecule type: mRNA

A:Residues: 1-513 <YAM>

A:Cross-references: UNIPROT:P97797; DBJ:D87968; NID:G1864014; PIDN:BA113521.1; PID:G1864014

C:Comment: This protein is a glycosylated receptor-like protein and plays a role in cell to the plasma

A:Gene: shps-1

A:Map position:2

Query Match 7.3%; Score 115.5; DB 2; Length 513;
Best Local Similarity 22.3%; Pred. No. 0.25;
Matches 56; Conservative 46; Mismatches 84; Indels 65; Gaps 13;

Oy 56 YYPWEIATADPVRISMRGRGHGQSFYSTPPSIHKDYRLFLNLTGCGSGFLNISL 115
||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
Db 279 FYF-----EDQLIWE---NGVSRNDIPKULTN-----TDGIYNTSLFLVNSSA 323

Oy 116 QKODSVYFCRVELDTRTSSGRQQMSIEGTLSITQAVTTTPRPSSMTTWLSTTTT 175
:|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
Db 324 HRSD-VVFETCVKRD-----QQ-----PATRN-----HTVLGLAHSSDQ 357

Oy 176 TGLRAVTGKRKRSDSWHISLETAGVAAYVTVLGIMILGICLRMRRRKKOQTAKTTPA 235
::: :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
Db 358 GSMTFPGNNATHNMNV---FIGVGACALLLVLLMAALYYLLRIKOKAKGSTSST-- 410

Oy 236 REPQNTPEEPENR--NEGONTDPKLNPDDGVASLAL---SSSTSPAPSHRPLKS 291
||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
Db 411 -----RLHPEPKARREITVOQLIQDTNDIND-ITADNLPRKKPAKPAPAP-----E 457

Oy 292 POMETLYSVLK 302
||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
Db 458 PNNTVEYASIE 468

RESULT 7

RHWUPD poliovirus receptor splice form delta precursor - human
N.Alternate names: poliovirus receptor H20B
C.Species: Homo sapiens (man)
C.Date: 30-Jun-1993 #sequence_revision 30-Jun-1993 #text_change 09-Jul-2004
C.Accession: A43024; B31496
R.Kojke, S.; Horie, H.; Ise, I.; Okitsu, A.; Yoshida, M.; Itzuka, N.; Takeuchi, K.; Takeuchi, J., 3217-3324, 1990
A.Title: The poliovirus receptor protein is produced both as membrane-bound and secreted
A.Reference number: S12048; PMID:91006015; PMID:2170108
A.Accession: A43024
A.Molecule type: DNA
A.Residues: 1-392 <KOI>
A.Cross-references: UNIPROT:P15151; EMBL:X64116
A.Note: 67-Ala was also found
R.Wendelsohn, C.L.; Wimmer, E.; Racanietto, V.R.
Cell 56, 855-865, 1989
A.Title: Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and e
A.Reference number: A90910; PMID:89168426; PMID:2538245
A.Accession: B31496
A.Molecule type: mRNA
A.Residues: 1-66, 'A', 68-392 <MEN>
A.Cross-references: GB:I24406
C.Comment: The normal function of this receptor is unknown. Membrane-bound and soluble F
C.Genetics:
A.Gene: GDB:PVR; PVS
A.Cross-references: GDB:120324; OMIM:173850
A.Map position: 19q13.2-19q13.2
A.Introns: 27/1; 143/1; 242/1; 281/2; 331/1
C.Superfamily: poliovirus receptor; immunoglobulin homology
C.Keywords: alternative splicing; duplication; glycoprotein; receptor; transmembrane prot
F.1-20/Domains: signal sequence #status predicted <SIG>
F.21-392/Product: poliovirus receptor delta #status predicted <EXT>
F.21-343/Domains: extracellular #status predicted <EXT>
F.142-125/Domains: immunoglobulin homology <IMM1>
F.159-223/Domains: immunoglobulin homology <IMM2>
F.259-314/Domains: immunoglobulin homology <IMM3>
F.334-357/Domains: transmembrane #status predicted <TMN>
F.368-392/Domains: intracellular #status predicted <INT>
F.149-123, 166-221, 266-312/Distal bonds: #status predicted
F.105, 120, 188, 218, 237, 278, 307, 313/Binding site: carbohydrate (asn) (covalent) #status pr

C>Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000
C/Accestion: G25758
R/CombiLato: G.; Kloeck, H.G.
Eur. J. Immunol. 21, 1513-1522, 1991
A>Title: V(lambda) and J(lambda)-C(lambda) gene segments of the human immunoglobulin lambda
A/Reference number: S16439; MUID:91257162; PMID:1904362
A/Accestion: G25758
A>Status: preliminary; translation not shown
A/Molecule type: mRNA
A/Residues: 1-235 <COM>
A/Cross-references: EMBL:X57823; NID:g33745; PIDN:CAA40960.1; PID:g33746
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F/150-218/Domain: immunoglobulin homology <IMM>

Query Match 6.9%; Score 110; Db 2; Length 235;
Best Local Similarity 24.2%; Pred. No. 0.27;
Matches 48; Conservative 28; Mismatches 70; Indels 52; Gaps 8;

Dy 26 GSGPSYLVGTVPQKHLASMGVSVEIPSPFYMEELATAPDRISMRGHFGSFTSTR 85
 :|::|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 14 GTGSMAGSALTPAPSVSSGPSQSITISCT-----GSSSDV-----GGYVSWYQQH 60
 :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

Dy 86 PPSIHK-----DYVRL--FLWTEGQSKG---PLRISLQKQDSYVFCRELDTBRSGR 136
 :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

Dy 61 PKAPKLMIVTVTKRPSSVSNRFSGSXSGNTASLTISGLQPEDADYYC-----TSKTSS 115
 :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

Oy 137 QQMOSIEGTKLSI---TQAVTTTTRPSS-----MTTWRLSS 171
 :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

Dy 116 SFYFGTGITKTSVLGPQANETVTLFPSSSELOQANKATLYCLISDFPGNAVTAWKADG 175
 :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

Oy 172 TTTTGLRVTGKKRRSDS 189
 :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

Dy 176 SPVKAGVETTKPKSQSN 193
 :|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

RESULT 11
JH0371
B-cell adhesion protein CD22 beta splice form precursor - human
N/Alternate names: B-cell membrane protein CD22
C/Species: Homo sapiens (man)
C/Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 09-Jul-2004
C/Accestion: JH0371; I56171
R/Wilson, G.L.; Fox, C.H.; Fauci, A.S.; Kehrl, J.H.
J. Exp. Med. 173, 137-146, 1991
A>Title: cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interaction
A/Reference number: JH0371; MUID:91086838; PMID:1985119
A/Accestion: JH0371
A/Molecule type: mRNA
A/Residues: 1-847 <WIL>
A/Cross-references: UNIPROT:O60262; GB:X59350; NID:g36090; PIDN:CAA42006.1; PID:g36091
A/Experimental source: B lymphocyte
A/Note: the authors translated the codon AAT for residue 358 as Met
R/Wilson, G.L.; Najfeld, V.; Kozlow, E.; Menliger, J.; Ward, D.; Kehrl, J.H.
J. Immunol. 150, 5013-5024, 1993
A>Title: Genomic structure and chromosomal mapping of the human CD22 gene.
A/Reference number: I56171; MUID:93267103; PMID:849602
A/Accestion: I56171
A>Status: translated from GB/EMBL/DDBT
A/Molecule type: DNA
A/Residues: 121-269, 'T', 271-473, 'K', 475-614, 'R', 616-638, 'Y', 640-711, 777-847 <WIL2>
A/Cross-references: GB:S61375; NID:g385980; PIDN:AC18956.1; PID:g3184492
C/Genetics:
A/Gene: GDB:CD22
A/Cross-references: GDB:127545; OMIM:107266
A/Map position: 19q13.1-19q13.1
A/Introm: 138/1; 240/1; 329/1; 417/1; 503/1; 591/1; 679/1; 711/2; 804/3
C/Keywords: alternative splicing; B-cell; cell adhesion; dimer; glycoprotein; phosphoprotein; phosphoprotection; status predicted <TRA>
F/1-19/Domain: signal sequence status predicted <SIG>
F/20-847/Product: B lymphocyte cell adhesion protein status predicted <MAT>
F/346-388/Domain: immunoglobulin homology <IMM1>
F/609-661/Domain: immunoglobulin homology <IMM2>
F/688-706/Domain: transmembrane status predicted <TRA>

```

F:67, 101, 112, 135, 164, 231, 363, 445, 448, 479, 574, 634/Binding site: carboxylate (Asn) (cova
F:764,789/Binding site: phosphate (Thr) (covalent) #status predicted

Query Match          6.9%; Score 110; DB 2; Length 847;
Best Local Similarity 22.1%; Pred. No. 1.2;
Matches 63; Conservative 40; Mismatches 116; Indels 66; Gaps 10;

OY 30 SYLYGVTPPKLALSMSGSVLEIPPSFYFWELATAPVRLISMRRGH--FIGQSFYST--- 84
DB 568 SYSCWVNNISIGQTSKAWLTLEV---LYAPRL-----RVSMSPGDQWBGKSAITLCE 618
OY 85 --RPPSHKDVNRLFLNWTGQSGFLRLSNLQKQDQSVFCFVELDPTSSGRQWQSI 142
DB 619 DANPVPVSHYTFD--MNNQSLPHHSQKLRLBPVAVGSHGAWCO--GTVSVGKR--- 669
OY 143 EGTKLSTQAVTTTTPORPSSMTTWRLSSTTTTGLRVTOGKRSDSMHISLETAVGAV 202
DB 670 -----SPLSTLTVYSPETIGRV-----AVGLGS 694
OY 203 AVTVLGMITGLICLFLMRRRKGGQRTKATTPAPREPQNTPEEYENIRNEGQNTDPKLN 262
DB 695 CIALLILALIGLAKQRWKRKTQSSQGIQENSSGQSFVRNKKYRAPLSEGPLGCGYN 754
OY 263 -KDDGIYASLALSSSTSPR-----APSHRLPLSPQNETLGYVL 301
DB 755 MMEGGISYTTLRFPEPMNIPRTGDAESSEMQRPPTCDTVYTSAL 799

RESULT 12
I9 lambda chain - human
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000
C:Accession: S25747
R:Combiarto, G.; Klobeck, H.G.
B: J. Immunol. 21, 1513-1522, 1991
A>Title: V(lambda) and J(lambda)-C(lambda) gene segments of the human immunoglobulin lam
A:Reference number: S16439; MUID:91257162; PMID:1904362
A:Accession: S25747
A:Status: preliminary; translation not shown
A:Molecule type: mRNA
A:Residues: 1-233 <COM>
A:Cross-references: EMBL:X57812; NID:933723; PIDN:CAA40949.1; PID:G33724
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:148-216/Domain: immunoglobulin homology <IMM>

Query Match          6.9%; Score 109.5; DB 2; Length 233;
Best Local Similarity 23.0%; Pred. No. 0.29;
Matches 53; Conservative 29; Mismatches 59; Indels 89; Gaps 11;

OY 5 LLEPLLLPLLPAPLQSGSGPSLYGVTPPKLALSMSGSVLEIPPSFYFWELATA 64
DB 6 LLLGLL-----SHCTGVTSTYV--LTQPPSVAPGQARI-----TC 41
OY 65 PDVVISMRGRGHFGQS-----FY--STRPPSHKDVNRLFLNWTGQSG--FLR 111
DB 42 GGINIAKSAVHWQKRGQAFLVLYVGDDRPSPGIPRF-----SGSNNGNATLN 92
OY 112 ISNLQKQDQSVYFCFVELDPTSSGRQWQSI-----GTVKLSI---TOAVTTTQRP 160
DB 93 ISRVADDEAAVYQCV-----WDSSDHVVVFGGCTKLTVLQGPAAASVTLFPP 141
OY 161 SS-----MTTWRLSSSTTTTGLRVTOGKRSDS 189
DB 142 SSEELQANKATLVCLISDFYPGAVTVAMKADSSPVKAGVETTPPSKQSN 191

RESULT 13
I9 lambda chain - duck
C:Species: Anas platyrhynchos (domestic duck)
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 21-Jan-2000

```

C:Accession: S49449
R:Magor, K.E.; Higgins, D.A.; Middleton, D.L.; Warr, G.W.
submitted to the EMBL Data Library, October 1994
A:Description: cDNA sequence and organization of the immunoglobulin light chain gene of
A:Reference number: S49449
A:Accession: S49449
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-230 <MAG>
A:Cross-references: EMBL:X82069; NID:g558548; PID:CA57568.1; PID:g558549
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:34-106/Domain: immunoglobulin homology <IMM>

Query Match	6.8%	Score 108.5;	DB 2;	Length 230;
Best Local Similarity	20.5%;	Pred. No. 0.34;		
Matches 48;	Conservative 36;	Mismatches 61;	Indels 89;	Gaps 8;

```

QY      4 PLLPLPLLLPFAFLQPSGSGTSGSPSYLYGVTPQKHLASMGGSVEIP---FSFYYPWE 600
      |||| :|| :||| :||| :||| :|||
Db      5 PLLLAVL-----AHMSGSLVQAALTPASKSVNPGDVTQGITSGSSSDVGMF 511

```

```

Oy      61  LATAP---DVRISWRGHFHGQSFYSTRPPSIHDDVNRLLPLNWTBCKQSG--FLRISN 11
      |      |      |      |      |      |      |      |      |      |
Db      52  QQKTPSAPVWYIYQN-----NKRPSGIPSRF-----SGSKSGSTATLLITG 93

```

```

QY      115 LQKQDQSVYFGRVELDTRSSGRQQWQSIEGTKLSTITQAVTTTQ----- 156
      ::::|::|      |:::|::|
Db      94  VQAEDEAVYVC-----GSYDSYVGVFGAGTTLTVLGQPKVSPVTHVPPSP 139

```

```
QY      159 -----RPSMTTWRLSTTTTGLRVGKRRSDWHIS 193
          || :||:::| ::| : ||:| ::|
Db      140 DEETSSQNKA TLVCLMSDFYPSPVTWTKMGSTRSGVETSASQRQSNKYMA 193
```

RESULT 14
S14675
Ts 14675a chain human

C:Species: Homo sapiens (man)
C:Date: 19-May-1994 #sequence 19-May-1994 #text_change 09-Jul-2004
C:Accession: S14675; S12445
C:Vastack m t

submitted to the EMBL Data Library, February 1990
A:Reference number: S14675
2:Accession: S14675
3:Molecule type: DNA

A/Residues: 1-235 <VASI>
A/Cross-references: UNIPROT:Q8WUK4; EMBL:X51754
R/Vasicek, T.J.; Leder, P.
Proc Natl Acad Sci USA 1973 60:620 1990

A1:Title: Structure and expression of the human immunoglobulin lambda genes.
A1:Reference number: S12440; WUID:90324881; PMID:2115572
A1:Accession: S12445
A1:Molecule type: DNA

A;Residues: 1-129 <VAS2>
A;Cross-references: EMBL:X51754
C;Genetics:
A;Introns: 16/1, 130/1

C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F,150-218/Domain: immunoglobulin homology <IMM>

Query Match	6.8%;	Score 108.5;	DB 2;	Length 235;
Best Local Similarity	23.9%;	Pred. No. 0.35;		
Matches 53;	Conservative 31;	Mismatches 67;	Indels 71;	Gaps 11;

Dy
5 LLLPLLPALPQSGSTGGSPSYLGVTPKHLSSMGGSVEIPFSFYYPMLATA 64

Db
6 LIITLL-----TQTGSMASALTDPFSAAGSLGGSVTFSCS-----GTS 45

```

Db      46 SDIGNYYVSMYRQH-PGKAPKLMIEYTKRPS---GVNPRF-----SGSKSGNTASLTIV 96
Oy      65 PDV-----RISMRGRHFGQS-----FYSRNPSPSHKDYNRRLFLMTTEGQSG---FLRI 11

```

```

Qy      113  SNLKQKDSVYFCRCRELDTRSSGRQWQSIETKSI-----TQAVTTTHQRPSS----- 162
        :      :      :      :      :      :      :      :      :      :
Db      97  SGLQAEADADYYC-----SYAAGNSLSLFGCGTRILTVLQPRKAPASVTILPFPSEBELQ 151
        :      :      :      :      :      :      :      :      :      :
Qy      163  -----MTTTRRLSSTTTTTHGLRVTGGRKRS 189
        :      :      :      :      :      :      :      :      :      :
Db      152  KATLVCLISDFPGAVTAMKADSSPVKAGVETTPSPKSN 193

```

RESULT 15
I49583

C:Accession: I49583
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Species: Mus musculus (house mouse)
C:Differentiation antigen - mouse

J. Immunol. 151, 175-187, 1993
A:Title: Organization of the murine Cd23 locus. Mapping to chromosome 7 and characterization of the gene structure.
A:Reference number: 149583; MID:93315834; PMID:810083

A/Status: preliminary; translated from GB/EMBL/DBD
A/Molecule type: mRNA
A/Residues: 1-862 <RES>
A/Accession: M10000. GB 110000. M10000

C;Genetics:
A;Gene: CD22

Query Match	6.8%	Score 108.5;	DB 2;	Length 862;
Best Local Similarity	20.1%	Pred. No. 1.6;		
Matches	60;	Conservative	39;	Mismatches 109;
				Indels 91;
				Gaps 10.

QY 10 LPPLLPALQPSSGTSGSPSYLVGVTQPKLSAMGGSVETPFSPYYPMELATAPDVRI 69
| : | : | : | : | : | :
Db 602 LQVLYAPRLRVSISPGD-----HMEGKATLSCESDANPIS-QYTWPDS----- 648

```

QY      70  SWRRGHFHQSFSYSTRPPSIHKDYVNRFLFWNTEQSGSGLRISNLOKQDQSVYFCVEL 129
           ||  ::  |||  ||:  |  |  |
Db      649  -----GQDLHSS-----GQK--LRLEPPEVQHTGSYRCKG-- 676

```

```

QY      130 DTRSSGRQWQSIESTKSLTQAVTTTTPQSSMTTWRLSRSTTTTGLRVYQGRKRSDS 169
          | : | | : | :
Db      677 -----TNGTGTGSEPPSTLTIVY-----SPETIGKRV----- 703

```

```

QY      190 WHISLETANGVAAVTVLGIMITGICLMMRRRGGQRTATTTPAREPFQUTEERFENI 249
          ||:  ::  :  ||  :  ::  ||  :  :  :  :  :  :
Db      704 -----ALGFGCTTICLAIWGNKIQKKWKQNSQQGLQENSQGSFFVNNKKAARTP 756

```

```

QY      250 RNEGQNTDPTLNP-KODGIYVASLALSSTSPRA-----PPSHRPLKSPQNETLYSVLK 302
      :||:  :  ||  ||:  ||:  |  :  :  :  :  :  :||:
Db      757 LSEGGQSGGCYNPAMDVTVSYAILRPESDMHNAGDAGTPATGAPPNNNSDVTYSVIG 815

```

Search completed: June 1, 2005, 22:14:01
Job time : 41 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 1, 2005, 22:02:25 ; Search time 43 seconds
(without alignments)
526.015 Million cell updates/sec

Title: US-10-777-524-2

Perfect score: 1591

Sequence: 1 MGRPLRLPLRLPLPAFLQ.....PSHRPLKSPQNETLYSVLKA 303

Scoring table: BLOSUM62

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/1/1aa/5A.COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/5B.COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/6A.COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/6B.COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/6C.COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/6D.COMB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1591	100.0	303	US-08-985-950-2	Sequence 2, Appli
2	1591	100.0	303	US-09-546-049-2	Sequence 2, Appli
3	1591	100.0	303	US-09-869-388-2	Sequence 2, Appli
4	1176.5	73.9	230	US-09-869-388-4	Sequence 4, Appli
5	973.5	61.2	226	US-09-869-388-10	Sequence 10, Appli
6	958	60.2	227	US-09-869-388-6	Sequence 6, Appli
7	934	58.7	238	US-09-149-476-485	Sequence 485, App
8	821	51.6	175	US-09-869-388-8	Sequence 8, Appli
9	517	32.5	101	US-09-149-476-754	Sequence 754, App
10	222	14.0	99	US-08-985-950-4	Sequence 4, Appli
11	222	14.0	99	US-09-546-049-4	Sequence 4, Appli
12	130.5	8.2	431	US-09-038-832-2	Sequence 2, Appli
13	130.5	8.2	431	US-09-038-832-4	Sequence 2, Appli
14	130.5	8.2	447	US-09-949-016-811	Sequence 811, Ap
15	119	7.5	341	US-09-336-536-29	Sequence 29, Appli
16	119	7.5	370	US-09-336-536-28	Sequence 28, Appli
17	114	7.2	390	US-08-979-424-1	Sequence 1, Appli
18	114	7.2	390	US-09-907-794A-39	Sequence 39, Appli
19	114	7.2	390	US-09-905-125A-39	Sequence 39, Appli
20	114	7.2	390	US-09-902-775A-39	Sequence 39, Appli
21	114	7.2	390	US-09-906-700-39	Sequence 39, Appli
22	114	7.2	390	US-09-903-603A-39	Sequence 39, Appli
23	114	7.2	390	US-09-904-920A-39	Sequence 39, Appli
24	114	7.2	390	US-09-909-064-39	Sequence 39, Appli
25	114	7.2	390	US-09-905-381A-39	Sequence 39, Appli
26	114	7.2	390	US-09-906-618-39	Sequence 39, Appli
27	114	7.2	417	US-09-949-016-6729	Sequence 6729, Ap

28	114	7.2	456	4	US-09-949-016-7564	Sequence 7564, Ap
29	113.5	7.1	319	1	US-08-597-495B-22	Sequence 22, Appli
30	113.5	7.1	319	3	US-09-066-051A-22	Sequence 22, Appli
31	113.5	7.1	319	4	US-09-336-536-67	Sequence 67, Appli
32	113.5	7.1	319	4	US-09-254-465A-6	Sequence 6, Appli
33	113.5	7.1	319	4	US-09-953-499-6	Sequence 6, Appli
34	113	7.1	316	4	US-09-397-243D-13	Sequence 13, Appli
35	111.5	7.0	306	4	US-09-369-247-63	Sequence 63, Appli
36	110.5	6.9	244	3	US-08-918-148-79	Sequence 79, Appli
37	110.5	6.9	244	4	US-09-138-091A-77	Sequence 77, Appli
38	110	6.9	300	2	US-08-661-052-4	Sequence 4, Appli
39	110	6.9	300	3	US-09-188-082-4	Sequence 4, Appli
40	110	6.9	300	3	US-09-364-088-4	Sequence 4, Appli
41	110	6.9	300	3	US-09-102-716-4	Sequence 4, Appli
42	110	6.9	501	2	US-08-408-095-31	Sequence 31, Appli
43	106.5	6.7	216	4	US-09-291-299A-9	Sequence 9, Appli
44	106.5	6.7	240	3	US-09-049-672A-11	Sequence 11, Appli
45	105	6.6	512	4	US-08-999-689A-7	Sequence 7, Appli

ALIGNMENTS

RESULT 1
US-08-985-950-2
; Sequence 2, Application US/08985950
; Patent No. 6140076
; GENERAL INFORMATION:
; APPLICANT: Adema, Gosse Jan
; TITLE OF INVENTION: Isolated Mammalian Monocyte Cell Genes;
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSER: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,950
; FILING DATE: 05-DEC-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/041,279
; FILING DATE: 21-MARCH-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/033,181
; FILING DATE: 16-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/032,252
; FILING DATE: 06-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0670K
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650)852-9196
; TELEFAX: (650)496-1204
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 303 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-985-950-2
; Query Match 100.0%; Score 1591; DB 3; Length 303;
; Best Local Similarity 100.0%; Pred. No. 1.9e-141;

Matches	303;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0
Qy	1	MGRPLLLPLPLLLPAPLQPSGSGSGSPSYGYGTOPRHLSASMGSGVEIPFSFYPM	60						
Db	1	MGRPLLLPLPLLLPAPLQPSGSGSGSPSYGYGTOPRHLSASMGSGVEIPFSFYPM	60						
Qy	61	LATAPDVASWRGHHFGHSGFSYSTRPSPSIHKDYVRLPLMTWEGKSGFLRSINLOKODQ	120						
Db	61	LATAPDVASWRGHHFGHSGFSYSTRPSPSIHKDYVRLPLMTWEGKSGFLRSINLOKODQ	120						
Qy	121	SVYFRRVLDTRSSRQOMOSIEGKLSITQAVTTTTTQRPSSMTTWRLSSTTTTGLRV	180						
Db	121	SVYFRRVLDTRSSRQOMOSIEGKLSITQAVTTTTTQRPSSMTTWRLSSTTTTGLRV	180						
Qy	181	TQGRRSQSMHISLETAVGAAYVVLGIMIGLICLRMRARKQOQRTKATTPAREPQ	240						
Db	181	TQGRRSQSMHISLETAVGAAYVVLGIMIGLICLRMRARKQOQRTKATTPAREPQ	240						
Qy	241	NTEEPYENIRNEGQNTDPLKNDGDIYVASIALSSSPRAPSHRPLKSPQNETLYSV	300						
Db	241	NTEEPYENIRNEGQNTDPLKNDGDIYVASIALSSSPRAPSHRPLKSPQNETLYSV	300						
Qy	301	LKA 303							
Db	301	LKA 303							

RESULT 2
US-09-546-049-2
Sequence 2, Application US/09546049
Patent No. 6479638
GENERAL INFORMATION:
APPLICANT: Adema, Gosse Jan
Meygaard, Linde
Gorman, Daniel M.
McClanahan, Terrill K.
Zurawski, Sandra M.
Zurawski, Gerard
Lanier, Lewis L.
Phillips Jr., Joseph H.
TITLE OF INVENTION: Isolated Mammalian Monocyte Cell Genes;
Related Reagents
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: DNAX Research Institute
STREET: 901 California Avenue
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94304-1104
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/546, 049
FILING DATE: 10-Apr-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/985, 950
FILING DATE: 05-DEC-1997
APPLICATION NUMBER: US 60/041, 279
FILING DATE: 21-MARCH-1997
APPLICATION NUMBER: US 60/033, 181
FILING DATE: 16-DEC-1996
APPLICATION NUMBER: US 60/032, 252
FILING DATE: 06-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Ching, Edwin P.
REGISTRATION NUMBER: 34 090
REFERENCE/DOCKET NUMBER: DX0670K
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 852-9196

```

; TELEFAX: (650) 496-1204
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
;     LENGTH: 303 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;     MOLECULE TYPE: protein
;     SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-546-049-2

Query Match      100.0%; Score 1591; DB 4; Length 303;
Best Local Similarity 100.0%; Pred. No. 1.9e-141;
Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MGRPLLLPLPLLPAPFLQPSGSGTSGSPSYLYGVTPQHLLASMGSGVEIPSPFYYPWE 60
Db 1 MGRPLLLPLPLLPAPFLQPSGSGTSGSPSYLYGVTPQHLLASMGSGVEIPSPFYYPWE 60

OY 61 LATAPDVIRSMRGRGHFGQGSFYSTRPPSIHKDYVNRFLPLNMTGQKSGFLRISNLQKQDQ 120
Db 61 LATAPDVIRSMRGRGHFGQGSFYSTRPPSIHKDYVNRFLPLNMTGQKSGFLRISNLQKQDQ 120

OY 121 SVYFQFVRLDTRSSGRQOMQSIIEGTKLSITQAVTTTQTPSSMTTWRLSSTTTTGLRV 180
Db 121 SVYFQFVRLDTRSSGRQOMQSIIEGTKLSITQAVTTTQTPSSMTTWRLSSTTTTGLRV 180

OY 181 TQGRKRSDSWHISLETAVGAVAVTVLGIIMILGICLLRWRRRKGGQRTYATTPAREPFQ 240
Db 181 TQGRKRSDSWHISLETAVGAVAVTVLGIIMILGICLLRWRRRKGGQRTYATTPAREPFQ 240

OY 241 NTEERYENIRRENGONTDPKLNPKDGIYVASLALSSTSPRAPPSHRPLKSPNETLYSV 300
Db 241 NTEERYENIRRENGONTDPKLNPKDGIYVASLALSSTSPRAPPSHRPLKSPNETLYSV 300

OY 301 LKA 303
Db 301 LKA 303

RESULT 3
US-09-869-388-2
; Sequence 2, Application US/09869388
; Patent No. 6774214
; GENERAL INFORMATION:
; APPLICANT: Bates, Elizabeth
; APPLICANT: Pournier, Nathalie
; APPLICANT: Chalus, Lionel
; APPLICANT: Garrone, Pierre
; FILE REFERENCE: SF0977X
; CURRENT APPLICATION NUMBER: US/09/869,388
; CURRENT FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: IBM PC compatible
; SEQ ID NO 2
; LENGTH: 303
; TYPE: PRT
; ORGANISM: homo sapiens
US-09-869-388-2

Query Match      100.0%; Score 1591; DB 4; Length 303;
Best Local Similarity 100.0%; Pred. No. 1.9e-141;
Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MGRPLLLPLPLLPAPFLQPSGSGTSGSPSYLYGVTPQHLLASMGSGVEIPSPFYYPWE 60
Db 1 MGRPLLLPLPLLPAPFLQPSGSGTSGSPSYLYGVTPQHLLASMGSGVEIPSPFYYPWE 60

OY 61 LATAPDVIRSMRGRGHFGQGSFYSTRPPSIHKDYVNRFLPLNMTGQKSGFLRISNLQKQDQ 120
Db 61 LATAPDVIRSMRGRGHFGQGSFYSTRPPSIHKDYVNRFLPLNMTGQKSGFLRISNLQKQDQ 120

OY 121 SVYFQFVRLDTRSSGRQOMQSIIEGTKLSITQAVTTTQTPSSMTTWRLSSTTTTGLRV 180
Db 121 SVYFQFVRLDTRSSGRQOMQSIIEGTKLSITQAVTTTQTPSSMTTWRLSSTTTTGLRV 180

```

```

Db      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTQRPSSMTTWLSTTTTGLRV 180
Qy      181 TQGRKRSWSMHSLETAAGVAATVVLGIMIGLICLLMRRRKQOQRTKATTPAREPQ 240
Db      181 TQGRKRSWSMHSLETAAGVAATVVLGIMIGLICLLMRRRKQOQRTKATTPAREPQ 240
Qy      241 NTEBYENIRNEGONTDPKLNPKDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
Db      241 NTEBYENIRNEGONTDPKLNPKDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
Qy      301 LKA 303
Db      301 LKA 303

```

RESULT 4
US-09-869-388-4
Sequence 4, Application US/09869388
Patent No. 6774214

```

GENERAL INFORMATION:
APPLICANT: Bates, Elizabeth
APPLICANT: Fournier, Nathalie
APPLICANT: Chalus, Lionel
APPLICANT: Garrone, Pierre
TITLE OF INVENTION: MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHO
FILE REFERENCE: SF0977X
CURRENT APPLICATION NUMBER: US/09/869,388
CURRENT FILING DATE: 2002-02-21
NUMBER OF SEQ ID NOS: 14
SOFTWARE: IBM PC compatible
SEQ ID NO: 4
LENGTH: 230
TYPE: PRT
ORGANISM: homo sapiens
US-09-869-388-4

```

Query Match 73.9%; Score 1176.5; DB 4; Length 230;
Best Local Similarity 75.9%; Pred. No. 1.2e-102;
Matches 230; Conservative 0; Mismatches 0; Indels 73; Gaps 1;

```

Qy      1 MGRPLLLPLPLLPALPQPSGSGSPSYLVGVTOPKHLASMGSGVEIPFSFYPMW 60
Db      1 MGRPLLLPLPLLPALPQPSGSGSPSYLVGVTOPKHLASMGSGVEIPFSFYPMW 60
Qy      61 LATAADVIRISWRGHFHGQSFYSTRPSIHKDYVNRFLNMTGQSGFLRISNLQKQDQ 120
Db      61 LATAADVIRISWRGHFHGQSFYSTRPSIHKDYVNRFLNMTGQSGFLRISNLQKQDQ 120
Qy      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTQRPSSMTTWLSTTTTGLRV 180
Db      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTQRPSSMTTWLSTTTTGLRV 180
Qy      181 TQGRKRSWSMHSLETAAGVAATVVLGIMIGLICLLMRRRKQOQRTKATTPAREPQ 240
Db      181 TQGRKRSWSMHSLETAAGVAATVVLGIMIGLICLLMRRRKQOQRTKATTPAREPQ 240
Qy      241 NTEBYENIRNEGONTDPKLNPKDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
Db      241 NTEBYENIRNEGONTDPKLNPKDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
Qy      301 LKA 303
Db      301 LKA 303

```

RESULT 5
US-09-869-388-10
Sequence 10, Application US/09869388
Patent No. 6774214
GENERAL INFORMATION:
APPLICANT: Bates, Elizabeth
APPLICANT: Fournier, Nathalie

```

APPLICANT: Chalus, Lionel
APPLICANT: Garrone, Pierre
TITLE OF INVENTION: MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHO
FILE REFERENCE: SF0977X
CURRENT APPLICATION NUMBER: US/09/869,388
CURRENT FILING DATE: 2002-02-21
NUMBER OF SEQ ID NOS: 14
SOFTWARE: IBM PC compatible
SEQ ID NO: 10
LENGTH: 226
TYPE: PRT
ORGANISM: homo sapiens
US-09-869-388-10

```

Query Match 61.2%; Score 973.5; DB 4; Length 226;
Best Local Similarity 82.5%; Pred. No. 1.5e-83;
Matches 188; Conservative 14; Mismatches 17; Indels 9; Gaps 2;

```

Qy      1 MGRPLLLPLPLLPALPQPSGSGSPSYLVGVTOPKHLASMGSGVEIPFSFYPMW 60
Db      1 MGRPLLLPLPLLPALPQPSGSGSPSYLVGVTOPKHLASMGSGVEIPFSFYPMW 60
Qy      61 LATAADVIRISWRGHFHGQSFYSTRPSIHKDYVNRFLNMTGQSGFLRISNLQKQDQ 120
Db      61 LATAADVIRISWRGHFHGQSFYSTRPSIHKDYVNRFLNMTGQSGFLRISNLQKQDQ 120
Qy      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTQRPSSMTTWLSTTTTGLRV 180
Db      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTQRPSSMTTWLSTTTTGLRV 180
Qy      181 TQGRKRSWSMHSLETAAGVAATVVLGIMIGLICLLMRRRKQO 227
Db      173 TSKGHSWSMHSLETAAGVAATVVLGIMIGLICLLMRRRKQO 220

```

RESULT 6
US-09-869-388-6
Sequence 6, Application US/09869388
Patent No. 6774214

```

GENERAL INFORMATION:
APPLICANT: Bates, Elizabeth
APPLICANT: Fournier, Nathalie
APPLICANT: Chalus, Lionel
APPLICANT: Garrone, Pierre
TITLE OF INVENTION: MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHO
FILE REFERENCE: SF0977X
CURRENT APPLICATION NUMBER: US/09/869,388
CURRENT FILING DATE: 2002-02-21
NUMBER OF SEQ ID NOS: 14
SOFTWARE: IBM PC compatible
SEQ ID NO: 6
LENGTH: 227
TYPE: PRT
ORGANISM: homo sapiens
US-09-869-388-6

```

Query Match 60.2%; Score 958; DB 4; Length 227;
Best Local Similarity 80.8%; Pred. No. 4.2e-82;
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

```

Qy      1 MGRPLLLPLPLLPALPQPSGSGSPSYLVGVTOPKHLASMGSGVEIPFSFYPMW 60
Db      1 MGRPLLLPLPLLPALPQPSGSGSPSYLVGVTOPKHLASMGSGVEIPFSFYPMW 60
Qy      61 LATAADVIRISWRGHFHGQSFYSTRPSIHKDYVNRFLNMTGQSGFLRISNLQKQDQ 120
Db      61 LATAADVIRISWRGHFHGQSFYSTRPSIHKDYVNRFLNMTGQSGFLRISNLQKQDQ 120
Qy      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTQRPSSMTTWLSTTTTGLRV 180
Db      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTQRPSSMTTWLSTTTTGLRV 180
Qy      181 TQGRKRSWSMHSLETAAGVAATVVLGIMIGLICLLMRRRKQO 227

```

```
Db      173 TESKGHSESWHLSDTAIRVALAVAVLKTVIGILCLLLLMWRRKGRS 221
```

```

1 RESULT 7 19-476-485
2 US-09-149-476-485
3 Sequence 485, Application US/09149476
4 Patent No. 6420526
5 GENERAL INFORMATION:
6 APPLICANT: Rosen et al.
7 TITLE OF INVENTION: 186 Human Secreted proteins
8 FILE REFERENCE: P2002p1
9 CURRENT APPLICATION NUMBER: US/09/149, 476
10 CURRENT FILING DATE: 1998-09-08
11 EARLIER APPLICATION NUMBER: PCT/US98/04493
12 EARLIER FILING DATE: 1998-03-06
13 EARLIER APPLICATION NUMBER: 60/040, 162
14 EARLIER FILING DATE: 1997-03-07
15 EARLIER APPLICATION NUMBER: 60/040, 333
16 EARLIER FILING DATE: 1997-03-07
17 EARLIER APPLICATION NUMBER: 60/038, 621
18 EARLIER FILING DATE: 1997-03-07
19 EARLIER APPLICATION NUMBER: 60/040, 626
20 EARLIER FILING DATE: 1997-03-07
21 EARLIER APPLICATION NUMBER: 60/040, 334
22 EARLIER FILING DATE: 1997-03-07
23 EARLIER APPLICATION NUMBER: 60/040, 336
24 EARLIER FILING DATE: 1997-03-07
25 EARLIER APPLICATION NUMBER: 60/040, 163
26 EARLIER FILING DATE: 1997-03-07
27 EARLIER APPLICATION NUMBER: 60/047, 600
28 EARLIER FILING DATE: 1997-05-23
29 EARLIER APPLICATION NUMBER: 60/047, 615
30 EARLIER FILING DATE: 1997-05-23
31 EARLIER APPLICATION NUMBER: 60/047, 597
32 EARLIER FILING DATE: 1997-05-23
33 EARLIER APPLICATION NUMBER: 60/047, 502
34 EARLIER FILING DATE: 1997-05-23
35 EARLIER APPLICATION NUMBER: 60/047, 633
36 EARLIER FILING DATE: 1997-05-23
37 EARLIER APPLICATION NUMBER: 60/047, 583
38 EARLIER FILING DATE: 1997-05-23
39 EARLIER APPLICATION NUMBER: 60/047, 617
40 EARLIER FILING DATE: 1997-05-23
41 EARLIER APPLICATION NUMBER: 60/047, 618
42 EARLIER FILING DATE: 1997-05-23
43 EARLIER APPLICATION NUMBER: 60/047, 503
44 EARLIER FILING DATE: 1997-05-23
45 EARLIER APPLICATION NUMBER: 60/047, 592
46 EARLIER FILING DATE: 1997-05-23
47 EARLIER APPLICATION NUMBER: 60/047, 581
48 EARLIER FILING DATE: 1997-05-23
49 EARLIER APPLICATION NUMBER: 60/047, 584
50 EARLIER FILING DATE: 1997-05-23
51 EARLIER APPLICATION NUMBER: 60/047, 500
52 EARLIER FILING DATE: 1997-05-23
53 EARLIER APPLICATION NUMBER: 60/047, 587
54 EARLIER FILING DATE: 1997-05-23
55 EARLIER APPLICATION NUMBER: 60/047, 492
56 EARLIER FILING DATE: 1997-05-23
57 EARLIER APPLICATION NUMBER: 60/047, 598
58 EARLIER FILING DATE: 1997-05-23
59 EARLIER APPLICATION NUMBER: 60/047, 613
60 EARLIER FILING DATE: 1997-05-23
61 EARLIER APPLICATION NUMBER: 60/047, 582
62 EARLIER FILING DATE: 1997-05-23
63 EARLIER APPLICATION NUMBER: 60/047, 596
64 EARLIER FILING DATE: 1997-05-23
65 EARLIER APPLICATION NUMBER: 60/047, 612
66 EARLIER FILING DATE: 1997-05-23
67 EARLIER APPLICATION NUMBER: 60/047, 632
68 EARLIER FILING DATE: 1997-05-23
69 EARLIER APPLICATION NUMBER: 60/047, 601

```

[illegible]

```

; EARLIER APPLICATION NUMBER: 60/057,761
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/047,595
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,599
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,588
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,585
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,586
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,590
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,594
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,614
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,578
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,576
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/047,501
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,670
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/056,632
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,664
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,881
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,909
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,875
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/056,884
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/057,669
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/049,610
; EARLIER FILING DATE: 1997-06-13
; EARLIER APPLICATION NUMBER: 60/061,060
; EARLIER FILING DATE: 1997-10-02

Query Match      58.7%; Score 934; DB 4; Length 238;
Best Local Similarity 82.1%; Pred. No. 8,2e-80;
Matches 179; Conservative 13; Mismatches 18; Indels 8; Gaps 1;

Qy      1 MGRPLLPPLLPPLPPAFLOPSGSGPSYLYGVYTOPKHLASNGSGVEIPFSFYPMW 60
      1 MGRPLLPPLLPPLPPAFLOPSGSGPSYLYGVYTOPKHLASNGSGVEIPFSFYPMW 60
Db      1 MGRPLLPPLLPPLPPAFLOPSGSGPSYLYGVYTOPKHLASNGSGVEIPFSFYPMW 60
      61 LATAPDVRIWMRGHFGHGSFYSTRPPSIHKDYVNRFLFNMTEGQSGFLRISNIQKODQ 120
      61 LAXXFXVRIWMRGHFGHGSFYSTRPPSIHKDYVNRFLFNMTEGQSGFLRISNIQKODQ 120
Db
```

```

Qy      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTORPSPMTTMRSLSTTTTGLRV 180
      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTT-----TTTMRPSTTTIAGLRV 172
Db      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTT-----TTTMRPSTTTIAGLRV 172
Qy      181 TQKRRSDSMHISLETAVGVAATVIGIMILGICLL 218
      173 TESKHSSEMSHLSLDTAIVLAVALKVILGLICLL 210
Db      173 TESKHSSEMSHLSLDTAIVLAVALKVILGLICLL 210

RESULT 8
US-09-869-388-8
; Sequence 8, Application US/09869388
; Patent No. 6774214
; GENERAL INFORMATION:
; APPLICANT: Bates, Elizabeth
; APPLICANT: Fournier, Nathalie
; APPLICANT: Chalus, Lionel
; APPLICANT: Garrone, Pierre
; TITLE OF INVENTION: MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHO
; FILE REFERENCE: SP0972X
; CURRENT APPLICATION NUMBER: US/09/869,388
; CURRENT FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: IBM PC compatible
; SEQ ID NO 8
; LENGTH: 175
; TYPE: PRT
; ORGANISM: homo sapiens
US-09-869-388-8

Query Match      51.6%; Score 821; DB 4; Length 175;
Best Local Similarity 96.9%; Pred. No. 1,2e-69;
Matches 154; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      1 MGRPLLPPLLPPLPPAFLOPSGSGPSYLYGVYTOPKHLASNGSGVEIPFSFYPMW 60
      1 MGRPLLPPLLPPLPPAFLOPSGSGPSYLYGVYTOPKHLASNGSGVEIPFSFYPMW 60
Db      1 MGRPLLPPLLPPLPPAFLOPSGSGPSYLYGVYTOPKHLASNGSGVEIPFSFYPMW 60
      61 LATAPDVRIWMRGHFGHGSFYSTRPPSIHKDYVNRFLFNMTEGQSGFLRISNIQKODQ 120
      61 LATAPDVRIWMRGHFGHGSFYSTRPPSIHKDYVNRFLFNMTEGQSGFLRISNIQKODQ 120
Db      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTOR 159
      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTOR 159
Qy      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTOR 159
      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTOR 159
Db      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTOR 159
      121 SVYFCRVELDTRSSGRQOMOSIEGKLSITQAVTTTOR 159

RESULT 9
US-09-149-476-754
; Sequence 754, Application US/09149476
; Patent No. 6420526
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 186 Human Secreted proteins
; FILE REFERENCE: P2002P1
; CURRENT APPLICATION NUMBER: US/09/149,476
; CURRENT FILING DATE: 1998-09-08
; EARLIER APPLICATION NUMBER: PCT/US98/04493
; EARLIER FILING DATE: 1998-03-06
; EARLIER APPLICATION NUMBER: 60/040,162
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,333
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/038,621
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,626
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,334
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,336
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,163
; EARLIER FILING DATE: 1997-03-07
```

[illegible]

EARLIER APPLICATION NUMBER: 60/056,632
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,664
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,876
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,881
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,909
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,875
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,862
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,887
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,908
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/048,964
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/057,650
EARLIER FILING DATE: 1997-09-05
EARLIER APPLICATION NUMBER: 60/056,884
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/057,669
EARLIER FILING DATE: 1997-09-05
EARLIER APPLICATION NUMBER: 60/049,610
EARLIER FILING DATE: 1997-06-13
EARLIER APPLICATION NUMBER: 60/061,060
EARLIER FILING DATE: 1997-10-02

Query Match 32.5%; Score 517; DB 4; Length 101;

Best Local Similarity 93.1%; Pred. No. 4e-41; Matches 94; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Oy 35 VTQPHLSASMGSGVEIPSFYYPWEIATAPDVRI SMRGHFGOSFYSTRPPSIHKDYV 94
Db 1 VTQPHLSASMGSGVEIPSFYYPWEIATAPDVRI SMRGHFGOSFYSTRPPSIHKDYV 60
Oy 95 NRLFNTMGOKSGFLRISNLTOKODQSYVFCVVELDTRSSG 135
Db 61 NRLFNTMGOKSGFLRISNLTOKODQSYVFCVVELDTRSSG 101

RESULT 10
US-08-985-950-4
Sequence 4, Application US/08985950
Patent No. 6140076
GENERAL INFORMATION:
APPLICANT: Adema, Gosse Jan
TITLE OF INVENTION: Isolated Mammalian Monocyte Cell Genes;
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: DNAX Research Institute
STREET: 901 California Avenue
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94304-1104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,950
FILING DATE: 05-DEC-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/041,279
FILING DATE: 21-MARCH-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/033,181

FILING DATE: 16-DEC-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/032,252
FILING DATE: 06-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Ching, Edwin P.
REGISTRATION NUMBER: 34,090
REFERENCE/DOCKET NUMBER: DX0670X
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650)852-9196
TELEFAX: (650)496-1204
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 99 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-985-950-4

Query Match 14.0%; Score 222; DB 3; Length 99;
Best Local Similarity 45.2%; Pred. No. 2.1e-13;
Matches 42; Conservative 15; Mismatches 30; Indels 6; Gaps 1;

Oy 19 LQPSGSTGSPSYLT-----GVTPKHLASMGSGVEIPSFYYPWEIATAPDVRI SMR 72
Db 7 LLSGCLHAGNSERNRNGFGVNPGRCSGVGGSSIIPIPSFYYPWEIATAPDVRI SMR 66
Oy 73 RGHFHGSGFYSTRPPSIHKDYVNRFLNWTGQ 105
Db 67 WDFHGEVLYNSLPIFHEHFGRLLNWTGQ 99

RESULT 11
US-09-546-049-4
Sequence 4, Application US/09546049
Patent No. 6479638
GENERAL INFORMATION:
APPLICANT: Adema, Gosse Jan
TITLE OF INVENTION: Isolated Mammalian Monocyte Cell Genes;
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: DNAX Research Institute
STREET: 901 California Avenue
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94304-1104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/546,049
FILING DATE: 10-APR-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/985,950
FILING DATE: 05-DEC-1997
APPLICATION NUMBER: US 60/041,279
FILING DATE: 21-MARCH-1997
APPLICATION NUMBER: US 60/033,181
FILING DATE: 16-DEC-1996
APPLICATION NUMBER: US 60/032,252
FILING DATE: 06-DEC-1996
ATTORNEY/AGENT INFORMATION:

NAME: Ching, Edwin P.
REGISTRATION NUMBER: 34,090
REFERENCE/DOCKET NUMBER: DX0670X
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650)852-9196
TELEFAX: (650)496-1204
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 99 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 4:
-US-09-546-049-4

Query Match 14.0%; Score 222; DB 4; Length 99;
Best Local Similarity 45.2%; Pred. No. 2,1e-13;
Matches 42; Conservative 15; Mismatches 30; Indels 6; Gaps 1;

Qy 19 LQPSGSGSGPSYLY-----GVTPQKHLASMGSGVSEIPSFYYPWELATAPDVRIISWR 72
Db 7 LLSGCLHAGNSERYNKRNGVQVQPERCSGVQGSIDIPPSFYFWKLAKDPQMSIAWK 66

Qy 73 RGHFGQSFYSTRPSPSIHKDYVNRLLFLNWTGQ 105
Db 67 WKDFHGEIVYNSLPLFIHEHPKGRLLINWTGQ 99

RESULT 12
US-09-038-832-2
Sequence 2, Application US/09038832
Patent No. 6146845
GENERAL INFORMATION:
APPLICANT: KIKLY, KRISTINE
APPLICANT: ERICKSON-MILLER, CONNIE
TITLE OF INVENTION: Sialoadhesin Family Member-2
TITLE OF INVENTION: (SAF-2)
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: RATNER & PRESTIA
STREET: P.O. BOX 980
CITY: VALLEY FORGE
STATE: PA
COUNTRY: USA
ZIP: 19482
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,832
FILING DATE: 11-MAR-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/041,886
FILING DATE: 02-APR-1997
ATTORNEY/AGENT INFORMATION:
NAME: PRESTIA, PAUL F
REGISTRATION NUMBER: 23,031
REFERENCE/DOCKET NUMBER: GH-50018
TELECOMMUNICATION INFORMATION:
TELEPHONE: 610-407-0700
TELEFAX: 610-407-0701
TELEX: 846169
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 431 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-038-832-2

Query Match 8.2%; Score 130.5; DB 3; Length 431;
Best Local Similarity 22.6%; Pred. No. 0.00067;
Matches 83; Conservative 45; Mismatches 138; Indels 101; Gaps 14;

Qy 5 LLLPLPLLPAPLQPSGSGSGPSYLYGVTPQKHLASMGSGVSEIPSFYYPWELATA 64
Db 3 LLLLLPLLMGTGKMB--GDRQGDGYLLQVOE--LVTVQEGICVAVPCSFSPQDGTWD 58

Qy 65 PD-VRIISWRGHFHGQSFYSTRPSPSIHKDYVNRLLFLNWTGQ-----XSGFLRIISN 114
Db 59 SDPVHGYWFRPA--GDRPYQDAPVATNPN--PREVOAETQGRQLGDIWISNDCSLISIRD 113

Qy 115 LOKODSVYFCRYE-----LDTSSSGHQQ-- 138
Db 114 ARGRDQSGYFPLRERSMKTMSYKSQNLTKQLSVFVTLATHRPDLLIGLTSGHSRNL 173

Qy 139 -----WOSIEGTYKLSIT-----QAVTTTQRPSSMTTWRSLSTTTTGL 178
Db 174 TCSVPACKQGFPPMISWIGASVSPGPTTARSSVLTLPKPDHGTSLTCQVTLPGTV 213

Qy 179 RYVQGRBDS--WHISL-----ETAVGVAAVTVLGIMIGLCL-----L 218
Db 234 TTTSTVRLDVSYPPMNLTWIVFGDATASTALGNGSSLSVLGQSURLVCVANSPPARL 293

Qy 219 RWRRRKQQRKTATTPARPPQN--TEEPYENIRNEGQNTDPKLNPDGDIIVASLASS 277
Db 294 SWTR-----GSLTLCPSRSSNPGLELPRVHVRDEGEFTCRQNAQSGQHSLSLSLQNE 348

Qy 278 TSPRAPP 284
Db 349 GTGTSRP 355

RESULT 13
US-09-038-832-4
Sequence 4, Application US/09038832
Patent No. 6146845
GENERAL INFORMATION:
APPLICANT: KIKLY, KRISTINE
APPLICANT: ERICKSON-MILLER, CONNIE
TITLE OF INVENTION: Sialoadhesin Family Member-2
TITLE OF INVENTION: (SAF-2)
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: RATNER & PRESTIA
STREET: P.O. BOX 980
CITY: VALLEY FORGE
STATE: PA
COUNTRY: USA
ZIP: 19482
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,832
FILING DATE: 11-MAR-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/041,886
FILING DATE: 02-APR-1997
ATTORNEY/AGENT INFORMATION:
NAME: PRESTIA, PAUL F
REGISTRATION NUMBER: 23,031
REFERENCE/DOCKET NUMBER: GH-50018
TELECOMMUNICATION INFORMATION:
TELEPHONE: 610-407-0700
TELEFAX: 610-407-0701
TELEX: 846169
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:

LENGTH: 431 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-038-832-4

Query Match 8.2%; Score 130.5; DB 3; Length 431;
Best Local Similarity 22.6%; Pred. No. 0.00067;
Matches 83; Conservative 45; Mismatches 138; Indels 101; Gaps 14;

QY LLLPLPLPLPPAFLOPSGSGTSGPSYLYGVYTOPKHLASMGSGVEIPFSFYPMELATA 64
DB LLLPLPLPLMTGKME---GDRYQDGYYLQVQE--LVTVQBELCYHVCSCFSYPODGMTD 58
QY 65 PD-VRIWRGHHFGQSFYSTRPSIHKDYVNLFLNMTGQ-----KSGFLRISN 114
DB 59 SDPVHGYWFR---GDRPYQDAPVATNPN--DREVQAEQGRFQLLDIWSNDCSLIRD 113
QY 115 LQKQDQSYVFCRVE-----LDRSSGRQ-- 138
DB 114 ARKDKGSGYFFRLERGSWMKMSYKQLNKTQLSVFTALTHRPDILLGLTLESCHSNL 173
QY 139 ---WQIEGTLSIT-----QAVTTTORPSSMTTWRLSTTTTGL 178
DB 174 TCSVPWACKQGTTPMISWIGASVSPGPTTARSSVLTLPKQDHGTSLTQCVTLPGTGV 233
QY 179 RVYQKRSDS---WHISL-----ETAVGVAVAVTVIGIMILGICL-----L 218
DB 234 TTTSTVRLDVSPNNLTMTVTFQGDATASTALGNGSSLSVLEGQSLRVLCVANSNPPARL 293
QY 219 RWRRRKQGTATKATTPAREPQN--TEEPYENIRNEGQNTDPLANKDGIYASIALSSS 277
DB 294 SWTR-----GSLTLCPSRSSNPGLELPRVHVREDGEFTCRAQNAQSGSHISLSIQNE 348
QY 278 TSPRAP 284
DB 349 GTGTSRP 355

RESULT 14
US-09-949-016-8211
Sequence 8211, Application US/09949016
Patent No. 6612339
GENERAL INFORMATION:
APPLICANT: VENTER, J. Craig et al.
TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
FILE REFERENCE: CLO01307
CURRENT APPLICATION NUMBER: US/09/949,016
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/241,755
PRIOR FILING DATE: 2000-10-20
PRIOR APPLICATION NUMBER: 60/237,768
PRIOR FILING DATE: 2000-10-03
PRIOR APPLICATION NUMBER: 60/231,498
PRIOR FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 207012
SOFTWARE: FASTSEQ for Windows Version 4.0
SEQ ID NO 8211
LENGTH: 447
TYPE: PRT
ORGANISM: Human
US-09-949-016-8211

Query Match 8.2%; Score 130.5; DB 4; Length 447;
Best Local Similarity 22.6%; Pred. No. 0.00071;
Matches 83; Conservative 45; Mismatches 138; Indels 101; Gaps 14;

QY LLLPLPLPLPPAFLOPSGSGTSGPSYLYGVYTOPKHLASMGSGVEIPFSFYPMELATA 64
DB LLLPLPLPLMTGKME---GDRYQDGYYLQVQE--LVTVQBELCYHVCSCFSYPODGMTD 74

QY 65 PD-VRIWRGHHFGQSFYSTRPSIHKDYVNLFLNMTGQ-----KSGFLRISN 114
DB 75 SDPVHGYWFR---GDRPYQDAPVATNPN--DREVQAEQGRFQLLDIWSNDCSLIRD 129
QY 115 LQKQDQSYVFCRVE-----LDRSSGRQ-- 138
DB 130 ARKDKGSGYFFRLERGSWMKMSYKQLNKTQLSVFTALTHRPDILLGLTLESCHSNL 189
QY 139 ---WQIEGTLSIT-----QAVTTTORPSSMTTWRLSTTTTGL 178
DB 190 TCSVPWACKQGTTPMISWIGASVSPGPTTARSSVLTLPKQDHGTSLTQCVTLPGTGV 249
QY 179 RVYQKRSDS---WHISL-----ETAVGVAVAVTVIGIMILGICL-----L 218
DB 250 TTTSTVRLDVSPNNLTMTVTFQGDATASTALGNGSSLSVLEGQSLRVLCVANSNPPARL 309
QY 219 RWRRRKQGTATKATTPAREPQN--TEEPYENIRNEGQNTDPLANKDGIYASIALSSS 277
DB 310 SWTR-----GSLTLCPSRSSNPGLELPRVHVREDGEFTCRAQNAQSGSHISLSIQNE 364
QY 278 TSPRAP 284
DB 365 GTGTSRP 371

RESULT 15
US-09-336-536-29
Sequence 29, Application US/09336536
Patent No. 6406884
GENERAL INFORMATION:
APPLICANT: Leiby, K.
APPLICANT: McKay, C.
TITLE OF INVENTION: SECRETED PROTEINS AND USES THEREOF
FILE REFERENCE: 7853-144
CURRENT APPLICATION NUMBER: US/09/336,536
PRIOR FILING DATE: 1999-06-18
NUMBER OF SEQ ID NOS: 75
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 29
LENGTH: 341
TYPE: PRT
ORGANISM: Mus musculus
US-09-336-536-29

Query Match 7.5%; Score 119; DB 4; Length 341;
Best Local Similarity 21.4%; Pred. No. 0.0058;
Matches 71; Conservative 44; Mismatches 127; Indels 90; Gaps 11;

QY 10 LPLPLPPAFLOPSGSGTSGPSYLYGVYTOPKHLASMGSGVEIPFSFYPMELATAPDVRI 69
DB 2 LQHLFANRLQAVEGEGSASAWYTL---HREVSSQPMVEVPVWVF--FKQKEKEDVL 56
QY 70 SWRGHHFGQSFYSTRPSIHKDYVNLFLNMTGQSGFLRISNLQKQDQSYVFCRVEL 129
DB 57 SYING-----VTSKRGVS-----LVYSMPRSLSRVGLQKDGSPYSCSYNV 101
QY 130 DTRSSGRQWQIEGTLSIT-----QAVTTTORPSSMTTWRLSTTTTGL 167
DB 102 QDK-QGKSRGHSITLDELNVLPAPAPSCRLQGVPHGANVTLSCQSPRSKPAVQYQDR 160
QY 168 -----RLSTTTTGLRVYQKRSDSWMHISLETAVGAVAV 204
DB 161 QLPSTQTFAPALDVIRGSLTLYTSSMAGVYCKAHNEVGTACQCVTLLEVSTGPGAAV 220
QY 205 -----TVLGIMILGICLRWRRRKQGTATTPAREPQNTEEPYENIRNEGQNTD 257
DB 221 VAEAVGTVLVGLAGLIVLYHRGKA-----LEEPANDIKEDALAPR 264
QY 258 PKLNPKQDGIYASIALSSSTSPRA--PESHAP 288
DB 265 TLPMWKSQDITSKNGTILSSVTSARALRPHGF 296

Search completed: June 1, 2005, 22:14:50
Job time : 45 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 1, 2005, 22:00:25 ; Search time 173 Seconds

(without alignments)
896.879 Million cell updates/sec

Title: US-10-777-524-2

Perfect score: 1591

Sequence: 1 MGRPLLPPLLPPLPPAPLQ.....PSHRPLKSPQNETLYSVLKA 303

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot_03:*

1: uniprot_03:*

2: uniprot_03:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1588	99.8	303	Q9UKJ1	Q9UKJ1 homo sapien
2	997.5	62.7	226	Q8NH11	Q8NH11 homo sapien
3	958	60.2	227	Q9UKJ0	Q9UKJ0 homo sapien
4	630	39.6	299	Q8BYA6	Q8BYA6 mus musculus
5	144.5	9.1	823	AXL2 YEAST	P38928 saccharomyc
6	139	8.7	290	Q6UX24	Q6UX24 homo sapien
7	139	8.7	290	Q726A6	Q726A6 homo sapien
8	136	8.5	290	Q8TDQ1	Q8TDQ1 homo sapien
9	135.5	8.5	293	Q72715	Q72715 homo sapien
10	130.5	8.2	499	SIL8 HUMAN	Q9NY24 homo sapien
11	130	8.2	289	Q6QX36	Q6QX36 mus musculus
12	129.5	8.1	233	Q8RBC9	Q8RBC9 homo sapien
13	129.5	8.1	499	Q72728	Q72728 homo sapien
14	129.5	7.8	328	Q6ZMC9	Q6ZMC9 homo sapien
15	123.5	7.8	353	Q7SDQ5	Q7SDQ5 homo sapien
16	122.5	7.7	235	Q99M11	Q99M11 mus musculus
17	122	7.7	288	Q46707	Q46707 fugu rubrip
18	122	7.7	288	Q6GJEA	Q6GJEA fugu rubrip
19	120	7.5	367	Q6RI07	Q6RI07 homo sapien
20	119.5	7.5	434	Q872V2	Q872V2 neurospora
21	119	7.4	318	Q91B03	Q91B03 spherooides
22	117.5	7.4	235	Q6P2J1	Q6P2J1 homo sapien
23	117.5	7.4	366	Q46705	Q46705 fugu rubrip
24	116	7.3	417	PVR CERAB	P32506 cercopithec
25	115.5	7.3	513	SHS1 MOUSE	P97797 m protein-t
26	115	7.2	367	Q46706	Q46706 fugu rubrip
27	114.5	7.2	235	Q6F0G0	Q6F0G0 homo sapien
28	114	7.2	390	Q96AP7	Q96AP7 homo sapien
29	114	7.2	390	Q96T50	Q96T50 homo sapien
30	114	7.2	417	PVR HUMAN	P15151 homo sapien
31	113.5	7.1	319	A33_HUMAN	Q99795 homo sapien

32	113.5	7.1	387	2	Q64JA4	Q64JA4 pan troglod
33	113	7.1	401	2	Q08835	Q08835 cercopithec
34	113	7.1	718	2	Q73675	Q73675 xenopus lae
35	113	7.1	718	2	Q6PCK4	Q6PCK4 xenopus lae
36	112.5	7.1	403	1	CD33 MOUSE	Q63994 mus musculus
37	112.5	7.1	700	2	Q8TGO0	Q8TGO0 aspergillus
38	112.5	7.1	1795	2	Q76894	Q76894 drosophila
39	112	7.0	233	2	Q6PJA3	Q6PJA3 homo sapien
40	111.5	7.0	369	2	Q46704	Q46704 fugu rubrip
41	111.5	7.0	506	1	SHS1_BOVIN	Q46631 bos taurus
42	111.5	7.0	509	1	SHS1_RAT	P97710 r protein-t
43	110	6.9	253	2	Q8UZE2	Q8UZE2 cercopithec
44	109.5	6.9	233	2	Q8N5F4	Q8N5F4 homo sapien
45	109.5	6.9	1225	2	Q6GPE1	Q6GPE1 xenopus lae

ALIGNMENTS

Query Match	Score	DB 2	Length	303
Best Local Similarity	99.8%	Pred. No. 5.6e-124		
Matches	302	Conservative	1	Mismatches 0; Indels 0; Gaps 0;
QY	1	MGRPLLPPLLPPLPPAPLQPSGSGPSLYGVTPQKHSAMGSGVEIPFSFYWE	60	
DB	1	MGRPLLPPLLPPLPPAPLQPSGSGPSLYGVTPQKHSAMGSGVEIPFSFYWE	60	
QY	61	LATPVDVIRSRGPHGQSFYSTRPPIHKDYNNRFLPNTTEGOKSGFLRISNLOKODQ	120	
DB	61	LATPVDVIRSRGPHGQSFYSTRPPIHKDYNNRFLPNTTEGOKSGFLRISNLOKODQ	120	
QY	121	SVYFCRVELDTRSSGRQOQSGIEGKLSITQAVTTTTPRPSMTTWTWLSSTTTTGILRV	180	
DB	121	SVYFCRVELDTRSSGRQOQSGIEGKLSITQAVTTTTPRPSMTTWTWLSSTTTTGILRV	180	
QY	181	TQGRSRDSWHSISETANGVAVATVVGIMTLGILCLRMRRRGQORTKATPARBEPQ	240	
DB	181	TQGRSRDSWHSISETANGVAVATVVGIMTLGILCLRMRRRGQORTKATPARBEPQ	240	
QY	241	NTEEPYENIRNEGQNTDPKLNPKDGIYVASLALSSSTPPAPSHPLKSPQNETLYSV	300	
DB	241	NTEEPYENIRNEGQNTDPKLNPKDGIYVASLALSSSTPPAPSHPLKSPQNETLYSV	300	

Db 241 NTEEPYENIRNEGONTDPKLNPKDDGIYVASIALSSSTSPKAPPSPHRLKSPQNETLYSV 300
Qy 301 LKA 303
Db 301 LKA 303

RESULT 2

08NH11 PRELIMINARY; PRT; 226 AA.
ID 08NH11
AC 08NH11
DT 01-OCT-2002 (TReMBLrel. 22, Created)
DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
DE PILRB protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.

RC TISSUE=Lung;
RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Straubeberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Schenken G.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ueda T.B., Toshitsuki S., Caranini P., Prange C.,
RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McGowan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smalins D.E., Schermer A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lung;
RA Straubeberg R.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC017812; AAH17812.1; -.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR SMART; SM00409; IG; 1.
DR PROSITE; PSS0835; IG LIKE; 1.
SQ SEQUENCE 226 AA; 25478 MW; 5938181797733A30 CRC64;

Query Match 62.7%; Score 997.5; DB 2; Length 226;
Best Local Similarity 67.8%; Pred. No. 5.7e-75;
Matches 196; Conservative 6; Mismatches 10; Indels 77; Gaps 2;

Qy 1 MGRPILPLPLPLPPAFLOPSSGTSYLYGVTPQPKLSMGSGVEIPPSFYFWE 60
Db 1 MGRPILPLPLPLPPAFLOPSSGTSYLYGVTPQPKLSMGSGVEIPPSFYFWE 60
Qy 61 LATAPDVRIISMRGRHFGHGFSTRPPIHKDYVNRFLFWMTGSGGFLRISNLQKOD 120
Db 61 LATAPDVRIISMRGRHFGHGFSTRPPIHKDYVNRFLFWMTGSGGFLRISNLQKOD 120
Qy 121 SVYFCRVELDTRSSGROQWOSIEGTSLSTQAVTTTTPRSSMTTWRLSTTTTGLRV 180
Db 121 SVYFCRVELDTRSSGROQWOSIEGTSLSTQAVTTTTPRSSMTTWRLSTTTTGLRV 180
Qy 181 TQGRKRSDSWHISLETAVGAVAATVVLGIMILGLICLLMRRRRKGQRTATTPAREPFQ 240
Db 181 TQGRKRSDSWHISLETAVGAVAATVVLGIMILGLICLLMRRRRKGQRTATTPAREPFQ 240

Db 152 -----GOQRTATTPAREPFQ 167
Qy 241 NTEEPYENIRNEGONTDPKLNPKDDGIYVASIALSSSTSPRAPPSPHRL 289
Db 168 NTEEPYENIRNEGONTDPKLNPK---LHUTOSTSQPPSQEPPEPDPV 212

RESULT 3

09UKJO PRELIMINARY; PRT; 227 AA.
ID 09UKJO
AC 09UKJO
DT 01-MAY-2000 (TReMBLrel. 13, Created)
DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
DT 25-OCT-2004 (TReMBLrel. 28, Last annotation update)
DE Activating receptor PILRBeta (Hypothetical protein DKFZp4340079).
GN Name=DKFZp4340079;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.

RC TISSUE=Testis;
RX MEDLINE=20127940; PubMed=10660620; DOI=10.1074/jbc.275.6.4467;
RA Mousseau D.D., Banville D., L'Abbe D., Bouchard P., Shen S.H.,
RT "PILRBeta, a novel immunoreceptor tyrosine-based inhibitory motif-
RT bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is
RT paired with the truncated counterpart PILRBeta";
RL J. Biol. Chem. 275:4467-4474(2000).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA The German cDNA Consortium;
RA Pouska A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weill B., Amd C., Oeanger A., Fobg G., Han M., Wiemann S.;
RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF161081; AAD52965.1; -.
DR EMBL; AL834336; CAH10711.1; -.
DR Inact; 09UKJO; -.
DR GO; GO:0005887; C:integral to plasma membrane; NAS.
DR GO; GO:000515; F:protein binding; IPT.
DR GO; GO:000771; P:transmembrane receptor protein tyrosine kin. .; NAS.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR SMART; SM00409; IG; 1.
DR PROSITE; PSS0835; IG LIKE; 1.
KW Hypothetical protein; Receptor.
SQ SEQUENCE 227 AA; 25542 MW; 7FF960C60AB7EF09 CRC64;

Query Match 60.2%; Score 958; DB 2; Length 227;
Best Local Similarity 80.8%; Pred. No. 1.1e-71;
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

Qy 1 MGRPILPLPLPLPPAFLOPSSGTSYLYGVTPQPKLSMGSGVEIPPSFYFWE 60
Db 1 MGRPILPLPLPLPPAFLOPSSGTSYLYGVTPQPKLSMGSGVEIPPSFYFWE 60
Qy 61 LATAPDVRIISMRGRHFGHGFSTRPPIHKDYVNRFLFWMTGSGGFLRISNLQKOD 120
Db 61 LATAPDVRIISMRGRHFGHGFSTRPPIHKDYVNRFLFWMTGSGGFLRISNLQKOD 120
Qy 121 SVYFCRVELDTRSSGROQWOSIEGTSLSTQAVTTTTPRSSMTTWRLSTTTTGLRV 180
Db 121 SVYFCRVELDTRSSGROQWOSIEGTSLSTQAVTTTTPRSSMTTWRLSTTTTGLRV 180
Qy 181 TQGRKRSDSWHISLETAVGAVAATVVLGIMILGLICLLMRRRRKGQRTATTPAREPFQ 240
Db 173 TQGRKRSDSWHISLETAVGAVAATVVLGIMILGLICLLMRRRRKGQRTATTPAREPFQ 221
RESULT 4
Qy 08BYA6 PRELIMINARY; PRT; 299 AA.
ID 08BYA6
AC 08BYA6

DT 01-MAR-2003 (Tremblrel. 23, Created)
 DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
 DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
 DE Mus musculus 3 days neonate thymus cDNA, RIKEN full-length enriched
 DE library, clone:A630007P20 product:weakly similar to INHIBITORY
 DE RECEPTOR P1LRALPHA.
 GN Name=P1Lra; Synonym=AV021745;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Thymus;
 RX MEDLINE=9279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
 RA Carninci P., Hayashizaki Y.;
 RT "High-efficiency full-length cDNA cloning";
 RL Mech. Enzymol. 303:19-44(1999).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Thymus;
 RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
 RA RIKEN FANTOM Consortium;
 RT "Functional annotation of a full-length mouse cDNA collection";
 RL Nature 409:685-690(2001).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Thymus;
 RA the FANTOM Consortium;
 RT "Analysis of the mouse transcriptome based on functional annotation of
 60,770 full-length cDNAs";
 RL Nature 420:563-573(2002).
 RN [4]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Thymus;
 RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
 RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
 RA Kono H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
 RT "Normalization and subtraction of cap-trapper-selected cDNAs to
 prepare full-length cDNA libraries for rapid discovery of new genes";
 RL Genome Res. 10:1617-1630(2000).
 RN [5]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Thymus;
 RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
 RA Shibata K., Itoh M., Azawa K., Nagaoka S., Sasaki N., Carninci P.,
 RA Kono H., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,
 RA Suni N., Ishii Y., Nakamura S., Hazama M., Nishino T., Harada A.,
 RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
 RA Fujiwaki S., Inoue K., Togawa Y., Izawa M., Ohara E., Wachihi M.,
 RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsura S., Kawai J.,
 RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
 RT "RIKEN integrated sequence analysis (RISA) system-384-format
 sequencing pipeline with 384 multicapillary sequencer";
 RL Genome Res. 10:1757-1771(2000).
 RN [6]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Thymus;
 RA Adachi J., Azawa K., Akimura T., Arakawa T., Bono H., Carninci P.,
 RA Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,
 RA Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,
 RA Hori F., Imocani K., Ishii Y., Itoh M., Kagawa I., Kasukawa T.,
 RA Katoh H., Kawai J., Kojima Y., Kondo S., Kono H., Kouda M., Koya S.,
 RA Kuyihara C., Matsumura T., Miyazaki A., Murata M., Nakamura M.,
 RA Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,
 RA Saito R., Saitoh H., Sakai C., Sakai K., Sakazume N., Sano H.,
 RA Sasaki D., Shibata K., Shingawa A., Shiraki T., Sogabe Y., Tagami M.,
 RA Tagawa A., Takahashi F., Takaku-Akahira S., Takeda Y., Tanaka T.,
 RA Tomaru A., Toya T., Yasunishi A., Muramatsu M., Hayashizaki Y.;
 RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AK041413; BAC30935.1; -
 DR MGD; MGI:2450529; P1Lra.

DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR007110; Ig-like.
 KW Receptor.
 SQ SEQUENCE 299 AA; 32992 MW; 11580C3E1B3F74F CRC64;
 Query Match 39.6%; Score 630; DB 2; Length 299;
 Best Local Similarity 44.4%; Pred. No. 3.2e-44;
 Matches 136; Conservative 56; Mismatches 96; Indels 18; Gaps 6;
 QY 5 LLLPLLLPLD-----PAFLPDSGSGSPSYLYGYTOPKHLASMGSGVEIIPSPFY 57
 DB 4 VVLSMPFVTVPCSGFRVSPSF--PQNSERSNRKNGFGVNPQSCSGVGSGSIDIPFSYF 61
 QY 58 PWEIATAPDVIRISRRGHGHCQSFYRPPSIRHDDYNNRLPLMTEGKSGFELISNLOK 117
 DB 62 PFKLAKOPMSIARWMDPHEPIYNSLSPFIHFHFGRLILNWTQGTGSLVILNLKE 121
 QY 118 QDSVYPCFVELDRSSGRQOQMSIEGTLKSLITQAVTTTQRPSPMTTWRLSSTTTTG 177
 DB 122 SDQTRFGRVFLQI-TSGIQFWQSIPTQLNVTNATCTPTLPST-----TAATSHTQ 174
 QY 178 LRVTGKRRSDSWHISLETAVGVAVATVIGIMLGLICLRMRKRGQRTKATTPARE 237
 DB 175 NDITEVK-SANIGGLDITQITVGLATAAVFLVGLVFLMWRRRRQGGTKKAIIPARE 233
 QY 238 PFQNTPEYENIRNGONTDPKLPKDDGYVYASLALSSSTSPRAPSPHRLKSPONETL 297
 DB 234 PLR-TSEKHSGVGHGQMDPENKDNNTVYASISLSSPTSGTAPMLPVHGNPQETV 292
 QY 298 YSVLKA 303
 DB 293 YSIVKA 298
 RESULT 5
 AXL2 YEAST STANDARD; PRT; 823 AA.
 ID AXL2 YEAST
 AC P38928; 096VY8;
 DT 01-FEB-1995 (Rel. 31, Created)
 DT 01-FEB-1995 (Rel. 31, Last sequence update)
 DT 25-OCT-2004 (Rel. 45, Last annotation update)
 DE AXL2 protein precursor (SR04 protein).
 GN Name=AXL2; Synonyms=REV7, SR04; Ordered locus names=YIL140W;
 OS Saccharomyces cerevisiae (Baker's yeast).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
 OC NCBI_TaxID=4932;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Roemer T., Madden K., Chang J., Snyder M.;
 RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=S288C / AB972;
 RX MEDLINE=97313266; PubMed=9169870;
 RA Churcher C.M., Bowman S., Badcock K., Bankier A., Brown D.,
 RA Chillingworth T., Connor R., Devlin K., Gentles S., Hamlin N.,
 RA Harris D.B., Hornebell T., Hunt S., Jagsels K., Jones M., Lye G.,
 RA Moulis S., Odell C., Pearson D., Rajandream M.A., Rice P., Rowley N.,
 RA Skelton J., Smith V., Walsh S., Whitehead S., Barrett B.G.;
 RT "The nucleotide sequence of Saccharomyces cerevisiae chromosome IX";
 RL Nature 387:84-87(1997).
 RN [3]
 RP SEQUENCE OF 1-775 FROM N.A.
 RA Mathew P.W.;
 RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
 RN [4]
 RP SEQUENCE OF 80-823 FROM N.A.
 RA Torpey L.E., Gibbs P.E.M., Nelson J., Lawrence C.W.;
 RL Submitted (MAR-1994) to the EMBL/GenBank/DBJ databases.
 RN [5]
 RP INTERACTION WITH BUD5.
 RX PubMed=11313501; DOI=10.1126/science.1060360;

RA Kang P.J., Sanson A., Lee B., Park H.-O.;
RT "A GTP/GMP exchange factor involved in linking a spatial landmark to
RT cell polarity".
RL Science 292:1376-1378(2001).
CC -|- FUNCTION: Required for axial budding pattern.
CC -|- SUBUNIT: Interacts with BUD5.
CC -|- SUBCELLULAR LOCATION: Must be delivered to the plasma membrane via
CC the secretory pathway. Once anchored in the plasma membrane, it
CC may recruit additional components to the incipient bud site.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.1sb-sib.ch/announce/>
CC or send an email to license@1sb-sib.ch).
CC -----
DR EMBL; U49845; AAA98666.1; -;
DR EMBL; Z38059; CAA86138.1; -;
DR EMBL; AF395906; AAK81884.1; -;
DR EMBL; U07228; AAA67919.1; -;
DR PIR; S48394; S48394.
DR GerMOnLine; 139675; -;
DR SGD; S000001402; AXL2.
DR InterPro; IPR006644; Ccdg.
DR InterPro; IPR008009; He_PIG.
DR Pfam; PF05345; He_PIG; I.
DR SMART; SM00736; CADG; 4.
KW Glycoprotein; Signal; Transmembrane.
FT SIGNAL 1 22 potential.
FT CHAIN 23 823 AXL2 protein.
FT TRANSMEM 509 529 potential.
FT CARBOHYD 41 41 N-linked (GlcNAc...) (potential).
FT CARBOHYD 50 50 N-linked (GlcNAc...) (potential).
FT CARBOHYD 96 96 N-linked (GlcNAc...) (potential).
FT CARBOHYD 117 117 N-linked (GlcNAc...) (potential).
FT CARBOHYD 163 163 N-linked (GlcNAc...) (potential).
FT CARBOHYD 260 260 N-linked (GlcNAc...) (potential).
FT CARBOHYD 266 266 N-linked (GlcNAc...) (potential).
FT CARBOHYD 304 304 N-linked (GlcNAc...) (potential).
FT CARBOHYD 324 324 N-linked (GlcNAc...) (potential).
FT CARBOHYD 359 359 N-linked (GlcNAc...) (potential).
FT CARBOHYD 382 382 N-linked (GlcNAc...) (potential).
FT CARBOHYD 389 389 N-linked (GlcNAc...) (potential).
FT CARBOHYD 403 403 N-linked (GlcNAc...) (potential).
FT CARBOHYD 447 447 N-linked (GlcNAc...) (potential).
FT CARBOHYD 451 451 N-linked (GlcNAc...) (potential).
FT CARBOHYD 495 495 N-linked (GlcNAc...) (potential).
FT CARBOHYD 595 595 N-linked (GlcNAc...) (potential).
FT CARBOHYD 649 649 N-linked (GlcNAc...) (potential).
FT CARBOHYD 663 663 N-linked (GlcNAc...) (potential).
FT CARBOHYD 737 737 N-linked (GlcNAc...) (potential).
FT CARBOHYD 803 803 N-linked (GlcNAc...) (potential).
SQ SEQUENCE 823 AA; 90783 MW; 350D79758BF30771 CRC64;
Query Match 9.1%; Score 144.5; DB 1; Length 823;
Best Local Similarity 24.7%; Pred. No. 0.0031;
Matches 72; Conservative 45; Mismatches 96; Indels 79; Gaps 16;
QY 25 TSGSPSYLYGV-TQPKLASM--GGSVEIPPSFYPMELATAPDV-----RISWRR 73
DB 308 SGSVPELLKSNSPANFSVIYDTGVD-----IYNFEVSTTDLFAISLPININATR 362
QY 74 GHRHGGSFYSTRPSIKHYVNR---LFLN-----WTGQKS-----GFLRIS 113
DB 363 GEFWSYFL-----PSQPTDYNTNVSLEFTNSGDHDMVKFQSSNLTLAGVEPKNPKLS 418
QY 114 -----NLQKODQSYFRCVELDTRSSGRQOMOSIEGFKLSITQAVTTTQRPSSMTTWR 168
DB 419 LGLKANQGSQSELYFNIIIGDKSKITSHNSANATSTRSS--HHSITSTSYSSITTTAK 475
QY 169 LSSFT---TTTGLRVTOGKRKRSDSWHISLETAVGAVAVTV-LGIMILGLIC-LLRWRR 223

DB 476 ISTSAATSSAPALPAANKTSSHN---KKAVAIACGVAIPGLVILVALICFLIPWRRR 532
QY 224 KQOQRK-----ATTPAREPQNTREYEYENIRNGOYTPDKLNKXD 265
DB 533 RNPDPENLPHAISGPLNPNANKPNQ-----ENATPLNPFDD 571
RESULT 6
ID Q6UX24 PRELIMINARY; PRT; 290 AA.
AC Q6UX24;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE PIGR.
GN OLFNames=UNQ3105;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA Eaton D., Foster J., Grimaldi C., Gu Q., Haas P.E., Heidens S.,
RA Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
RA Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA Vandlen R., Watanabe C., Weand D., Woods K., Xie M.H., Yansura D.,
RA Yi S., Yu G., Yuan Y., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA Godowski P.;
RT "The secreted protein discovery initiative (SPDI), a large-scale
RT effort to identify novel human secreted and transmembrane proteins: a
RT bioinformatics assessment.";
RL Genome Res. 13:2265-2270(2003).
DR EMBL; AY358545; AAO88909.1; -;
DR InterPro; IPR001986; EPPS_synth.
DR InterPro; IPR003599; IG_1like.
DR InterPro; IPR007110; IG_1like.
DR SMART; SM00409; IG_1.
DR PROSITE; PS00104; EPPS_SYNTHASE_1; UNKNOWN_1.
DR PROSITE; PS50835; IG_LIKE_1.
SQ SEQUENCE 290 AA; 32335 MW; B3D84A6B417AB941 CRC64;
Query Match 8.7%; Score 139; DB 2; Length 290;
Best Local Similarity 23.7%; Pred. No. 0.0024;
Matches 78; Conservative 49; Mismatches 126; Indels 76; Gaps 16;
QY 7 LPLPLPLPPAFIOPSGTSGSPSYLYGVTPKHLASWGSVEIPPSFYPMELATAPD 66
DB 1 MPLLTLYLLPLF-----SGYSTATQITGTPTVNGLEKSLITQCVYRSGMETYLK-- 51
QY 67 VRISWRGHFGHQSFPYSTRPSIHKDYVNRFLNMTGKSGFLRIS--NLQKODQSYF 124
DB 52 ---WMCRGAIWRPDKILVTKSGEGE-VKRDVSIKDNQKNRTFTVMTEDLMKTDADFTW 107
QY 125 CRVELDTRSSGRQOMOSIEGFKLSITQAVTTTQRPSSMTTWRSLSTTTTGLRVTOGK 184
DB 108 CGIEK-----TGNDLGVTVQVITD--PAPYQE-ETSSSPFLTG----- 143
QY 185 RSDSWHISLETAVGAVAVTVLGIILGLILKLRKRRKGOORTATTPAR--EPPQNT 242
DB 144 HHLDNHKLKLSVLLPLFTLL-LILLVAASLLMRMKYQOKAAGSPQVLOPLBG- 201
QY 243 EEPYENIRNGOYTPD-----KLN-----EPDGIYVASIALSSSTSP 280
DB 202 DLCAVADLTQLAGTSRKATTKLSSAOVDVEVEVYTMASLPRED-ISAASLTIGA--ED 258
QY 281 RKP-----PSHRPKSPQNETLYSVL 301
DB 259 QEPYCNMGLSHSLPGRGPPEPTEYSTI 287

```
RESULT 7
Q726A6 PRELIMINARY; PRT; 290 AA.
AC Q726A6;
DT 01-OCT-2003 (TREMBlrel. 25, Created)
DT 01-OCT-2003 (TREMBlrel. 25, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE Inhibitory receptor IREMI.
GN Name=IREMI;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Alvarez-Errico D., Kitzig F., Sayos J., Lopez-Botet M.;
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY303545; AAF57942.1; -.
DR HSSP; O95944; IHKF.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR001986; EESP_synth.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR SMART; SM00409; IG; 1.
DR PROSITE; PS00104; EESP_SYNTHASE_1; UNKNOWN_1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR Receptor.
SQ SEQUENCE 290 AA; 32354 MW; E9D84A6B417AA9B CRC64;

Query Match 8.7%; Score 139; DB 2; Length 290;
Best Local Similarity 23.7%; Pred. No. 0.0024;
Matches 78; Conservative 49; Mismatches 126; Indels 76; Gaps 16;

QY 7 LPLPLLPAPFLQPSGSGSYLYGVTPQKHLASMGSGVEIPFSFYPMELATAPD 66
DB 1 MPLLTLYLLFWL-----SGYSIAQTQITGPTVNGLERSLTVQCYVRSGMETYLK-- 51
QY 67 VRISMRGHFGQSFYSTRPSIHKDYVNRFLFNTTEGQSGFLRIS--NLQKODQSYVF 124
DB 52 ---WMCRAIWRDCKILVKTSGSEQ--VKRDVSIKDNQKRTFTVWMEDLMKTDADTYW 107
QY 125 CRVELDTRSSGRQMGQSIETGKLSITQAVTTTQRPSSMTTWRSLSTTTTGLRVYQK 184
DB 108 CGIERK-----TGNDLGVTQVTTD--PAVTOE-ETSSSPITLTG----- 143
QY 185 RRSDSWHISLETAVGAVAVTVLIGIMILGLICLWRRRKQGOQRTKATTPAR--EPQNT 242
DB 144 HHLNDRHKLKLSVLLPLIFTL--LLLVASLLAMRMKTYQQAAGMSPEQVLQPLEG- 201
QY 243 EEPYENIRNEGQNTDP-----KLN-----PKDDGIYASIALSSSTSP 280
DB 202 DLCAVDLTQLAGTSPRKATTKLSSAQVDQVEVEYVTVMAISLPKED--ISYASLTIGA--ED 258
QY 281 RAP-----PSHRPLKSPQNETLYSVL 301
DB 259 QEPYCNMGHLSHLPGRGPEEPTEYSTI 287

RESULT 8
Q8TD01 PRELIMINARY; PRT; 290 AA.
AC Q8TD01;
DT 01-JUN-2002 (TREMBlrel. 21, Created)
DT 01-JUN-2002 (TREMBlrel. 21, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE NK inhibitory receptor.
GN Name=NKIR;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
```

```
RN [1]
RP SEQUENCE FROM N.A.
RX Pubmed=15184070; DOI=10.1016/j.jbirc.2004.05.065;
RA Sut L., Li N., Liu Q., Zhang W., Wan T., Wang B., Luo K., Sun H.,
RA Cao X.;
RT "IGSF1, a novel human inhibitory receptor of the immunoglobulin
RT superfamily, is preferentially expressed in dendritic cells and
RT monocytes.";
RL Biochem. Biophys. Res. Commun. 319:920-928(2004).
DR EMBL; AF251706; AAM19099.1; -.
DR HSSP; O95944; IHKF.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR001986; EESP_synth.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR SMART; SM00409; IG; 1.
DR PROSITE; PS00104; EESP_SYNTHASE_1; UNKNOWN_1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR Receptor.
SQ SEQUENCE 290 AA; 32395 MW; D14FC04A047AAD10 CRC64;

Query Match 8.5%; Score 136; DB 2; Length 290;
Best Local Similarity 23.7%; Pred. No. 0.0042;
Matches 78; Conservative 48; Mismatches 127; Indels 76; Gaps 16;

QY 7 LPLPLLPAPFLQPSGSGSYLYGVTPQKHLASMGSGVEIPFSFYPMELATAPD 66
DB 1 MPLLTLYLLFWL-----SGYSIAQTQITGPTVNGLERSLTVQCYVRSGMETYLK-- 51
QY 67 VRISMRGHFGQSFYSTRPSIHKDYVNRFLFNTTEGQSGFLRIS--NLQKODQSYVF 124
DB 52 ---WMCRAIWRDCKILVKTSGSEQ--VKRDVSIKDNQKRTFTVWMEDLMKTDADTYW 107
QY 125 CRVELDTRSSGRQMGQSIETGKLSITQAVTTTQRPSSMTTWRSLSTTTTGLRVYQK 184
DB 108 CGIERK-----TGNDLGVTQVTTD--PAVTOE-ETSSSPITLTG----- 143
QY 185 RRSDSWHISLETAVGAVAVTVLIGIMILGLICLWRRRKQGOQRTKATTPAR--EPQNT 242
DB 144 HHLNDRHKLKLSVLLPLIFTL--LLLVASLLAMRMKTYQQAAGMSPEQVLQPLEG- 201
QY 243 EEPYENIRNEGQNTDP-----KLN-----PKDDGIYASIALSSSTSP 280
DB 202 DLCAVDLTQLAGTSPRKATTKLSSAQVDQVEVEYVTVMAISLPKED--ISYASLTIGA--ED 258
QY 281 RAP-----PSHRPLKSPQNETLYSVL 301
DB 259 QEPYCNMGHLSHLPGRGPEEPTEYSTI 287

RESULT 9
Q72715 PRELIMINARY; PRT; 293 AA.
AC Q72715;
DT 01-OCT-2003 (TREMBlrel. 25, Created)
DT 01-OCT-2003 (TREMBlrel. 25, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE Immune receptor expressed on myeloid cells splice variant 1.
GN Name=IREMI;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Alvarez-Errico D., Kitzig F., Sayos J., Lopez-Botet M.;
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF375480; AAF42152.1; -.
DR HSSP; O95944; IHKF.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR SMART; SM00409; IG; 1.
```

DR PROSITE; PS50835; IG_LIKE; 1.
 KM RECEPTOR.
 SQ SEQUENCE 293 AA; 32655 MW; 66EBBA2F8D3CF43E CRC64;
 Query Match 8.5%; Score 135.5; DB 2; Length 293;
 Best Local Similarity 22.8%; Pred. No. 0.0047;
 Matches 75; Conservative 51; Mismatches 128; Indels 75; Gaps 16;
 7 LPLPLPLPPAPLOPSSGSGSYLVQOPKHLISMGSVSEIIPSEFYYPWELTAPD 66
 3 LPQLDL-----MKVISAQSGSIAIQTGPTTVNGLESGSLVQCVVSGMEYLUK-- 54
 67 VRISWRGHFHGSGFVSTRPPSIHKDVNRLFLNTEGQSGSLRLS--NMQKODSVYP 124
 55 ---WMCGLAIWROCKILVKTSGSGQE-VKRDVSIKDNQKNRFFPTVMELMTADPTW 110
 125 CRVELDTRSSGRQWOSIEGKLSITQAVTTTTPRPSMTTWRLSSTTTTGLRVTQCK 184
 111 CGIEK-----TNDLGVTVQVTVID--PAVTVQE-EISSSPILTQ----- 146
 185 RASDSWHISLETAVGVAVAVTVGIMTGLICLLRWRRRKGQORTKATTPAR--EPRQNT 242
 147 HHLDNHKLILKLSLPLPLTTL-LLLVLAASLLAMWKKYQQQAAGMSPEQVLQPLEG- 204
 243 EEPYENIRNEGQNTDP-----KLN-----PRDDGIVVASLASSSTSP 280
 205 DLQCADTLTQAGTSPKATTKLSSAQVDQVEVEYVTMAFLPKED-ISVASLTIGA--ED 261
 281 RAP-----PSHRPLKSPQNTLSVL 301
 262 QEPYTCNMGHLSHLPGRGPEEPTEYSTI 290
 RESULT 10
 ID SITE_HUMAN STANDARD; PRT; 499 AA.
 AC Q9NYZ4;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 25-OCT-2004 (Rel. 45, Last annotation update)
 DE Stialic acid binding Ig-1-like lectin 8 precursor (siglec-8)
 DE (Stialoadhesin family member-2) (SAF-2).
 GN Name=SIGLEC8; Synonyms=SAF2;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OC NCBI_TaxId=9606;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RX MEDLINE=20549027; PubMed=11095963; DOI=10.1006/bdrc.2000.3866;
 RA Fousheas G., Yousef G.M., Diamandis E.P.;
 RT "Molecular characterization of a siglec8 variant containing
 cytoplasmic tyrosine-based motifs, and mapping of the siglec8 gene";
 RL Biochem. Biophys. Res. Commun. 278:775-781(2000).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM 3).
 RX MEDLINE=20314554; PubMed=10856141; DOI=10.1067/mai.2000.107127;
 RA Kikly K.K., Bochner B.S., Freeman S.D., Tan K.B., Gallagher K.T.,
 RA D'Alessio K.J., Holmes S.D., Abrahamson J.A., Erickson-Miller C.L.,
 RA Mordock P.R., Tachimoto H., Schleimer R.P., White J.R.;
 RT "Identification of SAF-2, a novel siglec expressed on eosinophils,
 mast cells, and basophils";
 RL J. Allergy Clin. Immunol. 105:1093-1100(2000).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM 3).
 TTSSUB=Basophil;
 RX MEDLINE=20092847; PubMed=10625519; DOI=10.1074/jbc.275.2.861;
 RA Floyd H., Ni J., Cornish A.L., Zeng Z., Liu D., Carter K.C., Steel J.,
 RA Crocker P.R.;
 RT "siglec-8, A novel eosinophil-specific member of the immunoglobulin
 superfamily";
 RL J. Biol. Chem. 275:861-866(2000).
 RN [4]

RP SEQUENCE FROM N.A. (ISOFORM 2).
 RA Floyd H., Zhang J.O., Crocker P.R.;
 RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.
 CC
 CC -1- FUNCTION: Putative adhesion molecule that mediates stialic-acid
 dependent binding to cells. Preferentially binds to alpha2,3-linked
 stialic acid. Also binds to alpha2,6-linked stialic acid. The
 CC stialic acid recognition site may be masked by cis interactions
 with stialic acids on the same cell surface.
 CC
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
 CC
 CC -1- ALTERNATIVE PRODUCTS: Type I membrane protein.
 CC
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=1; Synonyms=long;
 CC IsoId=Q9NYZ4-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=Q9NYZ4-2; Sequence=VSP_002559;
 CC Name=3;
 CC IsoId=Q9NYZ4-3; Sequence=VSP_002560;
 CC
 CC -1- TISSUE SPECIFICITY: Expressed specifically on eosinophils.
 CC -1- DOMAIN: Contains 1 copy of a cytoplasmic motif that is referred to
 CC as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This
 CC motif is involved in modulation of cellular responses. The
 CC phosphorylated ITIM motif can bind the SH2 domain of several SH2-
 CC containing phosphatases.
 CC
 CC -1- SIMILARITY: Belongs to the immunoglobulin superfamily. SIGLEC
 CC (stialic acid binding Ig-1-like lectin) family.
 CC -1- SIMILARITY: Contains 2 immunoglobulin-like C2-type domains.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like V-type domain.
 CC
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; AF287892; AAG00573.1; -
 CC EMBL; AF223403; AAF34702.1; -
 CC EMBL; AF195092; AAF27622.1; -
 CC EMBL; AF310234; AAK55140.1; -
 CC HSSP; Q9Y286; 1078.
 CC
 CC DR GeneW; HGNC:10877; SIGLEC8.
 CC
 CC DR GO; GO:0016021; C:integral to membrane; TAS.
 CC DR GO; GO:0005529; F:sugar binding; TAS.
 CC DR GO; GO:0004888; F:transmembrane receptor activity; TAS.
 CC DR GO; GO:007165; P:signal transduction; TAS.
 CC DR InterPro; IPR007110; Ig-1-like.
 CC DR InterPro; IPR003598; Ig_C2.
 CC DR Pfam; PF00047; Ig_2.
 CC DR SMART; SM00408; IGC2; 1.
 CC DR PROSITE; PS50835; IG_LIKE; 2.
 CC
 CC KW Alternative splicing; Cell adhesion; Glycoprotein;
 CC Immunoglobulin domain; Lectin; Repeat; Signal; Transmembrane.
 CC
 CC FT CHAIN 1
 CC FT SIGNAL 16
 CC FT DOMAIN 17 499
 CC FT DOMAIN 17 363
 CC FT TRANSMEM 364 384
 CC FT DOMAIN 385 489
 CC FT DOMAIN 40 123
 CC FT DOMAIN 157 240
 CC FT DOMAIN 246 344
 CC FT DOMAIN 445 450
 CC FT SITE 468 473
 CC FT SITE 468 473
 CC FT DISULFID 42 181
 CC FT DISULFID 47 107
 CC FT DISULFID 175 224
 CC FT DISULFID 283 328
 CC FT CARBOHYD 172 172
 CC FT CARBOHYD 249 249
 CC FT CARBOHYD 267 267
 CC FT CARBOHYD 267 267
 CC FT VARSPLIC 152 245

TTSTVRDLVSY -> D (in isoform 2).
 FT FT VARSPLIC 416 499 /FTID=VSP 0025559.
 FT FT Q6GX36 GPTLSMKDGNPKRPPPAVAPSSGSEBGLHAYATLSFKHKV
 FT FT Q6GX36 PQDPQOQATDSEYSEIKIHKRETEYACLNHNPSSKEV
 FT FT Q6GX36 RQ -> VSDVGFSTPSIQPHL (in isoform 3).
 FT FT Q6GX36 /FTID=VSP 002560.
 SQ SEQUENCE 499 AA; 54042 MW; 086E9F98974123C CRC64;
 Query Match 8.2%; Score 130.5; DB 1; Length 499;
 Best Local Similarity 22.6%; Pred. No. 0.024;
 Matches 83; Conservative 45; Mismatches 138; Indels 101; Gaps 14;
 QY 5 LLLPLPLPLPPAFLOPSGSGSYLYGVYQPHGLSAGSGSEIPEPSFYPMELATA 64
 DB 3 LLLPLPLPLMKGTGHE--GDRPYGDGYLLQVOE--LTVQBSGLCVHPCSFESYPODGMTD 58
 QY 65 PD-VRIISRRGHFHGQSFYSTPSPSIHKDYVNRLEPLNTEGQ-----KSGFLRIISN 114
 DB 59 SDPVHGYVFRFA---GDRPYQDAFVATNPN--DREVQATQGRFOLLGDIWSNDCSLSID 113
 QY 115 LOKODQSYVFCRVE-----LDTRSSGRQO-- 138
 DB 114 ARKDKGYSFFRLERGSMMKYSQOLANYTKQLSVFVATLTHRPDILLGLTLESGHSNLL 173
 QY 139 -----WQSIEGTKLSIT-----QAVTTTQRPSSMTTWRLSTTTTGL 178
 DB 174 TCSVPMACKQGPPIIMISWIGASVSSPGPTTARSSVLTLPKPDHGTSLTCVTLPGTGV 233
 -QY 179 RVTOGKRKRSDS---WHISL-----ETAVGVAVAVTVLGIMILGICL-----L 218
 DB 234 TTTSTVRDLVSYPPNLTMTVYQGDATASTALNGNSSLSYLEGQSLRLVCAVNSNPAPRL 293
 QY 219 RWRRRKGQORTKATTPAPREPON--TEPEYENIRNEGQNTDPKLANPKDGIYASIALSSS 277
 DB 294 SWTR-----GSLITLCPSSRSNGLLELPVHVHDEGEFTCAQNQSGSHISLSISLONE 348
 QY 278 TSPRAP 284
 DB 349 GTGTSRP 355
 RESULT 11
 Q6GX36 PRELIMINARY; PRT; 289 AA.
 AC Q6GX36;
 DT 05-JUL-2004 (TREMBLrel. 27, Created)
 DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
 DE CRMD-binding protein.
 GN Name=Ctr;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10990;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=CD1;
 RA Corbitt K.C., Kuo A.C., Chen F., Crabtree G.R.;
 RL Submitted (JAN-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AY522648; AAS13453.1; -
 DR InterPro: IPR003599; IG-1-like.
 DR InterPro: IPR007110; IG-1-like.
 DR SMART: SM00409; IG, 1.
 DR PROSITE: PS50835; IG LINE; 1.
 SQ SEQUENCE 289 AA; 32831 MW; 9B97CA7C01B6F17D CRC64;
 Query Match 8.2%; Score 130; DB 2; Length 289;
 Best Local Similarity 22.4%; Pred. No. 0.013;
 Matches 69; Conservative 41; Mismatches 114; Indels 84; Gaps 12;
 QY 5 LLLPLPLPLPPAFLOPSGSGSYLYGVYQPHGLSAGSGSEIPEPSFYPMELATA 64
 DB 8 LLSFVLLLL-----ASGS-----WQKPELRAQSEETVSL----- 39

QY 65 PDVRIISRRGHFHGQSFYSTPSPSIHKDYVNRLEPLNTEGQKSGFL-----RI 112
 DB 40 -----TCWYSDLYHSEDKIMCK-----QIDNLCYLFVS--KSARKRPLIQOQSRFNFVTM 90
 QY 113 SNLOKODQSYVFCRVELDTPRSSGRQOQOSIGTKLSITQAVTTTQRPSSMTTWRLST 172
 DB 91 TKLKMSDSGIYHCGIAVTR-----IYIRSLHLVYSKAS--TTTWRTTL 135
 QY 173 TTTGLRVTOGKRKRSDSWHISLETAVGVAVAVTVLGIMILGICLLRWRRKGQORTKAT 232
 DB 136 ASTHSPTVNRSPSPSPMKW---AIVAGVAVVALLLFVILVILYLRKARRKALNVQNOQ 192
 QY 223 TPAREPONTPEPEYENIRNEGQNTDPKLANPKDDG-IYVASL-----ALSSSTPR 281
 DB 193 HPYIEDFSQKEETTSFNQTHSE-----DTGITCYASLIHLNRPVNPDSIYSNTQPY 246
 QY 282 APPSHRPL 289
 DB 247 KPSPDPL 254
 RESULT 12
 Q8TBC9 PRELIMINARY; PRT; 233 AA.
 AC Q8TBC9;
 DT 01-JUN-2002 (TREMBLrel. 21, Created)
 DT 01-JUN-2002 (TREMBLrel. 21, Last sequence update)
 DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Straubeberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.F.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosnak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Faney J., Helton E., Kerteman M., Madan A., Rodriguez S., Sanchez A.,
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Buterfield Y.S.,
 RA Krzywnski M.I., Skalska U., Smalls D.E., Scherch A., Schein J.E.,
 RA Jones S.J., Mair M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RA Straubeberg R.;
 RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL: BC022823; AAH22823.1; -
 DR PIR: S12442; S12442.
 DR PIR: S30525; S30525.
 DR PIR: S30526; S30526.
 DR HSSP: F01842; ILTL.
 DR InterPro: IPR007110; IG-1-like.
 DR InterPro: IPR003597; IG CL.
 DR InterPro: IPR003006; IG MHC.
 DR InterPro: IPR003596; IG V.
 DR Pfam: PF07654; CL-sec; I.

QY 105 QKSGFLRISNLOKODQSYFCRVELDTRSSGQOQOSIEGTLSITQA----- 152
DB 124 DLS--LRVERLMLADRRFCRVEF--AGVDHRYESRRHGLHTAALPRIVNISVLPS 179
QY 153 -----VTTTTPRSSMT-----TWRLSSTT-----TTTG 177
DB 160 AAAPALCTABEGFPPALAMSGPALGNSLAIVRSRFGHGLVTLALHTDGRYTTCTA 239
QY 178 LRVTOGKRSDSWHISLETAVGAVAVTVLG-----IMILGLICLRWRRRKGOQRTKA 231
DB 240 AN-SIGRSEASVYLFRPHGASGASTVALLGLGFKALLLGVL-ABAARRRPHLPTP 297
QY 232 TTPAREPONTPEPENTRNREGQNDPKLPKDDGIVASLALSSSTSPRAPS 285
DB 298 DTPPRS--QAQESNYENL-----SQMNPSPSPA 323

RESULT 15

Q7SDOS PRELIMINARY; PRT; 353 AA.
AC Q7SDOS;
DT 01-MAR-2004 (TREMBlrel. 26, Created)
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)
DT 25-OCT-2004 (TREMBlrel. 28, Last annotation update)
DE Predicted protein (Hypothetical protein B10D6.180).
GN Name=NCU02847.1; Synonyms=B10D6.180;
OS Neurospora crassa.
-OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
[1]

RP SEQUENCE FROM N.A.
RC STRAIN=OR74A;
RA Galagan J.E., Calvo S.E., Borkovich K.A., Selker E.U., Read N.D.,
Jaffe D., Fitzhugh W., Ma L.-J., Smirnov S., Purcell S., Rehman B.,
Elkins T., Engle R., Wang S., Nielsen C.B., Butler J., Endrizzi M.,
Qui D., Ianakiev P., Pedersen D., Nelson M., Maehurne M.,
Selitrennikoff C.P., Kinsey J.A., Braun E.L., Zelter A., Schulte U.,
Koche G.O., Jedd G., Mewes W., Staben C., Marcotte E., Greenberg D.,
Roy A., Foley K., Naylor J., Thomann N., Barrett R., Gnerre S.,
Kamel M., Kamyssele M., Mauceli E., Bielke C., Rudd S., Frishman D.,
Kryofova S., Rasmussen C., Metzberg R.L., Perkins D.D., Kroken S.,
Cogoni C., Macino G., Catchside D., Li W., Pratt R.U., Omani S.A.,
Desouza C.C., Glass L., Orbach M., Berglund J., Voelker R.,
Yarden O., Plamann M., Siller S., Dunlap J., Radford A., Aramayo R.,
Nativg D.O., Alex L.A., Manhaupt G., Ebdole D.J., Freitag M.,
Paulsen I., Sachs M.S., Lander E.S., Nussbaum C., Birren B.,
RT "The Genome Sequence of the Filamentous Fungus Neurospora crassa."
RL Nature 0:0-0(2003).
[2]
*NN SEQUENCE FROM N.A.
RP Schulte U., Aign V., Hohelsel J., Brandt P., Fartmann B., Holland R.,
RA Nyakatura G., Mewes H.W., Manhaupt G.;
RL Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.
[3]
*NN SEQUENCE FROM N.A.
RA German Neurospora genome project;
RL Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL: AABX0100046; EAA34901.1; -.
DR EMBL: BX842624; CAE76234.1; -.
KM Hypothetical protein.
SQ SEQUENCE 353 AA; 36684 MW; CFPD9BA2429891A CRC64;

Query Match 7.8%; Score 123.5; DB 2; Length 353;

Best Local Similarity 23.1%; Pred. No. 0.059; 81; Indels 107; Gaps 12;

Matches 66; Conservative 32; Mismatches 81; Indels 107; Gaps 12;

26 GSGPSYLVGVTPQPKLISASMGSGVEIPFSFYPMWELATAPDVRISMRGHFGQSFYSTR 85

DB 146 GSDPADL-----ATMTISDDKDMFY-----APLIQINMQS-----SDR 179
QY 86 PPSIHKDYVNRFLFLNWTGEGQSGFLRISNLOKODQSYFCRVELDTRSSGQOQOSIEGT 145
DB 180 P-----TETVPSGTVSL-----VDVDTMST-----LAT 203
QY 146 KLSITQAVTTTTPRSSMTTWRLSSTTTTGLRVTOGKRSDSWH-ISLETA--VGVAV 202
DB 204 AGDAPAGVTSRVGPPSOSVVLVSGOSNKPFG--ASEGNKEEDGVKPVSLSTGFRVGMAY 261
QY 203 AVTVGIMILGLICLRWRRRKGOOR-----TKATTPAREPONT----- 243
DB 262 AGVLAVALVAIIFICAWRRRKQMEEEFPDMYGMKOVGSPSTADFRIEELPGWHRGPTR 321
QY 244 ----EPYENIRNEGQNDPKLPKDDGIVASLALSSSTSPRAPS 285
DB 322 RQPPAPVDPFRSDGS-----ELMAPAPAYHPSP 350

Search completed: June 1, 2005, 22:13:16
Job time : 176 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 1, 2005, 21:56:35 ; Search time 162 Seconds
(without alignments)
723.385 Million cell updates/sec

Title: US-10-777-524-2
Perfect score: 1591
Sequence: 1 MGRPLRLPLRLPLPPAFLQ.....PSHRPLKSPQNETLYSVLKA 303

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 10%
Listing first 45 summaries

Database : A.GeneSeq.16Dec04:*

1: Genesegp1980s:*
2: Genesegp1990s:*
3: Genesegp2000s:*
4: Genesegp2001s:*
5: Genesegp2002s:*
6: Genesegp2003as:*
7: Genesegp2003bs:*
8: Genesegp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1591	100.0	303	2	AAW62772 Human imm
2	1591	100.0	303	3	AAW62772 Human imm
3	1588	99.8	303	8	ADP25129 PRO polyp
4	1176.5	73.9	230	3	AAW62772 Human imm
5	1171.5	73.6	230	7	ADP25129 PRO polyp
6	1010.5	63.5	206	7	ADP25129 PRO polyp
7	973.5	61.2	226	2	AAW62772 Human imm
8	973.5	61.2	226	2	AAW62772 Human imm
9	967.5	60.8	226	2	AAW62772 Human imm
10	967.5	60.8	226	2	AAW62772 Human imm
11	958	60.2	227	3	AAW62772 Human imm
12	958	60.2	227	3	AAW62772 Human imm
13	958	60.2	227	3	AAW62772 Human imm
14	958	60.2	227	3	AAW62772 Human imm
15	945	59.4	227	3	AAW62772 Human imm
16	934	58.7	238	6	ABO34539 Region of
17	934	58.7	238	6	ABO34539 Region of
18	934	58.7	238	6	ABO34539 Region of
19	934	58.7	238	6	ABO34539 Region of
20	927.5	58.3	228	8	ADP25129 PRO polyp
21	821	51.6	175	3	AAW62772 Human imm
22	808	50.8	1012	4	ABG16869 Novel hum
23	808	50.8	1012	4	ABG16869 Novel hum
24	808	50.8	1012	4	ABG16869 Novel hum
25	808	50.8	1012	4	ABG16869 Novel hum

26	517	32.5	101	2	AAW75053 Fragment
27	517	32.5	101	6	ABG95614 Human nov
28	517	32.5	101	6	ABG95614 Human nov
29	517	32.5	101	7	ADP25129 PRO polyp
30	511	32.5	101	8	ADP25129 PRO polyp
31	411	25.8	224	5	ADP25129 PRO polyp
32	405.5	25.5	212	7	ADP25129 PRO polyp
33	222	14.0	99	2	AAW62772 Human imm
34	148.5	9.3	305	4	AAU14284 Human nov
35	146.5	9.2	305	4	AAU14284 Human nov
36	146.5	9.2	305	4	AAU14284 Human nov
37	146.5	9.2	305	5	AAU14284 Human nov
38	146.5	9.2	305	5	AAU14284 Human nov
39	146.5	9.2	305	8	ADP25129 PRO polyp
40	146.5	9.2	305	8	ADP25129 PRO polyp
41	146.5	9.2	305	8	ADP25129 PRO polyp
42	146.5	9.2	305	8	ADP25129 PRO polyp
43	145.5	9.1	305	8	ADP25129 PRO polyp
44	139	8.7	290	4	AAW62772 Human imm
45	139	8.7	290	5	AAW62772 Human imm

ALIGNMENTS

AAW62772	1	AAW62772 standard; protein; 303 AA.
XX	XX	AAW62772;
XX	XX	23-SEP-1998 (first entry)
XX	XX	Human immunoglobulin receptor designated FDF03.
XX	XX	Human, type I transmembrane protein; immunoglobulin-like domain; FDF03; activated monocyte; YB01; KTB03; control; development; differentiation; mammalian immune system; treatment; cancerous condition; degenerative condition; autoimmune response; transplantation rejection; graft versus host disease; inflammatory condition; diagnosis; drug screening.
XX	XX	Homo sapiens.
XX	XX	WO9824906-A2.
XX	XX	11-JUN-1998.
XX	XX	05-DEC-1997; 97WO-US021101.
XX	XX	06-DEC-1996; 96US-0032252P.
XX	XX	09-DEC-1996; 96US-00762187.
XX	XX	16-DEC-1996; 96US-0033181P.
XX	XX	21-MAR-1997; 97US-0041279P.
XX	XX	(SCHE) SCHERING CORP.
XX	XX	Adema GJ, Meynard L, Gorman DM, McClanahan TK, Zurawski SM; Zurawski G, Lanier JL, Phillips JH;
XX	XX	WPI; 1998-333325/29.
XX	XX	N-PSDB; AAV38987.
XX	XX	New isolated activated monocyte cell gene(s) - used to develop products for treating e.g. cancer, degenerative conditions, autoimmune responses, transplant rejection or inflammatory conditions.
XX	XX	Claim 1; Page 60-61; 104pp; English.
XX	XX	The present sequence represents a human protein, FDF03, which is a type I transmembrane protein comprising an extracellular portion characterised by immunoglobulin-like domains, indicating that the protein is a receptor member of the immunoglobulin superfamily. The FDF03 gene is found in

CC activated monocytes. The specification also describes other proteins
CC encoded by activated monocytes, which are designated Y601 and KTR63. The
CC genes function in controlling development, differentiation, and/or
CC physiology of the mammalian immune system. The products can be used for
CC treating abnormal proliferation, regeneration, degeneration or atrophy.
CC They can be used for treating e.g. cancerous conditions, degenerative
CC conditions, autoimmune responses, transplantation rejection, graft versus
CC host disease, or inflammatory conditions. The products can also be used
CC for detection, diagnosis and drug screening

XX
SQ Sequence 303 AA;

Query Match 100.0%; Score 1591; DB 2; Length 303;
Best Local Similarity 100.0%; Pred. No. 6.7e-122;

Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRPLLPPLPLLPAPFLQPSGSGPSYLYGVTPQKLSASMGSGVEIPPSFYYPWE 60
DB 1 MGRPLLPPLPLLPAPFLQPSGSGPSYLYGVTPQKLSASMGSGVEIPPSFYYPWE 60

QY 61 LATAPDVRIISMRGHEHFGSGFYSRPSIHKDYVNRFLNWTGQSGFLRISNLQKODQ 120
DB 61 LATAPDVRIISMRGHEHFGSGFYSRPSIHKDYVNRFLNWTGQSGFLRISNLQKODQ 120

QY 121 SVYFCRVELDTRSSGRQWQSIIEGTLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
DB 121 SVYFCRVELDTRSSGRQWQSIIEGTLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180

QY 181 TOGKRSDSWHISLETAAGVAVAVTVLGIMILGICLLMRRRKGGQRTKATTPAREPFO 240
DB 181 TOGKRSDSWHISLETAAGVAVAVTVLGIMILGICLLMRRRKGGQRTKATTPAREPFO 240

QY 241 NTEBPYENIRNEGQNTDPKLNPKDGIYVASLALSSSTSPRAPPSHRLKSPQNETLYSY 300
DB 241 NTEBPYENIRNEGQNTDPKLNPKDGIYVASLALSSSTSPRAPPSHRLKSPQNETLYSY 300

QY 301 LKA 303
DB 301 LKA 303

QY 301 LKA 303
DB 301 LKA 303

RESULT 2
ID AAB07443 standard; protein; 303 AA.

XX
AC AAB07443;

XX
DT 20-OCT-2000 (first entry)

XX
DE A human monocyte-derived protein FDP03.

XX
KW Human; monocyte-derived protein; FDP03; FDP03deltaTM, FDP03-S1;
KW FDP03-M14; FDP03-S2; haematopoietic cell; monocyte hyperplasia;
KW tissue rejection; inflammation; infection.

XX
OS Homo sapiens.

XX
FT Key Location/Qualifiers

FT Peptide 1..19 /note= "signal peptide"

FT Protein 20..303 /note= "mature protein"

XX
PN MO200040721-A1.

XX
PD 13-JUL-2000.

XX
PF 29-DEC-1999; 99MO-US030004.

XX
PR 31-DEC-1998; 98US-00223919.

XX
PR 31-DEC-1998; 98US-00224604.

XX
PA (SCHE) SCHERING CORP.

XX
PI Bates E, Fournier N, Chaulus L, Garrone P;

XX
DR WPI, 2000-465984/40.

XX
DR N-PSDB; AAA58814.

XX
PT Novel monocyte-derived polypeptides and polynucleotides, used to diagnose
PT diseases associated with changes in monocyte numbers, e.g. bacterial or
PT viral infections.

XX
PS Claim 1; Page 32-33; 45pp; English.

XX
CC The present sequence represents a human monocyte-derived protein. The
CC specification describes monocyte-derived proteins FDP03, FDP03deltaTM,
CC FDP03-S1, FDP03-M14, and FDP03-S2. The proteins are involved in the
CC regulation, or development, of haematopoietic cells. Antibodies specific
CC for antigenic components of the proteins can be used to detect the
CC components in samples. The proteins can also be used to screen for
CC candidate therapeutic agents. The monocyte-derived proteins and
CC polynucleotides can be used for diagnosis of diseases related to an
CC increase, or decrease, in the number of monocytes in a tissue or lymph
CC system, such as monocyte hyperplasia, tissue or graft rejection,
CC inflammation, or bacterial or viral infections. The proteins can also be
CC used in the treatment of disorders associated with abnormal expression or
CC signalling by a monocyte

XX
SQ Sequence 303 AA;

Query Match 100.0%; Score 1591; DB 3; Length 303;
Best Local Similarity 100.0%; Pred. No. 6.7e-122;

Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRPLLPPLPLLPAPFLQPSGSGPSYLYGVTPQKLSASMGSGVEIPPSFYYPWE 60
DB 1 MGRPLLPPLPLLPAPFLQPSGSGPSYLYGVTPQKLSASMGSGVEIPPSFYYPWE 60

QY 61 LATAPDVRIISMRGHEHFGSGFYSRPSIHKDYVNRFLNWTGQSGFLRISNLQKODQ 120
DB 61 LATAPDVRIISMRGHEHFGSGFYSRPSIHKDYVNRFLNWTGQSGFLRISNLQKODQ 120

QY 121 SVYFCRVELDTRSSGRQWQSIIEGTLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
DB 121 SVYFCRVELDTRSSGRQWQSIIEGTLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180

QY 181 TOGKRSDSWHISLETAAGVAVAVTVLGIMILGICLLMRRRKGGQRTKATTPAREPFO 240
DB 181 TOGKRSDSWHISLETAAGVAVAVTVLGIMILGICLLMRRRKGGQRTKATTPAREPFO 240

QY 241 NTEBPYENIRNEGQNTDPKLNPKDGIYVASLALSSSTSPRAPPSHRLKSPQNETLYSY 300
DB 241 NTEBPYENIRNEGQNTDPKLNPKDGIYVASLALSSSTSPRAPPSHRLKSPQNETLYSY 300

QY 301 LKA 303
DB 301 LKA 303

QY 301 LKA 303
DB 301 LKA 303

XX
OS Unidentified.

XX
FT Key Location/Qualifiers

FT Peptide 1..19 /note= "signal peptide"

FT Protein 20..303 /note= "mature protein"

XX
PN 18-NOV-2004 (first entry)

XX
PD PRO polypeptide SEQ ID NO:2307.

XX
PF PRO; antiinflammatory; antiatheritic; antirheumatic; immunosuppressive;
XX osteopathic; antidiabetic; dermatological; antiparasitic; antiallergic;
XX antisthmatic; hepatotropic; respiratory; gene therapy; immune system.

XX
PA Unidentified.

PN WO2004041170-A2.
 XX 21-MAY-2004.
 PD 30-OCT-2003; 2003WO-US034312.
 XX 01-NOV-2002; 2002US-0423394P.
 XX (GETH) GENENTECH INC.
 PA Clark H, Schoenfeld J, Van Lookeren M, Williams PM, Wood WI;
 PI Mu TD;
 XX WPI: 2004-419628/39.
 DR N-PSDB; ADP25128.
 XX
 PT New PRO polypeptides and polynucleotides, useful for treating e.g.
 PT erythematous, rheumatoid arthritis, diabetes mellitus, immune-mediated
 PT renal disease, or demyelinating diseases of the central or peripheral
 PT nervous system.
 XX
 PS Claim 7; SEQ ID NO 2307; 2940bp; English.
 XX
 CC The invention relates to a novel isolated nucleic acid and the PRO
 CC polypeptide encoded by it. A protein of the invention has
 CC antiinflammatory, antiarthritic, antirheumatic, immunosuppressive,
 CC osteopathic, antidiabetic, dermatological, antipsoriatic, antiallergic,
 CC antineoplastic, hepatocrotic, and respiratory activity. A polynucleotide
 CC of the invention may have a use in gene therapy. The PRO polypeptide, its
 CC agonist, antagonist, or antibody that specifically binds to the
 CC polypeptide is useful for treating an immune related disorder such as
 CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, an
 CC juvenile chronic arthritis, a spondyloarthropathy, systemic sclerosis, an
 CC idiopathic inflammatory myopathy, Sjogren's syndrome, autoimmune
 CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
 CC thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal
 CC disease, a demyelinating disease of the central or peripheral nervous
 CC system, idiopathic demyelinating polynuropathy, Guillain-Barre syndrome,
 CC a chronic inflammatory demyelinating polynuropathy, a hepatobiliary
 CC disease, infectious or autoimmune chronic active hepatitis, primary
 CC biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis,
 CC inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's
 CC disease, an autoimmune or immune-mediated skin disease, a bullous skin
 CC disease, erythema multiforme, contact dermatitis, psoriasis, an allergic
 CC disease, asthma, allergic rhinitis, atopic dermatitis, food
 CC hypersensitivity, urticaria, an immunologic disease of the lung,
 CC eosinophilic pneumonia, idiopathic pulmonary fibrosis, hypersensitivity
 CC pneumonitis, a transplantacion associated disease, graft rejection or
 CC graft-versus-host disease. The present sequence represents a PRO protein
 CC of the invention.
 XX
 SQ Sequence 303 AA;
 Query Match 99.8%; Score 1588; DB 8; Length 303;
 Best Local Similarity 99.7%; Pred. No. 1,2e-121;
 Matches 302; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MGRPLLPPLLPPLPAFLQPSGSGSPSYLYGYTOPKHLASASMGSGVEIIPFSFYRWE 60
 DB 1 MGRPLLPPLLPPLPAFLQPSGSGSPSYLYGYTOPKHLASASMGSGVEIIPFSFYRWE 60
 QY 61 LATADVAISWRGHFGHOSFSTPSPSTIKDYVRLPLANTTEGKSGFLISNOKQDO 120
 DB 61 LATADVAISWRGHFGHOSFSTPSPSTIKDYVRLPLANTTEGKSGFLISNOKQDO 120
 QY 121 SVYFCRVLDTRSSGROQMSIEGTLKSIITQAVTTTTPSSMTTWLSSSTTTTGLRV 180
 DB 121 SVYFCRVLDTRSSGROQMSIEGTLKSIITQAVTTTTPSSMTTWLSSSTTTTGLRV 180
 QY 181 TQGRKRSWSHISLETAVGAVAVTVLIGIMILGILCLRMRRRKQOQRTKATTPAREPQ 240
 DB 181 TQGRKRSWSHISLETAVGAVAVTVLIGIMILGILCLRMRRRKQOQRTKATTPAREPQ 240

QY 241 NTEPEYENIRNEGONTDPKLNPKDDGIYVASIALSSSTSPRAPSPHRLPKSPONETLYSV 300
 DB 241 NTEPEYENIRNEGONTDPKLNPKDDGIYVASIALSSSTSPRAPSPHRLPKSPONETLYSV 300
 QY 301 LKA 303
 DB 301 LKA 303
 RESULT 4
 AAB07444
 ID AAB07444 standard; protein; 230 AA.
 XX
 AC AAB07444;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE A human monocyte-derived protein FDF03DeltaTM.
 XX
 KW Human; monocyte-derived protein; FDF03; FDF03DeltaTM; FDF03-S1;
 KW FDF03-M14; FDF03-S2; hematopoietic cell; monocyte hyperplasia;
 KW tissue rejection; inflammation; infection.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..17
 FT /note= "signal peptide"
 FT Protein 18..230
 FT /note= "mature protein"
 XX
 PN WO20040721-A1.
 XX
 PD 13-JUL-2000.
 XX
 PF 29-DEC-1999; 99WO-US030004.
 XX
 PR 31-DEC-1998; 98US-00223919.
 PR 31-DEC-1998; 98US-00224604.
 XX
 PA (SCHE) SCHERING CORP.
 PI Bates E, Fournier N, Chalus L, Garrone P;
 DR WPI: 2000-465984/40.
 DR N-PSDB; AAS58815.
 XX
 PT Novel monocyte-derived polypeptides and polynucleotides, used to diagnose
 PT diseases associated with changes in monocyte numbers, e.g. bacterial or
 PT viral infections.
 XX
 PS Claim 1; Page 34-35; 45pp; English.
 XX
 CC The present sequence represents a human monocyte-derived protein. The
 CC specification describes monocyte-derived proteins FDF03, FDF03DeltaTM,
 CC FDF03-S1, FDF03-M14, and FDF03-S2. The proteins are involved in the
 CC regulation, or development, of hematopoietic cells. Antibodies specific
 CC for antigenic components of the proteins can be used to detect the
 CC components in samples. The proteins can also be used to screen for
 CC candidate therapeutic agents. The monocyte-derived proteins and
 CC polynucleotides can be used for diagnosis of diseases related to an
 CC increase, or decrease, in the number of monocytes in a tissue or lymph
 CC system, such as monocyte hyperplasia, tissue or graft rejection,
 CC inflammation, or bacterial or viral infections. The proteins can also be
 CC used in the treatment of disorders associated with abnormal expression or
 CC signalling by a monocyte
 XX
 SQ Sequence 230 AA;
 Query Match 73.9%; Score 1176.5; DB 3; Length 230;
 Best Local Similarity 75.9%; Pred. No. 4.2e-88;
 Matches 230; Conservative 0; Mismatches 0; Indels 73; Gaps 1;

```

QY 1 MGRPLLLP.LP.LLPAPLQPSGSGTSGPSYLYGVTPQKHLASMGSGVEIPPSFYYPWE 60
DB 1 MGRPLLLP.LP.LLPAPLQPSGSGTSGPSYLYGVTPQKHLASMGSGVEIPPSFYYPWE 60
QY 61 LATAPDVRIKWRGHHFGSGFYSTRPPSIHKDYVNLFLNWTBQKSGFLRISNLQKODQ 120
DB 61 LATAPDVRIKWRGHHFGSGFYSTRPPSIHKDYVNLFLNWTBQKSGFLRISNLQKODQ 120
QY 121 SVYECRVELDTRSSGQOMOSIEGTKLSTQAVTTTQRPSSMTTWRISSTTTTGLAV 180
DB 121 SVYECRVELDTRSSGQOMOSIEGTKLSTQ----- 151
QY 181 TQGRKRSDSWHISLETAVGVAVAATVGLIMLGLICLLRWRKRGQORTKATTPAREPFQ 240
DB 152 -----GQORTKATTPAREPFQ 167
QY 241 NTEEPYENIRNEGQNTDPKLNPKODGIVYASLALSSSTSPRAPPSHRPLKSPONETLYSV 300
DB 168 NTEEPYENIRNEGQNTDPKLNPKODGIVYASLALSSSTSPRAPPSHRPLKSPONETLYSV 227
QY 301 LKA 303
DB 228 LKA 230

RESULT 5
ADE95578
ID ADE95578 standard; protein: 230 AA.
XX
AC ADE95578;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human NOVX18a protein.
XX
KW NOVX protein; biochemical stimulation; physiological stimulation;
KW cardiant; antiarteriosclerotic; hypotensive; cytosolic; anorectic;
KW antirheumatic; antiarthritic; antidiabetic; nephrotoxic; dermatological;
KW immunosuppressive; anti-HIV; antiinflammatory; neuroprotective;
KW noctropic; antipsoriatic; antiparkinsonian; antisthmatic; neuroleptic;
KW antidepressant; antiallergic; gynaecological; gene therapy; vaccine;
KW NOVX-associated disorder; cardiomyopathy; atherosclerosis; hypertension;
KW cancer; obesity; rheumatoid arthritis; diabetes; glomerulonephritis;
KW psoriasis; skin disorder; AIDS; inflammation; multiple sclerosis;
KW Alzheimer's disease; Parkinson's disease; asthma; schizophrenia;
KW depression; allergy; fertility disorder; NOVX18a.
XX
OS Homo sapiens.
XX
PN MO2003050245-A2.
XX
PD 19-JUN-2003.
XX
PF 03-DEC-2002; 2002MO-US038594.
XX
PR 05-DEC-2001; 2001US-033600P.
PR 07-DEC-2001; 2001US-038285P.
PR 12-DEC-2001; 2001US-041346P.
PR 17-DEC-2001; 2001US-034147P.
PR 17-DEC-2001; 2001US-041540P.
PR 20-DEC-2001; 2001US-034252P.
PR 27-DEC-2001; 2001US-034429P.
PR 31-DEC-2001; 2001US-034903P.
PR 17-APR-2002; 2002US-0373288P.
PR 15-MAY-2002; 2002US-0380981P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.
PR 29-MAY-2002; 2002US-0384024P.
PR 07-AUG-2002; 2002US-0411788P.
PR 26-AUG-2002; 2002US-0406353P.
PR 31-OCT-2002; 2002US-00401788.

```

```

PR 02-DEC-2002; 2002US-00406353.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Alsbrook JP, Anderson DW, Boldog FL, Burgess CE, Chilikuru RA;
PI Binger SR, Gerlach VL, Gorman L, Gould-Rothberg BE, Guo X;
PI Jeffers ME, Ji W, Li L, Malpankar UM, Miller CE, Murphy R;
PI Paturajan M, Peyman JA, Rastelli L, Rieger DK, Shenoy SG;
PI Smithson G, Stirling G, Taupier RJ, Voas EZ, Zhong H, Zhong M;
DR WPI, 2003-513974/48.
DR N-PDB; ADE95577.
XX
PT New NOVX polypeptides and nucleic acids, useful for preventing or
PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy,
PT atherosclerosis or diabetes, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
PS Claim 2; SEQ ID NO 110; 211pp; English.
XX
CC This invention relates to novel NOVX proteins, and the DNA sequence which
CC encode them, having properties related to stimulation of biochemical or
CC physiological responses in a cell, a tissue, an organ or an organism.
CC Compounds which modulate the proteins of the invention may have cardiant,
CC antiatherosclerotic, hypotensive, cytosolic, anorectic, antirheumatic,
CC antiarthritic, antidiabetic, nephrotoxic, dermatological,
CC immunosuppressive, anti-HIV, antiinflammatory, neuroprotective,
CC noctropic, antipsoriatic, antiparkinsonian, antisthmatic, neuroleptic,
CC antidepressant, antiallergic or gynaecological activities. The DNA
CC sequences of the invention may be useful for gene therapy whilst the
CC protein sequences may allow the development of a vaccine. The protein is
CC useful in the manufacture of a medicament for treating a syndrome
CC associated with a human disease. The invention may be useful in
CC diagnosing, treating or preventing NOVX-associated disorders, for example
CC cardiomyopathy, atherosclerosis, hypertension, cancer, obesity,
CC rheumatoid arthritis, diabetes, glomerulonephritis, psoriasis, skin
CC disorders, AIDS, inflammation, multiple sclerosis, Alzheimer's disease,
CC Parkinson's disease, asthma, schizophrenia, depression, allergies or
CC fertility disorders. The nucleic acids may further be used as
CC hybridisation probes, in chromosome mapping, tissue typing, preventive
CC medicine, and pharmacogenomics. The present sequence is the amino acid
CC sequence of the human NOVX18a protein of the invention.
XX
SQ Sequence 230 AA:
Query Match 73.6%; Score 1171.5; DB 7; Length 230;
Best Local Similarity 75.6%; Pred. No. 1.1e-87;
Matches 229; Conservative 0; Mismatches 1; Indels 73; Gaps 1;
QY 1 MGRPLLLP.LP.LLPAPLQPSGSGTSGPSYLYGVTPQKHLASMGSGVEIPPSFYYPWE 60
DB 1 MGRPLLLP.LP.LLPAPLQPSGSGTSGPSYLYGVTPQKHLASMGSGVEIPPSFYYPWE 60
QY 61 LATAPDVRIKWRGHHFGSGFYSTRPPSIHKDYVNLFLNWTBQKSGFLRISNLQKODQ 120
DB 61 LATAPDVRIKWRGHHFGSGFYSTRPPSIHKDYVNLFLNWTBQKSGFLRISNLQKODQ 120
QY 121 SVYECRVELDTRSSGQOMOSIEGTKLSTQAVTTTQRPSSMTTWRISSTTTTGLAV 180
DB 121 SVYECRVELDTRSSGQOMOSIEGTKLSTQ----- 151
QY 181 TQGRKRSDSWHISLETAVGVAVAATVGLIMLGLICLLRWRKRGQORTKATTPAREPFQ 240
DB 152 -----GQORTKATTPAREPFQ 167
QY 241 NTEEPYENIRNEGQNTDPKLNPKODGIVYASLALSSSTSPRAPPSHRPLKSPONETLYSV 300
DB 168 NTEEPYENIRNEGQNTDPKLNPKODGIVYASLALSSSTSPRAPPSHRPLKSPONETLYSV 227
QY 301 LKA 303
DB 228 LKA 230

```


RESULT 6
ADE95580
ID ADE95580 standard; protein, 206 AA.
XX
AC ADE95580;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human NOVX18b protein.
XX
KW NOVX protein; biochemical stimulation; physiological stimulation;
KW cardiatic; antihypertensive; hypotensive; cytoskeletal; anorectic;
KW antirheumatic; antirheumatic; antidiabetic; nephrotropic; dermatological;
KW immunosuppressive; anti-HIV; antineoplastic; neuroprotective;
KW neurotropic; antiparkinsonian; antiparkinsonian; neuroleptic;
KW NOVX-associated disorder; cardiovascular; gene therapy; vaccine;
KW NOVX-associated disorder; cardiovascular; atherosclerosis; hypertension;
KW cancer; obesity; rheumatoid arthritis; diabetes; glomerulonephritis;
KW psoriasis; skin disorder; AIDS; inflammation; multiple sclerosis;
KW Alzheimer's disease; Parkinson's disease; asthma; schizophrenia;
KW depression; allergy; fertility disorder; NOVX18b.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 99
FT /label= OTHER
FT /note= "OTHER= May be substituted by Cys as a result of a
FT single nucleotide polymorphism"
FT Misc-difference 147
FT /label= OTHER
FT /note= "OTHER= May be substituted by Gly as a result of a
FT single nucleotide polymorphism"
FT Misc-difference 170
FT /label= OTHER
FT /note= "OTHER= May be substituted by Thr as a result of a
FT single nucleotide polymorphism"
XX
FN WO2003050245-A2.
XX
PD 19-JUN-2003.
XX
PF 03-DEC-2002; 2002WO-US038594.
XX
PR 05-DEC-2001; 2001US-0336600P.
PR 07-DEC-2001; 2001US-0338285P.
PR 12-DEC-2001; 2001US-0341346P.
PR 17-DEC-2001; 2001US-0341477P.
PR 17-DEC-2001; 2001US-0341540P.
PR 20-DEC-2001; 2001US-0342592P.
PR 27-DEC-2001; 2001US-0344297P.
PR 31-DEC-2001; 2001US-0344903P.
PR 17-APR-2002; 2002US-0373288P.
PR 15-MAY-2002; 2002US-0380981P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.
PR 29-MAY-2002; 2002US-0384024P.
PR 07-AUG-2002; 2002US-0401786P.
PR 26-AUG-2002; 2002US-0406353P.
PR 31-OCT-2002; 2002US-00401788.
PR 02-DEC-2002; 2002US-00406353.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Alabrook JP, Anderson DW, Boldog FL, Burgess CE, Chilikuru RA,
PI Edinger SR, Gerlach VL, Gorman L, Gould-Rotberg BE, Guo X,
PI Jeffers ME, Ji W, Li L, Malyankar UM, Miller CB, Murphy R,
PI Patursajan M, Peyman JA, Rieker DK, Shenoy SG,
PI Smithson G, Starling G, Taupier RJ, Voss EZ, Zhong H, Zhong M;
XX

DR WPI; 2003-513974/48.
DR N-PSDB; ADE95579.
XX
XX New NOVX polypeptides and nucleic acids, useful for preventing or
PT treating NOVX-associated disorders, e.g. cancer, cardiovascular,
PT atherosclerosis or diabetes, and in chromosome mapping, tissue typing or
XX pharmacogenomics.
XX
PS Claim 2; SEQ ID NO 112; 211pp; English.
XX
XX This invention relates to novel NOVX proteins, and the DNA sequence which
XX encode them, having properties related to stimulation of biochemical or
XX physiological responses in a cell, a tissue, an organ or an organism.
XX Compounds which modulate the proteins of the invention may have cardiatic,
XX antihypertensive, hypotensive, cytoskeletal, anorectic, antineumatic,
XX antirheumatic, antidiabetic, nephrotropic, dermatological,
XX immunosuppressive, anti-HIV, antineoplastic, neuroprotective,
XX neurotropic, antiparkinsonian, antiparkinsonian, neuroleptic,
XX antidepressant, antiallergic or gynaecological activities. The DNA
XX sequences of the invention may be useful for gene therapy whilst the
XX protein sequences may allow the development of a vaccine. The protein is
XX useful in the manufacture of a medicament for treating a syndrome
XX associated with a human disease. The invention may be useful in
XX diagnosing, treating or preventing NOVX-associated disorders, for example
XX cardiovascular, atherosclerosis, hypertension, cancer, obesity,
XX rheumatoid arthritis, diabetes, glomerulonephritis, psoriasis, skin
XX disorders, AIDS, inflammation, multiple sclerosis, Alzheimer's disease,
XX Parkinson's disease, asthma, schizophrenia, depression, allergies or
XX fertility disorders. The nucleic acids may further be used as
XX hybridisation probes, in chromosome mapping, tissue typing, preventive
XX medicine, and pharmacogenomics. The present sequence is the amino acid
XX sequence of the human NOVX18b protein of the invention.
SQ Sequence 206 AA:
Query Match 63.5%; Score 1010.5; DB 7; Length 206;
Best Local Similarity 67.7%; Pred. No. 1.5e-74;
Matches 205; Conservative 0; Mismatches 1; Indels 97; Gaps 2;
QY 1 MGRPLLPPLLPPLPAFLQSGSGSYLYGVTPKHLASMGSGVEIPSPFYRWE 60
DB 1 MGRPLLPPLLPPLPAFLQSGSGSYLYGVTPKHLASMGSGVEIPSPFYRWE 60
QY 61 LATAPDVRLSMRKHFGHSGSYSTRPSPHNDYNNRLPLNTEBOKSFLATISNQLKXDO 120
DB 61 LAT-----SIHNDYNNRLPLNTEBOKSFLATISNQLKXDO 96
QY 121 SVYFCRVELDTRSSGROQMOISIEGKLSITQAVTTTQRPSPMTTWTSLSTTTTGLRV 180
DB 97 SVYFCRVELDTRSSGROQMOISIEGKLSITQ----- 127
QY 181 TQGRKRSDSWHISLETAVGAVAVTALGIMILGLICLLMRRRKQOQTKATTPAREPFQ 240
DB 128 -----GQQTAKATTPAREPFQ 143
QY 241 NTEEPYENIRNEGQNTDPKLPKDDGIYVYASLASSSPSPAPSPSHRLKSPQNETLXSV 300
DB 144 NTEEPYENIRNEGQNTDPKLPKDDGIYVYASLASSSPSPAPSPSHRLKSPQNETLXSV 203
QY 301 LKA 303
DB 204 LKA 206
RESULT 7
AAV08015
ID AAV08015 standard; protein, 226 AA.
XX
AC AAV08015;
XX
DT 08-JUL-1999 (first entry)
XX
DE Human LSP-1 protein.
XX

XX LSP-1; signal peptide; leucocyte-specific protein-1; PA-I; TAP-1; cancer;
 KW proliferin analogue I; thrombopoietin analogue protein 1; anticancer;
 KW angiogenic; anticancer; anti-inflammatory; anti-thrombocytopenic;
 KW anti-arthritic; signal transduction; inflammatory; disease; growth;
 KW proliferation; differentiation; cell survival; angiogenesis; diagnosis;
 KW haematopoietic stem cell; erythroid precursor; megakaryocytopenias;
 KW thrombopoiesis; prognosis; treatment; chromosome mapping; tissue typing;
 KW forensic; arthritis; thrombocytopenia; bone marrow transplant; infection;
 KW intravascular coagulation; iron deficiency; HIV; human.
 XX Homo sapiens.
 OS
 ■ PN WO918243-A1.
 XX
 PD 15-APR-1999.
 XX
 PP 06-OCT-1998; 98WO-US021151.
 XX
 PR 06-OCT-1997; 97US-0061143P.
 PR 06-OCT-1997; 97US-0061149P.
 PR 06-OCT-1997; 97US-0061159P.
 PR 08-JAN-1998; 98US-00004206.
 PR 22-JAN-1998; 98US-00010674.
 PR 27-JAN-1998; 98US-00014347.
 XX
 PA (MILL-) MILLENNIUM BIOTHERAPEUTICS INC.
 XX
 PI Pan Y, Gearing DP, McCarthy SA;
 DR WPI; 1999-264042/22.
 DR N-PSDB; AAX37558.
 XX
 PT Signal-peptide containing proteins that modulate cellular processes.
 XX
 PS Claim 2; Fig 1; 124pp; English.
 XX
 CC This invention describes the isolation of nucleic acids encoding the
 CC signal-peptide-containing molecules leucocyte-specific protein-1 (LSP-1),
 CC proliferin analog I (PA-I) and thrombopoietin analog protein 1 (TAP-1).
 CC These proteins have angiogenic, anticancer, anti-inflammatory, anti-
 CC arthritic and anti-thrombocytopenic activity. The products of the
 CC invention and their modulators are involved in signal transduction,
 CC inflammatory responses, growth, proliferation, differentiation and
 CC survival of cells; angiogenesis; maturation of haematopoietic stem cells
 CC and erythroid precursors; megakaryocytopenias and thrombopoiesis.
 CC Antibodies, or other binding agents, specific for the products of the
 CC invention are useful for diagnosis, prognosis and monitoring of treatment
 CC of diseases. Other uses include chromosome mapping, identification of
 CC individuals (tissue typing) and in forensic studies. LSP-1, PA-I and TAP-
 CC 1 proteins and nucleic acids are modulators of cellular processes,
 CC particularly they are used to treat or prevent diseases associated with
 CC deregulation of angiogenesis, immune responses and haematopoiesis, e.g.
 CC cancer, arthritis (and other inflammatory diseases), thrombocytopenia
 CC (caused by cancer treatment, bone marrow transplant, human immune
 CC deficiency virus infection etc.), intravascular coagulation, iron
 CC deficiency etc
 XX
 SQ Sequence 226 AA;
 Query Match 61.2%; Score 973.5; DB 2; Length 226;
 Best Local Similarity 82.5%; Pred. No. 1.8e-71;
 Matches 188; Conservative 14; Mismatches 17; Indels 9; Gaps 2;
 QY 1 MGRPLLLPLPLPPAFLQPSGSGPSYLVGVTPQKHLASMGSGVEIPPSFYYPWE 60
 DB 1 MGRPLLLPLPLLOPPAFLQPSGSGPSYLVGVTPQKHLASMGSGVEIPPSFYYPWE 60
 QY 61 LATPDVRIISWRHGFHFGSGFSYTRPPSIHKDYVNRILFLMWTBCKSGFPLRISLQKODQ 120
 DB 61 LATPDVRIISWRHGFHFGSGFSYTRPPSIHKDYVNRILFLMWTBCKSGFPLRISLQKEDQ 120
 QY 121 SVYFCRVELDTRSSGROQWOSIEGTKLSITQAVTTTTPRSSMTTWRLSTTTTGLRV 180

DB 121 SVYFCRVELDTRSSGROQWOSIEGTKLSITQAVTTTTPRSSMTTWRLSTTTTGLRV 172
 QY 181 TQCKRRSDSWHSLERAVGAAVAVYVGLMIGLIGLRL-WRRRKQO 227
 DB 173 TSKGHSBSWHSLDPAIRVALAVALKTVIIGLLCLLMWRKRSR 220
 RESULT 8
 AAB07447
 ID AAB07447 standard; protein, 226 AA.
 XX
 AC AAB07447;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE A human monocyte-derived protein FDF03-S2.
 XX
 KW Human; monocyte-derived protein; FDF03; FDF03deltaTW; FDF03-S1;
 KW FDF03-M4; FDF03-S2; haematopoietic cell; monocyte hyperplasia;
 KW tissue rejection; inflammation; infection.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..17
 FT Protein /note="signal sequence"
 FT Protein /note="mature protein"
 XX
 PN WO200040721-A1.
 XX
 PD 13-JUL-2000.
 XX
 PP 29-DEC-1999; 99WO-US030004.
 XX
 PR 31-DEC-1998; 98US-00223919.
 PR 31-DEC-1998; 98US-00224604.
 XX
 PA (SCHE) SCHERING CORP.
 XX
 PI Bates E, Fournier N, Chaulus L, Garrone P;
 DR WPI; 2000-465984/40.
 DR N-PSDB; AAA58818.
 XX
 PT Novel monocyte-derived polypeptides and polynucleotides, used to diagnose
 PT diseases associated with changes in monocyte numbers, e.g. bacterial or
 PT viral infections.
 XX
 PS Claim 1; Page 41-42; 45pp; English.
 XX
 CC The present sequence represents a human monocyte-derived protein. The
 CC specification describes monocyte-derived proteins FDF03, FDF03deltaTW,
 CC FDF03-S1, FDF03-M4, and FDF03-S2. The proteins are involved in the
 CC regulation, or development, of haematopoietic cells. Antibodies specific
 CC for antigenic components of the proteins can be used to detect the
 CC components in samples. The proteins can also be used to screen the
 CC candidate therapeutic agents. The monocyte-derived proteins and
 CC polynucleotides can be used for diagnosis of diseases related to an
 CC increase, or decrease, in the number of monocytes in a tissue or lymph
 CC system, such as monocyte hyperplasia, tissue or graft rejection,
 CC inflammation, or bacterial or viral infections. The proteins can also be
 CC used in the treatment of disorders associated with abnormal expression or
 CC signalling by a monocyte
 XX
 SQ Sequence 226 AA;
 Query Match 61.2%; Score 973.5; DB 3; Length 226;
 Best Local Similarity 82.5%; Pred. No. 1.8e-71;
 Matches 188; Conservative 14; Mismatches 17; Indels 9; Gaps 2;
 QY 1 MGRPLLLPLPLPPAFLQPSGSGPSYLVGVTPQKHLASMGSGVEIPPSFYYPWE 60

Db 1 MGRPLLLPLLLLPAPFLQPGSGSPSYLYGVTPQPKHLSASMGSGVELPFSTFYWE 60
 Qy 61 LATAPDVRIWRRGHFGQSFYSTRPSIHQDVNRLFLNWTGQSGFLRISNLKQDQ 120
 Db 61 LATAPDVRIWRRGHFGQSFYSTRPSIHQDVNRLFLNWTGQSGFLRISNLKQDQ 120
 Qy 121 SVYFCRVELDTRRSGROQOSIEGFKLSITQAVTTTTPRPSMTTWRLSSTTTTGLRV 180
 Db 121 SVYFCRVELDTRRSGROQOSIEGFKLSITQAVTTTTPRPSMTTWRLSSTTTTGLRV 172
 Qy 181 TQGRKRSQSWHISLETAVGAVAVATVGLIMILGICLLR-WRRKGGQ 227
 Db 173 TESKGSSESWHLSLDTAIRVALAVAVLKVTLIGLLCLLMMRRKRSR 220

RESULT 9
 ID AAW80407 standard; protein; 226 AA.
 XX
 AC AAW80407;
 DT 25-MAR-2003 (revised)
 DT 13-JAN-1999 (first entry)
 XX
 DE A secreted protein encoded by clone d139_9.

XX Secreted protein; immune stimulating; suppressing;
 KW haematopoiesis regulating activity; tissue growth activity; activin;
 KW inhibin activity; chemotactic; chemokinetic activity; haemostatic;
 KW thrombolytic activity; anti-inflammatory activity; cadherin;
 KW tumour invasion suppressor activity; tumour inhibition activity.

XX Homo sapiens.
 XX MO9844113-A1.
 XX
 PD 08-OCT-1998.
 XX
 XX 27-MAR-1998; 98MO-US006176.
 XX
 XX 28-MAR-1997; 97US-00823330.
 PR 25-MAR-1998; 98US-00047661.
 XX

PA (GEM) GENETICS INST INC.
 PI Jacobs K, Mccoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M,
 PI Spaulding V, Agostino MJ;
 XX
 DR WPI; 1998-542703/46.
 DR N-PSDB; AAV63191.

XX New isolated polynucleotide(s) and secreted proteins - are obtained from
 PT human cDNA libraries prepared from adult testes, foetal brain, adult
 PT brain, adult blood and placenta.
 XX

XX Claim 19, Page 76-77; 124pp; English.

XX The present sequence represents a secreted protein. The nucleic acid
 CC sequence is isolated from a human adult testes cDNA library using probe
 CC AAV63202. The polypeptide may have biological activities such as e.g.
 CC nutritional activity, immune stimulating or suppressing activity,
 CC haematopoiesis regulating activity, tissue growth activity,
 CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
 CC activity or other activities. (Updated on 25-MAR-2003 to correct PR
 CC field.)
 XX

XX Sequence 226 AA;

Query Match 60.8%; Score 967.5; DB 2; Length 226;
 Best Local Similarity 82.0%; Pred. No. 5.5e-71;

Matches 187; Conservative 14; Mismatches 18; Indels 9; Gaps 2;
 Qy 1 MGRPLLLPLLLLPAPFLQPGSGSPSYLYGVTPQPKHLSASMGSGVELPFSTFYWE 60
 Db 1 MGRPLLLPLLLLPAPFLQPGSGSPSYLYGVTPQPKHLSASMGSGVELPFSTFYWE 60
 Qy 61 LATAPDVRIWRRGHFGQSFYSTRPSIHQDVNRLFLNWTGQSGFLRISNLKQDQ 120
 Db 61 LATAPDVRIWRRGHFGQSFYSTRPSIHQDVNRLFLNWTGQSGFLRISNLKQDQ 120
 Qy 121 SVYFCRVELDTRRSGROQOSIEGFKLSITQAVTTTTPRPSMTTWRLSSTTTTGLRV 180
 Db 121 SVYFCRVELDTRRSGROQOSIEGFKLSITQAVTTTTPRPSMTTWRLSSTTTTGLRV 172
 Qy 181 TQGRKRSQSWHISLETAVGAVAVATVGLIMILGICLLR-WRRKGGQ 227
 Db 173 TESKGSSESWHLSLDTAIRVALAVAVLKVTLIGLLCLLMMRRKRSR 220

RESULT 10
 ID ABP61825 standard; protein; 226 AA.
 XX
 AC ABP61825;
 DT 04-OCT-2002 (first entry)
 DT
 XX
 DE Human polypeptide SEQ ID NO 179.

XX Human; cytosolic; antirheumatic; antiarthritic; vulnery; analgesic;
 KW antiinflammatory; antibacterial; immunosuppressive; antiparkinsonian;
 KW neuroprotective; nocotropic; osteopathic; haemostatic; vasotropic;
 KW antidiabetic; antidiabetic; antidiabetic; antidiabetic;
 KW immunostimulant; antiparalytic; secreted protein; transmembrane protein;
 KW cytokine; cell proliferation; cell differentiation; autoimmune disease;
 KW stem cell; growth factor; nervous system disease; neuropathy;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW osteoporosis; severe combined immunodeficiency; SCID; infection;
 KW multiple sclerosis; rheumatoid arthritis; gene therapy.

XX Homo sapiens.
 XX OS
 XX US2002065394-A1.
 XX
 XX 30-MAY-2002.
 XX
 XX 22-DEC-2000; 2000US-00745763.
 XX
 XX 18-MAR-1998; 98US-00040963.
 XX

PA (JACO) JACOBS K.
 PA (MCCO) MCCOY J M.
 PA (LAVA) LAVALLIE E R.
 PA (COLL) COLLINS-RACIE L A.
 PA (EVAN) EVANS C.
 PA (MERB) MERBERG D.
 PA (TREAC) TREACY M.
 PA (SPAUL) SPAULDING V.
 XX

XX Jacobs K, Mccoy JM, Lavallie ER, Collins-Racie LA, Evans C;
 PI Merberg D, Treacy M, Spaulding V;
 XX
 DR WPI; 2002-582343/62.
 DR N-PSDB; ABQ92041.

XX Novel secreted or transmembrane protein and polynucleotide encoding the
 PT protein, useful for diagnosis and treatment of neurological disorders,
 PT cancer, autoimmune diseases, bone disorders and lung or liver fibrosis.
 PT

XX Claim 136, Page 159; 284pp; English.

XX The invention relates to human secreted or transmembrane protein (I),
 CC their fragments and is encoded by specific complementary deoxyribonucleic

CC acid (cDNA) inserts (II), where the protein is substantially free from
 CC other mammalian proteins. (I) are useful for preventing, treating or
 CC ameliorating a medical condition, especially immunological treatment or
 CC prevention of tumours. (I) exhibits activity relating to angiogenesis,
 CC cytokine, cell proliferation, cell differentiation, anti-inflammatory,
 CC stem cell growth factor activity and activin or inhibin-related
 CC activities. (I) can be used to manipulate stem cells in culture to give
 CC rise to neuroepithelial cells that can be used to augment or replace
 CC cells damaged by illness, autoimmune disease, accidental damage or
 CC genetic disorders. (I) induces the proliferation of neural cells and
 CC regeneration of nerve and brain tissue and is useful for the treatment of
 CC central and peripheral nervous system diseases and neuropathies, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis. (I) is involved in chemotactic or chemokinetic
 CC activity, regulation of haemopoiesis and is useful for treating myeloid
 CC or lymphoid cell disorders, platelet disorders such as thrombocytopenia
 CC and for regeneration of bone, cartilage, tendon, ligament and/or nerve
 CC tissue growth and in tissue repair, healing of burns, incisions, ulcers,
 CC for creating osteoporosis, osteoarthritis, bone degenerative disorders or
 CC periodontal disease. (I) is also useful for gut protection or
 CC regeneration and treatment of lung or liver fibrosis, reperfusion injury
 CC in various tissues, various immune deficiencies and disorders including
 CC severe combined immunodeficiency (SCID), bacterial or fungal infections,
 CC autoimmune disorders e.g. multiple sclerosis, rheumatoid arthritis,
 CC diabetes mellitus, myasthenia gravis, allergic reactions and conditions,
 CC such as asthma or other respiratory problems. (II) is useful to express
 CC recombinant protein, as markers for tissues in which the corresponding
 CC protein is preferentially expressed and in gene therapy. The present
 CC sequence is that of a polypeptide of the invention

XX Sequence 226 AA;

SO Query Match 60.8%; Score 967.5; DB 5; Length 226;
 Best Local Similarity 82.0%; Pred. No. 5.5e-71;
 Matches 187; Conservative 14; Mismatches 18; Indels 9; Gaps 2;

Qy 1 MGRPLLLPLLLPLPAFLPQSGTSGSPSYLVGVTPKHLASMGSGVEIPPSFYYPME 60
 Db 1 MGRPLLLPLLLPLLPAPFLQPGSTGSGPSYLVGVTPKHLASMGSGVEIPPSFYYPME 60

Qy 61 LATAPDVRIISWRGHPFGSGFYSTRPPSIHKDYVNRFLFWMTGQSGFLRISNLQKQDQ 120
 Db 61 LATAPDVRIISWRGHPFGSGFYSTRPPSIHKDYVNRFLFWMTGQSGFLRISNLQKQDQ 120

Qy 121 SYVFCRVELDTRSSGRQOQOSIEGTGLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
 Db 121 SYVFCRVELDTRSSGRQOQOSIKGTGLTTQAVTT-----TTTWPSSTTTTGLRV 172

Qy 181 TQGRKRSDSMHISLETAVGVAVAVTYLGIMLGLICLLR-WRRRKGOQ 227
 Db 173 TESKGHSESWHLSLDTAIRVALAVALKTVILGLLCLLMWRRKRSR 220

RESULT 11
 AAB07445
 ID AAB07445 standard; protein; 227 AA.

XX AAB07445;
 XX 20-OCT-2000 (first entry)

DE A human monocyte-derived protein FDF03-S1.

XX Human; monocyte-derived protein; FDF03; FDF03deltaTM, FDF03-S1;
 KW FDF03-M14; FDF03-S2; haematopoietic cell; monocyte hyperplasia;
 KW tissue rejection; inflammation; infection.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..17

FT Protein /note="signal sequence"
 18..227

FT /note="mature protein"

XX MO200040721-AL.

XX 13-JUL-2000.

XX 29-DEC-1999; 99WO-US030004.

XX 31-DEC-1998; 98US-00223919.

XX 31-DEC-1998; 98US-00224604.

XX (SCHE) SCHERING CORP.

XX Bates E, Fournier N, Chauvis L, Garrone P;

XX WPI; 2000-465984/40.

XX N-PSDB; AAM58816.

XX Novel monocyte-derived polypeptides and polynucleotides, used to diagnose
 PT diseases associated with changes in monocyte numbers, e.g. bacterial or
 PT viral infections.

PS Claim 1; Page 37-38; 45pp; English.

XX The present sequence represents a human monocyte-derived protein. The
 CC specification describes monocyte-derived proteins FDF03, FDF03deltaTM,
 CC FDF03-S1, FDF03-M14, and FDF03-S2. The proteins are involved in the
 CC regulation, or development, of haematopoietic cells. Antibodies specific
 CC for antigenic components of the proteins can be used to detect the
 CC components in samples. The proteins can also be used to screen for
 CC candidate therapeutic agents. The monocyte-derived proteins and
 CC polynucleotides can be used for diagnosis of diseases related to an
 CC increase, or decrease, in the number of monocytes in a tissue or lymph
 CC system, such as monocyte hyperplasia, tissue or graft rejection, CC
 CC inflammation, or bacterial or viral infections. The proteins can also be
 CC used in the treatment of disorders associated with abnormal expression or
 CC signalling by a monocyte

SO Sequence 227 AA;

Query Match 60.2%; Score 958; DB 3; Length 227;
 Best Local Similarity 80.8%; Pred. No. 3.3e-70;
 Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

Qy 1 MGRPLLLPLLLPLPAFLPQSGTSGSPSYLVGVTPKHLASMGSGVEIPPSFYYPME 60
 Db 1 MGRPLLLPLLLPLLPAPFLQPGSTGSGPSYLVGVTPKHLASMGSGVEIPPSFYYPME 60

Qy 61 LATAPDVRIISWRGHPFGSGFYSTRPPSIHKDYVNRFLFWMTGQSGFLRISNLQKQDQ 120
 Db 61 LATAPDVRIISWRGHPFGSGFYSTRPPSIHKDYVNRFLFWMTGQSGFLRISNLQKQDQ 120

Qy 121 SYVFCRVELDTRSSGRQOQOSIEGTGLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
 Db 121 SYVFCRVELDTRSSGRQOQOSIKGTGLTTQAVTT-----TTTWPSSTTTTGLRV 172

Qy 181 TQGRKRSDSMHISLETAVGVAVAVTYLGIMLGLICLLR-WRRRKGOQ 227
 Db 173 TESKGHSESWHLSLDTAIRVALAVALKTVILGLLCLLMWRRKRSR 221

RESULT 12
 ABU89824
 ID ABU89824 standard; protein; 227 AA.

XX ABU89824;

XX 10-JUL-2003 (first entry)

DE TNF-receptor associated factor 5 (TRAF5) interacting protein #4.

XX Human; cytosolic; DAPK3-Agonist; DAPK3-Antagonist; cancer;

KW TNF-receptor associated factor 5 interacting protein;

KM Tumour necrosis factor associated factor 5 interacting protein;
KM TRAF5 Interacting protein.
XX Homo sapiens.
XX MO2003031571-AAZ.
XX
PD 17-APR-2003.
XX
PF 02-OCT-2002; 2002MO-US031357.
XX
PR 05-OCT-2001; 2001US-0327454P.
PR 09-OCT-2001; 2001US-0327917P.
PR 09-OCT-2001; 2001US-0328029P.
PR 09-OCT-2001; 2001US-0328056P.
PR 12-OCT-2001; 2001US-0328849P.
PR 15-OCT-2001; 2001US-0329414P.
PR 17-OCT-2001; 2001US-0330142P.
PR 22-OCT-2001; 2001US-0341058P.
PR 24-OCT-2001; 2001US-0343629P.
PR 29-OCT-2001; 2001US-0349575P.
PR 01-NOV-2001; 2001US-0346357P.
PR 25-JUN-2002; 2002US-0391342P.
PR 01-OCT-2002; 2002US-0026244S.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Alsebrook JP, Burgess CE, Catterson E, Chant JS, Chaudhuri A,
PI Edinger SR, Gerlich VL, Giot L, Gorman L, Guo X, Kekuda R,
PI Mezes PS, Milet I, Ooi CE, Paturnajan M, Rieger DK, Spytek KA;
PI Taupier RJ, Zerkhus BD, Zhong H, Zhong M;
XX
DR MPI; 2003-381704/36.
XX N-PESB; ACA90240.
XX
PT New DAPI3 polypeptide, useful for preparing a composition for treating or
PT preventing e.g., cancer.
XX
XX Example 20F, Page 242; 253pp; English.

CC The invention describes an isolated polypeptide comprising any of 33 90-
CC 1273 amino acid sequences (I) given in the specification or its mature
CC form, a sequence that is at least 95 % identical to (I), or a sequence
CC comprising one or more conservative substitutions in the amino acid
CC sequence of (I). The polypeptide is useful for preparing a composition
CC for treating or preventing e.g. cancer. This is the amino acid sequence
CC of a tumour necrosis factor (TNF)-receptor associated factor 5 (TRAF5)
CC interacting protein associated with the identification of novel human
CC proteins and their functions

XX
XX Sequence 227 AA;

Query Match 60.2%; Score 958; DB 6; Length 227;
Best Local Similarity 80.8%; Pred. No. 3,3e-70;
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2

OY 1 MGKPLLLPLPLLPALPPAGLPSGSGSYLYGVYTOPGHLSASMGSEIPSPFYPMW 60
DB 1 MKRPFLPLPLLLLQPPAFLOPGSGTSGSYLYGVYTOPGHLSASMGSEIPSPFYPMW 60
OY 61 LATAPPVRIKSMRGHFGHGSFYSTRPSIHKOYVRILFNWTEGGSGFRIRISLNOKDQ 120
DB 61 LAIVPVRIKSMRGHFGHGSFYSTRPSIHKOYVRILFNWTEGGSGFRIRISLNKEQ 120
OY 121 SYVFCVELDISSGSGQQOSIEGTGLSTIQAVTTTQRPSMTTWRLSGSTTTTGRLRV 180
DB 121 SYVFCVELDIRSGSQQLSIKGTGLTIQAVTT-----TTWRPSSTITIAGLRV 172
OY 181 TCGKRSDSWMHSLFTAVGVAVALTVLGIMIGLICULR--WRRKKQQ 227
DB 173 TSKGHSBSWMHLSDTAIRVALAVALKVIIGLICILLMLWRRRKGRS 221

	RESULT	13
ID	AAW63682	
XX	AAW63682 standard; protein; 291 AA.	
AC		
XX	AAW63682;	
DT		
XX	24-SEP-1998 (first entry)	
DE		
XX	Human secreted protein 2.	
KM	Secreted protein; human; cell proliferation; cytokine activity; tissue growth; cellular differentiation; regeneration; activin; inhibin; chemotactic; haemostatic; thrombolytic; tumour inhibition; anti-inflammatory activity; biomarker.	
KW		
OS	Homo sapiens.	
PX		
PN	WO9825959-A2.	
PD	18-JUN-1998.	
PF	11-DEC-1997; 97MO-US022787.	
PR	11-DEC-1996; 96US-0032757P.	
PA	(CHIR) CHIRON CORP.	
PI	Escobedo J, Hu Q, Garcia P, Williams LT, Kothakota S; MPI, 1998-348453/30. N-PSTDB; AAW43602.	
PT	Secreted human polypeptides - having cytokine, cell proliferation or differentiation, activin or inhibin, tumour inhibition or anti- inflammatory activities.	
PP		
XX	Claim 1; Page 49-50; 78pp; English.	
CC	This represents a human secreted protein. The specification provides secreted protein sequences (AAM63681 to AAM63699) encoded by the nucleic acid sequences shown in AAV43601 to AAV43619. The invention provides a method of identifying a secreted polypeptide which is modified by rough microsome. The secreted proteins can be used in assays to determine biological activities, such as cytokine, cell proliferation, or cellular differentiation activities, tissue growth or regeneration, activin or inhibin activity, chemotactic or chemokinetic activity, haemostatic or thrombolytic activity, receptor/ligand activity, tumour inhibition, or anti-inflammatory activity. The proteins can also be used as biomarkers, to identify tissues or cell types which express the proteins, or a stage- or disease-specific alteration in protein expression. They can be used in protein interaction assays, to identify ligands or binding proteins. Compounds which affect the biological activities of the secreted proteins or their ability to interact with specific ligands can be identified using the proteins in screening assays. The proteins and antibodies that bind specifically to the protein can also be used to design diagnostic tests and therapeutic compositions for diseases which may be associated with altered expression of these proteins. Fusion proteins comprising, e.g., signal sequences or transmembrane domains of the proteins can be used to target other protein domains to cellular membrane or they can be secreted extracellularly	
SQ	Sequence 291 AA;	
Query Match:	60.2%; Score 958; DB 2; Length 291;	
Best Local Similarity	80.8%; Pred. No. 4.5e-70;	
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2		
OY	1 MGRPLLLPLLPLLPAPAFLOPSGSGSPSYLYGVTPQRKLSASMGGSVEIPFSFYVWE 60	
Db	65 MGRIPLLELILLDGPALDPFGSGLSSPSFLVGTVTQPKHLSASMGGSVELIPEISFYVME 124	
OY	61 LATADVARISMRRGHFQGCSFTSRPSPSIHKDYNNRLFLNWTEGSKGFNLINSLQKODQ 120	

DB 125 LAIVPNVRISMRRGHFHGQSFYSTRPPSIHKDYVNRFLNMTGEGSGFLRISNLRKEDQ 184
 QY 121 SVYFCRVELDTRSSGROQMSIEGTLSITQAVTTTQRSSMTTWRRISSTTTTGLRV 180
 DB 185 SVYFCRVELDTRSSGROQMSIEGTLSITQAVTT-----TTWRRPSSTTTTGLRV 236
 QY 181 TQGRKRSDSMHSISLETAVGVAVAVTVLGMILGICLLR--WRRRKQO 227
 DB 237 TESKGHSESMHSLDTPAIRVALAVAVLKVITLGLCLLLMWRKRSR 285

RESULT 14
 ID ABB12010 standard; peptide; 326 AA.
 XX ABB12010;
 AC ABB12010;
 XX 11-JAN-2002 (first entry)
 DT Human secreted protein homologue, SEQ ID NO:2380.
 XX
 DE Human, cytokine; cell proliferation; cell differentiation; growth factor;
 KW haematopoietic regulation; tissue growth; immunomodulator; activin;
 KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;
 KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;
 KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
 KW chronic inflammatory condition; proliferative retinopathy;
 KW atherosclerosis; coronary heart disease; arterial ischaemia;
 KW bone disorder; osteoporosis; vascular growth disorder;
 KW tissue regeneration; wound healing; infection; immune disorder;
 KW cell culture; drug screening; gene therapy; antiinflammatory;
 KW antiaesthetic; antiarthritic; haemostatic; antiatherosclerotic;
 KW cytostatic; osteopathic; vasotropic; cardiac; virucide; antibacterial;
 KW antifungal; vulnery; antitumor.

XX Homo sapiens.
 OS
 XX MO200157188-A2.
 PN 09-AUG-2001.
 XX
 PD 05-FEB-2001; 2001MO-US003800.
 PF 03-FEB-2000; 2000US-00496914.
 PR 27-APR-2000; 2000US-00560875.
 XX
 PA (HYSE-) HYSED INC.
 XX
 PI Tang YT, Liu C, Drmanac RT;
 XX
 DR WPI: 2001-457740/49.
 DR N-PSDB; ABA09254.
 XX
 PT Human proteins and DNA encoding sequences useful for preventing, treating
 PT or ameliorating a medical condition in a mammalian subject e.g. arthritis
 PT and cancer.
 XX
 PS Claim 20; Page 295; 1963pp; English.
 XX
 CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
 CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
 CC invention also relates to vectors and recombinant host cells comprising a
 CC nucleotide of the invention, methods of producing the novel polypeptides,
 CC antibodies against the polypeptides, methods of detecting the nucleotides
 CC or polypeptides in a sample, and methods of identifying compounds which
 CC bind to polypeptides of the invention. Although novel, many of the
 CC polypeptides of the invention have homology to known proteins, thereby
 CC giving an insight into their probable biological activities, and hence
 CC potential therapeutic applications. The polypeptides of the invention may
 CC have various activities, including cytokine, cell proliferation or cell
 CC differentiation activities; stem cell growth factor activity;
 CC haematopoietic regulatory activity; tissue growth activity;
 CC immunomodulatory activity; activin- or inhibin-related activities;

CC chemotactic or chemokinetic activities; haemostatic, thrombotic or
 CC thrombolytic activities; receptor or ligand activities; or may be
 CC involved in oncogenesis, cancer cell proliferation or metastasis.
 CC Depending on their biological activities, polypeptides and nucleotides of
 CC the invention are useful for preventing, treating or ameliorating medical
 CC conditions, e.g., by protein or gene therapy. Such conditions include
 CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell
 CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
 CC proliferative retinopathy, atherosclerosis, coronary heart disease,
 CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
 CC vascular growth. Polypeptides involved with tissue regeneration and
 CC repair (or nucleic acids encoding them) may be used to promote wound
 CC healing (e.g., of burns, incisions and ulcers), while those with
 CC immunomodulatory activities may be used in the treatment of viral,
 CC bacterial and fungal infections in addition to immune disorders.
 CC Polypeptides with growth factor activity may be used in cell cultures to
 CC promote cell growth. For example, such polypeptides may be used to
 CC manipulate stem cells in culture to give rise to neuroepithelial cells
 CC that can be used to augment or replace cells damaged by illness,
 CC autoimmune disease or accidental damage. The polypeptides and nucleotides
 CC may also be used in the diagnosis of the above conditions, and in drug
 CC screening techniques. The present sequence represents a novel human
 CC polypeptide of the invention

XX
 SQ Sequence 326 AA;
 CC
 CC Query Match 60.2%; Score 958; DB 4; Length 326;
 CC Best Local Similarity 80.8%; Pred. No. 5.3e-70;
 CC Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

QY 1 MGRPLPLPLPLPLPLPAFLQPSGTSQSPSYLYGVTPRHLSNMGSEIIPSPFYRWE 60
 DB 100 MGRPLPLPLPLPLPLQPAFLQPGSGTSGSPSYLYGVTPRHLSNMGSEIIPSPFYRWE 159
 QY 61 LATAPVVRISMRRGHFHGQSFYSTRPPSIHKDYVNRFLNMTGEGSGFLRISNLRKEDQ 120
 DB 160 LAIVPNVRISMRRGHFHGQSFYSTRPPSIHKDYVNRFLNMTGEGSGFLRISNLRKEDQ 219
 QY 121 SVYFCRVELDTRSSGROQMSIEGTLSITQAVTTTQRSSMTTWRRISSTTTTGLRV 180
 DB 220 SVYFCRVELDTRSSGROQMSIEGTLSITQAVTT-----TTWRRPSSTTTTGLRV 271
 QY 181 TQGRKRSDSMHSISLETAVGVAVAVTVLGMILGICLLR--WRRRKQO 227
 DB 272 TESKGHSESMHSLDTPAIRVALAVAVLKVITLGLCLLLMWRKRSR 320

RESULT 15
 ID AAY87230
 XX AAY87230 standard; protein; 227 AA.
 XX
 AC AAY87230;
 XX
 DT 11-MAY-2000 (first entry)
 DT
 XX
 DE Human signal peptide containing protein HSP-7 SEQ ID NO:7.
 XX
 CC Human, signal peptide-containing protein; HSP; diagnosis; cancer;
 CC inflammation; cardiovascular disease; anticancer; anti-inflammatory;
 CC antimicrobial; neuroprotective; cardiovascular; hepatocytic;
 CC antiaesthetic; gene therapy; cell proliferation; neurological disorder;
 CC reproductive disorder; developmental disorder; atherosclerosis;
 CC cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
 CC asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
 CC Parkinson's disease; Huntington's disease; ovulatory defect;
 CC muscular dystrophy.
 KW
 XX
 XX Homo sapiens.
 OS
 XX MO200000610-A2.
 PN 06-JAN-2000.
 XX
 PD

PF 25-JUN-1999; 99WO-US014484.
XX
PR 26-JUN-1998; 98US-0090762P.
PR 31-JUL-1998; 98US-0094983P.
PR 01-OCT-1998; 98US-0102686P.
PR 11-DEC-1998; 98US-0112129P.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerbloom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX
DR MPI: 2000-150673/14.
DR N-PSDB; AA298115.
XX
PT New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT disease.
XX
PS Claim 1; Page 164-165; 327pp; English.

AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the
CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPPs have
CC anticancer, anti-inflammatory, antimicrobial, neurotropic, hepatotropic,
CC neuroprotective, cardiovascular and antidiabetic activities, and can be
CC used in gene therapy. HSPPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSP. Antagonists of
CC HSPP are used to treat or prevent disorders associated with increased
CC activity or function of HSP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
CC nucleic acids can be used for the recombinant production of HSP, for
CC detecting HSP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
CC or ribozyme therapeutic, for detecting related sequences or genetic
CC variations, and for chromosomal mapping. HSP are also used to raise
CC specific antibodies (Ab) and to screen for agonists and antagonists
CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
CC competitive drug screens, and for purification of HSP from natural
CC sources
XX
CC
SQ Sequence 227 AA;

Query Match 59.4%; Score 945; DB 3; Length 227;

Best Local Similarity 79.9%; Pred. No. 3.8e-69;
Matches 183; Conservative 15; Mismatches 21; Indels 10; Gaps 2;

QY 1 MGRPLLLPLPLPLPPAPFLOPSGSGPSVLYGVTOPKHLASMGSGVEIPFSFYPM 60
DB 1 MGRPLLLPLLLLOPPAPFLOPSGSGPSXXYGVTOPKHLASMGSGVEIPFSFYPM 60
QY 61 LATAADVAISMRGHFGSGFSYSTRPSIHKDYVRLFLNWTGQSGFLRISNLQKQD 120
DB 61 LAIVNVNVAISMRGHFGSGFSYSTRPSIHKDYVRLFLNWTGQSGFLRISNLKQD 120
QY 121 SVYFCRVLDTRSSGROQMSIEGKLSITQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
DB 121 SVYFCRVLDTRSSGROQMSIEGKLSITQAVTTTQRPSSMTTWRLSSTTTTGLRV 172
QY 181 TQGRSRDSWHSISLETAVGAVAVTVLGMIGLICLR--WRRRKGQ 227
DB 173 TESKGSSESWSLDTAIRVALAVLKVIIIGLICLLLMWRKRGSR 221

Search completed: June 1, 2005, 22:08:23
Job time : 165 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 1, 2005, 22:05:46 ; Search time 142 Seconds
(without alignments)
737.613 Million cell updates/sec

Title: US-10-777-524-2

Perfect score: 1591
Sequence: 1 MGRPLRLPLRLPLRLPLRLQ.....PSHRLKSPQNETLYSVLKA 303

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1465611 seqs, 345679903 residues

Total number of hits satisfying chosen parameters: 1465611

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications AA:*

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/1/pubpaa/US09C_NEW_PUB.pep.*
- 13: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
- 17: /cgn2_6/ptodata/1/pubpaa/US10D_NEW_PUB.pep.*
- 18: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
- 19: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
- 20: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1591	100.0	303	US-09-774-381-58	Sequence 58, Appli
2	1591	100.0	303	US-10-290-631-2	Sequence 2, Appli
3	1591	100.0	303	US-10-780-043-2	Sequence 2, Appli
4	1591	100.0	303	US-10-777-524-2	Sequence 2, Appli
5	1591	100.0	303	US-10-777-521-2	Sequence 2, Appli
6	1176.5	79.9	230	US-10-780-043-4	Sequence 4, Appli
7	1171.5	73.6	230	US-10-309-290-110	Sequence 110, App
8	1010.5	63.5	206	US-10-309-290-112	Sequence 112, App
9	973.5	61.2	226	US-09-774-381-44	Sequence 44, Appli
10	973.5	61.2	226	US-10-780-043-10	Sequence 10, Appli
11	967.5	60.8	226	US-09-745-763-106	Sequence 106, App
12	958	60.2	227	US-10-262-445-128	Sequence 128, App
13	958	60.2	227	US-10-780-043-6	Sequence 6, Appli

14	958	60.2	291	9	US-09-935-390A-21	Sequence 21, Appli
15	958	60.2	326	15	US-10-276-774-2380	Sequence 2380, Ap
16	934	58.7	238	10	US-09-809-391-485	Sequence 485, App
17	934	58.7	238	10	US-09-882-171-485	Sequence 485, App
18	934	58.7	238	15	US-10-164-861-485	Sequence 485, App
19	821	51.6	175	16	US-10-780-043-8	Sequence 8, Appli
20	517	32.5	101	10	US-09-809-391-754	Sequence 754, App
21	517	32.5	101	10	US-09-882-171-754	Sequence 754, App
22	517	32.5	101	15	US-10-164-861-754	Sequence 754, App
23	411	25.8	224	10	US-09-866-050A-711	Sequence 711, App
24	222	14.0	99	14	US-10-290-631-4	Sequence 4, Appli
25	222	14.0	99	16	US-10-777-524-4	Sequence 4, Appli
26	222	14.0	99	17	US-10-777-521-4	Sequence 391, App
27	148.5	9.3	305	15	US-10-291-265-391	Sequence 391, App
28	146.5	9.2	305	10	US-09-786-753-104	Sequence 104, App
29	146.5	9.2	305	10	US-09-796-753-120	Sequence 120, App
30	146.5	9.2	305	15	US-10-291-265-863	Sequence 863, App
31	139	8.7	290	9	US-09-965-529-18	Sequence 18, Appli
32	139	8.7	290	10	US-09-969-680A-18	Sequence 18, Appli
33	139	8.7	290	14	US-10-227-884-40	Sequence 40, Appli
34	139	8.7	290	14	US-10-230-163-40	Sequence 40, Appli
35	139	8.7	290	14	US-10-230-338-40	Sequence 40, Appli
36	139	8.7	290	14	US-10-218-531-40	Sequence 40, Appli
37	139	8.7	290	14	US-10-230-414-40	Sequence 40, Appli
38	139	8.7	290	14	US-10-232-224-40	Sequence 40, Appli
39	139	8.7	290	14	US-10-216-159A-40	Sequence 40, Appli
40	139	8.7	290	14	US-10-218-849-40	Sequence 40, Appli
41	139	8.7	290	14	US-10-227-873-40	Sequence 40, Appli
42	139	8.7	290	14	US-10-227-883-40	Sequence 40, Appli
43	139	8.7	290	14	US-10-219-076-40	Sequence 40, Appli
44	139	8.7	290	14	US-10-230-434-40	Sequence 40, Appli
45	139	8.7	290	14	US-10-219-003-40	Sequence 40, Appli

ALIGNMENTS

RESULT 1
US-09-774-381-58
; Sequence 58, Application US/09774381
; Publication No. US20030082677A1
GENERAL INFORMATION:
APPLICANT: Holtezman, Douglas A.
APPLICANT: McCarthy, Sean A.
APPLICANT: Pan, Yang
TITLE OF INVENTION: NOVEL EDIRF, MTR-1, LSP-1, TAP-1, AND PA-I MOLECULES
FILE REFERENCE: NMI-107CP2
CURRENT APPLICATION NUMBER: US/09/774,381
CURRENT FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: 08/941,354
PRIOR FILING DATE: 1999-09-30
PRIOR APPLICATION NUMBER: 09/010,674
PRIOR FILING DATE: 1998-01-22
PRIOR APPLICATION NUMBER: 60/061,149
PRIOR FILING DATE: 1997-10-06
PRIOR APPLICATION NUMBER: 09/014,347
PRIOR FILING DATE: 1998-01-27
PRIOR APPLICATION NUMBER: 60/061,159
PRIOR FILING DATE: 1997-10-06
PRIOR APPLICATION NUMBER: 09/474,151
PRIOR FILING DATE: 2000-12-21
PRIOR APPLICATION NUMBER: 09/004,206
PRIOR FILING DATE: 1998-01-08
PRIOR APPLICATION NUMBER: 60/061,143
PRIOR FILING DATE: 1997-10-06
PRIOR APPLICATION NUMBER: 09/483,414
PRIOR FILING DATE: 2000-01-14
PRIOR APPLICATION NUMBER: 09/213,571
PRIOR FILING DATE: 1998-12-18
PRIOR APPLICATION NUMBER: 08/994,890
PRIOR FILING DATE: 1997-12-19

NUMBER OF SEQ ID NOS: 59
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 58
LENGTH: 303
TYPE: PRT
ORGANISM: Homo sapiens
US-09-774-381-58

Query Match 100.0%; Score 1591; DB 10; Length 303;
Best Local Similarity 100.0%; Pred. No. 5.1e-126;
Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRPLLPPLPLPPLPAPFLOPSGSGSYLYGVTPKHLASMGSGVEIPPSFYYPWE 60
DB 1 MGRPLLPPLPLPPLPAPFLOPSGSGSYLYGVTPKHLASMGSGVEIPPSFYYPWE 60
QY 61 LATAPDVRIISWRGHHFGSGFYSTRPPSIHKDYVNRFLPLWTEGQKSGFLRISNLOKODQ 120
DB 61 LATAPDVRIISWRGHHFGSGFYSTRPPSIHKDYVNRFLPLWTEGQKSGFLRISNLOKODQ 120
QY 121 SVYFCRVELDTRSSGROQMSIEGTKLSTQAVTTTTPRSSMTTWRLSSTTTTGLRV 180
DB 121 SVYFCRVELDTRSSGROQMSIEGTKLSTQAVTTTTPRSSMTTWRLSSTTTTGLRV 180
QY 181 TOGKRSDSMHISLETAAGVAVAVTVLGMILGICLLMRRRKGGQRTKATTPAREPFQ 240
DB 181 TOGKRSDSMHISLETAAGVAVAVTVLGMILGICLLMRRRKGGQRTKATTPAREPFQ 240
QY 241 NTEPEYINIRNEGQNTDPKLNPKDGIIVYASLSSSTSPRAPPSHRPLKSPONETLYSV 300
DB 241 NTEPEYINIRNEGQNTDPKLNPKDGIIVYASLSSSTSPRAPPSHRPLKSPONETLYSV 300
QY 301 LKA 303
DB 301 LKA 303

RESULT 2

US-10-290-631-2

Sequence 2, Application US/10290631
Publication No. US20030105303A1

GENERAL INFORMATION:

APPLICANT: Adema, Gosee Jan
Meyard, Linde
Gorman, Daniel M.
McClanahan, Terrill K.
Zurawski, Sandra M.
Zurawski, Gerard
Lanier, Lewis L.
Phillips Jr., Joseph H.

TITLE OF INVENTION: Isolated Mammalian Monocyte Cell Genes;
Related Reagents

NUMBER OF SEQUENCES: 22

CORRESPONDENCE ADDRESS:

ADDRESSEE: DNAX Research Institute
STREET: 901 California Avenue
CITY: Palo Alto
STATE: California

COUNTRY: USA
ZIP: 94304-1104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/290,631

FILING DATE: 08-NO. US20030105303A1-2002

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/985,950

FILING DATE: 05-DEC-1997

APPLICATION NUMBER: US 60/041,279

FILING DATE: 21-MARCH-1997
APPLICATION NUMBER: US 60/033,181
FILING DATE: 16-DEC-1996
APPLICATION NUMBER: US 60/032,252
FILING DATE: 06-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Ching, Edwin P.
REGISTRATION NUMBER: 34,090
REFERENCE/DOCKET NUMBER: DX0670K
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 852-9196
TELEFAX: (650) 496-1204
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 303 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Query Match 100.0%; Score 1591; DB 14; Length 303;
Best Local Similarity 100.0%; Pred. No. 5.1e-126;
Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRPLLPPLPLPPLPAPFLOPSGSGSYLYGVTPKHLASMGSGVEIPPSFYYPWE 60
DB 1 MGRPLLPPLPLPPLPAPFLOPSGSGSYLYGVTPKHLASMGSGVEIPPSFYYPWE 60
QY 61 LATAPDVRIISWRGHHFGSGFYSTRPPSIHKDYVNRFLPLWTEGQKSGFLRISNLOKODQ 120
DB 61 LATAPDVRIISWRGHHFGSGFYSTRPPSIHKDYVNRFLPLWTEGQKSGFLRISNLOKODQ 120
QY 121 SVYFCRVELDTRSSGROQMSIEGTKLSTQAVTTTTPRSSMTTWRLSSTTTTGLRV 180
DB 121 SVYFCRVELDTRSSGROQMSIEGTKLSTQAVTTTTPRSSMTTWRLSSTTTTGLRV 180
QY 181 TOGKRSDSMHISLETAAGVAVAVTVLGMILGICLLMRRRKGGQRTKATTPAREPFQ 240
DB 181 TOGKRSDSMHISLETAAGVAVAVTVLGMILGICLLMRRRKGGQRTKATTPAREPFQ 240
QY 241 NTEPEYINIRNEGQNTDPKLNPKDGIIVYASLSSSTSPRAPPSHRPLKSPONETLYSV 300
DB 241 NTEPEYINIRNEGQNTDPKLNPKDGIIVYASLSSSTSPRAPPSHRPLKSPONETLYSV 300
QY 301 LKA 303
DB 301 LKA 303

RESULT 3

US-10-780-043-2

Sequence 2, Application US/10780043
Publication No. US20040137506A1

GENERAL INFORMATION:

APPLICANT: Bates, Elizabeth

APPLICANT: Fournier, Nathalie

APPLICANT: Chalus, Lionel

APPLICANT: Gattone, Pierre

TITLE OF INVENTION: MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHOD

FILE REFERENCE: SF0977X

CURRENT APPLICATION NUMBER: US/10/780,043

CURRENT FILING DATE: 2004-02-17

PRIOR APPLICATION NUMBER: US/09/669,388

PRIOR FILING DATE: 2002-02-21

NUMBER OF SEQ ID NOS: 14

SOFTWARE: IBM PC compatible

SEQ ID NO 2

LENGTH: 303

TYPE: PRT

ORGANISM: homo sapiens

US-10-780-043-2

Query Match 100.0%; Score 1591; DB 16; Length 303;
Best Local Similarity 100.0%; Pred. No. 5.1e-126;
Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRPLLPPLLPPLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIPFSFYPMW 60
1 MGRPLLPPLLPPLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIPFSFYPMW 60
DB 1 MGRPLLPPLLPPLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIPFSFYPMW 60
QY 61 LATAPDVARSRRGHFHGQSFYSTRPSPSIHKDYVNRFLNMTGQKSGFLRISNLQKODQ 120
61 LATAPDVARSRRGHFHGQSFYSTRPSPSIHKDYVNRFLNMTGQKSGFLRISNLQKODQ 120
DB 61 LATAPDVARSRRGHFHGQSFYSTRPSPSIHKDYVNRFLNMTGQKSGFLRISNLQKODQ 120
QY 121 SVYFCRVELDTRSSGROQWOSIEGKLSITQAVTTTTPRPSMTTWTMLSTTTTGLRV 180
121 SVYFCRVELDTRSSGROQWOSIEGKLSITQAVTTTTPRPSMTTWTMLSTTTTGLRV 180
DB 121 SVYFCRVELDTRSSGROQWOSIEGKLSITQAVTTTTPRPSMTTWTMLSTTTTGLRV 180
QY 181 TQGRKRSDSMHSISETAVGAVAVTVLGMILGLICLRMRRRKQOQRTKATTPAREPQ 240
181 TQGRKRSDSMHSISETAVGAVAVTVLGMILGLICLRMRRRKQOQRTKATTPAREPQ 240
DB 181 TQGRKRSDSMHSISETAVGAVAVTVLGMILGLICLRMRRRKQOQRTKATTPAREPQ 240
QY 241 NTEBPYENIRNEGQNTDPKLPKDDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
241 NTEBPYENIRNEGQNTDPKLPKDDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
DB 241 NTEBPYENIRNEGQNTDPKLPKDDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
QY 301 LKA 303
301 LKA 303
DB 301 LKA 303

RESULT 4
US-10-777-524-2
; Sequence 2, Application US/10777524
; Publication No. US20040143858A1
; GENERAL INFORMATION:
; APPLICANT: Adema, Gosee Jan
; Meyard, Linde
; Gorman, Daniel M.
; McClanahan, Terrill K.
; Zurawski, Sandra M.
; Zurawski, Gerard
; Lanier, Lewis L.
; Phillips Jr., Joseph H.
; TITLE OF INVENTION: Isolated Mammalian Monocyte Cell Genes;
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESSES:
; ADDRESS: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/777,524
; FILING DATE: 11-Feb-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/546,049
; FILING DATE: 10-Apr-2000
; APPLICATION NUMBER: US/08/985,950
; FILING DATE: 05-Dec-1997
; APPLICATION NUMBER: US 60/041,279
; FILING DATE: 21-MARCH-1997
; APPLICATION NUMBER: US 60/033,181
; FILING DATE: 16-Dec-1996
; APPLICATION NUMBER: US 60/032,252
; FILING DATE: 06-Dec-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.

REGISTRATION NUMBER: 34, 090
REFERENCE/DOCKET NUMBER: DX0670X
TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 852-9196
; TELEFAX: (650) 496-1204
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 303 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-777-524-2

Query Match 100.0%; Score 1591; DB 16; Length 303;
Best Local Similarity 100.0%; Pred. No. 5.1e-126;
Matches 303; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRPLLPPLLPPLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIPFSFYPMW 60
1 MGRPLLPPLLPPLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIPFSFYPMW 60
DB 1 MGRPLLPPLLPPLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIPFSFYPMW 60
QY 61 LATAPDVARSRRGHFHGQSFYSTRPSPSIHKDYVNRFLNMTGQKSGFLRISNLQKODQ 120
61 LATAPDVARSRRGHFHGQSFYSTRPSPSIHKDYVNRFLNMTGQKSGFLRISNLQKODQ 120
DB 61 LATAPDVARSRRGHFHGQSFYSTRPSPSIHKDYVNRFLNMTGQKSGFLRISNLQKODQ 120
QY 121 SVYFCRVELDTRSSGROQWOSIEGKLSITQAVTTTTPRPSMTTWTMLSTTTTGLRV 180
121 SVYFCRVELDTRSSGROQWOSIEGKLSITQAVTTTTPRPSMTTWTMLSTTTTGLRV 180
DB 121 SVYFCRVELDTRSSGROQWOSIEGKLSITQAVTTTTPRPSMTTWTMLSTTTTGLRV 180
QY 181 TQGRKRSDSMHSISETAVGAVAVTVLGMILGLICLRMRRRKQOQRTKATTPAREPQ 240
181 TQGRKRSDSMHSISETAVGAVAVTVLGMILGLICLRMRRRKQOQRTKATTPAREPQ 240
DB 181 TQGRKRSDSMHSISETAVGAVAVTVLGMILGLICLRMRRRKQOQRTKATTPAREPQ 240
QY 241 NTEBPYENIRNEGQNTDPKLPKDDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
241 NTEBPYENIRNEGQNTDPKLPKDDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
DB 241 NTEBPYENIRNEGQNTDPKLPKDDGIYASIALSSSTSPRAPSHRPLKSPQNETLYSV 300
QY 301 LKA 303
301 LKA 303
DB 301 LKA 303

RESULT 5
US-10-777-521-2
; Sequence 2, Application US/10777521
; Publication No. US20050059808A1
; GENERAL INFORMATION:
; APPLICANT: Adema, Gosee Jan
; Meyard, Linde
; Gorman, Daniel M.
; McClanahan, Terrill K.
; Zurawski, Sandra M.
; Zurawski, Gerard
; Lanier, Lewis L.
; Phillips Jr., Joseph H.
; TITLE OF INVENTION: Isolated Mammalian Monocyte Cell Genes;
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESSES:
; ADDRESS: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/777,521

```

; SOFTWARE: IBM PC compatible
; SEQ ID NO 4
; LENGTH: 230
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-780-043-4

Query Match      73.9%; Score 1176.5; DB 16; Length 230;
Best Local Similarity 75.9%; Pred. No. 3.7e-91;
Matches 230; Conservative 0; Mismatches 0; Indels 73; Gaps 1.

Qy      1 MGRPLLP.LP.LLP.LP.PA.FLOPSSGTSGSP.VLVCTQPKHLSASMGSGVELPFSPYPMW 60
        |||||
Db      1 MGRPLLP.LP.LLP.LP.PA.FLOPSSGTSGSP.VLVCTQPKHLSASMGSGVELPFSPYPMW 60

Qy      61 LATAPDVRI.SWRG.HFGQSFYSTR.PES.IH.DY.NR.L.FL.MNTEGOKSGFLRISNLOKODQ 120
        |||||
Db      61 LATAPDVRI.SWRG.HFGQSFYSTR.PES.IH.DY.NR.L.FL.MNTEGOKSGFLRISNLOKODQ 120

Qy      121 SVYFCRAVELDTRSSGROQWOSIECTKLSITQAVVTTTQRPSSMTTWRLSSTTTTTGLRV 180
        |||||
Db      121 SVYFCRAVELDTRSSGROQWOSIECTKLSITQ----- 151

Qy      181 TCGKRSDSWHISLETA.GVAVAVT.VL.GIMILGLICLLRRRRKGGQCTKATTPARREPO 240
        |||||
Db      152 -----GGQRTKATTPARREPO 167

```

Db 168 NTEEPYENIRNEGONTDPKLNPKDDGIYVASLSSSTSPRAPPSHRPLKSPONETLYSV 227

27 2018 503
||
||
Db 228 LKA 230

RESULT 7

US-10-309-290-110
; Sequence 110, Application US/10309290
; Publication No. US20040023241A1

```

: GENERAL INFORMATION:
:
: APPLICANT: Alsobrook II, John P.
:
: APPLICANT: Anderson, David W

```

```

; APPLICANT: Boldog, Ferenc L.
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Chikla, David A.

```

; APPLICANT: Edinger, Shlomit R.
 ; APPLICANT: Gerlach, Valerie L.
 ; APPLICANT: German, Rida

APPLICANT: Gould-Rothberg, Bonnie E.
APPLICANT: Guo, Xiaojia

```

; APPLICANT: Ji, Weizhen
; APPLICANT: Li, Li

```

APPLICANT: Miller, Charles E.
APPLICANT: Murphey, Ryan

```

; APPLICANT: Rastelli, John A.
; APPLICANT: Rastelli, Luca

```

```

: AFFILIANT: Krieger, Daniel A.
: APPLICANT: Shenoy, Suresh G.
: APPLICANT: Smithson, Glenda

```

```

: APPLICANT: Stirling, Gary
: APPLICANT: Taupier, Raymond J.
: APPLICANT: Voss, Edward Z.

```

:	APPLICANT:	Zhong, Hainong
:	APPLICANT:	Zhong, Mei
:	TITLE OF INVENTION:	TERAPEUTIC POLYPEPTIDES
:	TITLE OF INVENTION:	METABOLIC ACIDS ENCODING SAME

```

; FILE REFERENCE: 21402-502A
; CURRENT APPLICATION NUMBER: US/10/309,290
; CURRENT FILING DATE: 2002.12.02

```

; PRIOR APPLICATION NUMBER: 60/336,600

Query Match	73.6%	Score	1171.5	DB	15	Length	230
Best Local Similarity	75.6%	Pred.	No. 9.7e-91				
Matches 229; Conservative	0	Mismatches	1	Indels	73	Gaps	1

```

RESULT 8
US-10-309-290-112
; Sequence 112, Application US/10309290
; Publication No. US20040023241A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook II, John P.
; APPLICANT: Anderson, David W.
; APPLICANT: Boldog, Ferenc L.
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Chillaikuru, Rameev A.
; APPLICANT: Edinger, Shlomoit R.
; APPLICANT: Gerlach, Valerie L.
; APPLICANT: Gorman, Linda
; APPLICANT: Gould-Rothberg, Bonnie E.
; APPLICANT: Guo, Xiaojia
; APPLICANT: Jeffers, Michael E.

```

Query Match	63.5%	Score 1010.5;	DB 15;	length 206;
Best Local Similarity	67.7%	Pred. No. 3.3e-77;		
Matches 205; Conservative	0;	Mismatches 1;	Indels 97;	Gaps 2.

QY	1	IGRRPLLLPLPLPPALPQPSGSGSGSYLYGTQPHGLSASMGSGVEIPSPFFYPME	60
Db	1	MGRPLPLPLPLPPALPQPSGSGSGSYLYGTQPHGLSASMGSGVEIPSPFFYPME	60
QY	61	LATAPDVRI\$WRG\$HFG\$Q\$FYSTR\$P\$SI\$HKDYVR\$L\$FLN\$T\$EG\$Q\$G\$GL\$R\$IS\$NL\$OK\$DO	120
Db	61	LAT-----SIHKDYVR\$L\$FLN\$T\$EG\$Q\$G\$GL\$R\$IS\$NL\$OK\$DO	96
QY	121	SVYF\$CR\$VEL\$D\$TR\$SS\$GR\$Q\$M\$Q\$SI\$EG\$K\$LS\$ITQ\$AVTTTQ\$P\$SS\$MTT\$WR\$LS\$STTTTGL\$KV	180
Db	97	SVYF\$CR\$VEL\$D\$TR\$SS\$GR\$Q\$M\$Q\$SI\$EG\$K\$LS\$ITQ-----	127
QY	181	TQ\$K\$R\$SD\$SM\$H\$IS\$L\$ET\$AV\$G\$VA\$V\$V\$YL\$G\$IM\$IL\$G\$IC\$L\$R\$R\$R\$K\$Q\$Q\$RT\$K\$AT\$T\$P\$ARE\$P\$Q	240
Db	128	-----GQ\$Q\$K\$AT\$T\$P\$ARE\$P\$Q	143
QY	241	NTE\$E\$Y\$EN\$I\$R\$EG\$Q\$NT\$D\$PL\$N\$K\$D\$GI\$V\$Y\$AS\$IAL\$SS\$S\$TS\$P\$RA\$P\$SH\$R\$PL\$KS\$P\$ON\$ET\$L\$Y\$SV	300
Db	144	NTE\$E\$Y\$EN\$I\$R\$EG\$Q\$NT\$D\$PL\$N\$K\$D\$GI\$V\$Y\$AS\$IAL\$SS\$S\$TS\$P\$RA\$P\$SH\$R\$PL\$KS\$P\$ON\$ET\$L\$Y\$SV	203

QY 301 LKA 303
Db 204 LKA 206

RESULT 9
US-09-774-381-44
; Sequence 44, Application US/09774381
; Publication No. US20030082677A1
; GENERAL INFORMATION:
; APPLICANT: Holtzman, Douglas A.
; APPLICANT: McCarthy, Sean A.
; APPLICANT: Pan, Yang
; APPLICANT: Gearing, David P.
; TITLE OF INVENTION: NOVEL EDIRP, MTR-1, LSP-1, TAP-1, AND PA-I MOLECULES
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: WNT-107CP2
; CURRENT APPLICATION NUMBER: US/09/774,381
; CURRENT FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 08/941,354
; PRIOR FILING DATE: 1999-09-30
; PRIOR APPLICATION NUMBER: 09/010,674
; PRIOR FILING DATE: 1998-01-22
; PRIOR APPLICATION NUMBER: 60/061,149
; PRIOR FILING DATE: 1997-10-06
; PRIOR APPLICATION NUMBER: 09/014,347
; PRIOR FILING DATE: 1998-01-27
; PRIOR APPLICATION NUMBER: 60/061,159
; PRIOR FILING DATE: 1997-10-06
; PRIOR APPLICATION NUMBER: 09/474,151
; PRIOR FILING DATE: 2000-12-21
; PRIOR APPLICATION NUMBER: 09/004,206
; PRIOR FILING DATE: 1998-01-08
; PRIOR APPLICATION NUMBER: 60/061,143
; PRIOR FILING DATE: 1997-10-06
; PRIOR APPLICATION NUMBER: 09/483,414
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: 09/213,571
; PRIOR FILING DATE: 1998-12-18
; PRIOR APPLICATION NUMBER: 08/994,890
; PRIOR FILING DATE: 1997-12-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 44
; LENGTH: 226
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-774-381-44

Query Match 61.2%; Score 973.5; DB 10; Length 226;
Best Local Similarity 82.5%; Pred. No. 5e-74;
Matches 188; Conservative 14; Mismatches 17; Indels 9; Gaps 2;

QY 1 MGRPLLLPPLPPLPAPFLOPGSGTSGSPSYLYGVTPPKHLASMGSGVEIPPSFYYPWE 60
Db 1 MGRPLLLPPLLLLOPAPFLOPGSGTSGSPSYLYGVTPPKHLASMGSGSVIPPSFYYPWE 60

QY 61 LATAPDVRIISMRGHHGQSFYSTRPPIHKDYVNRFLFLNWTGQSGFLRISNLKQDQ 120
Db 61 LATAPDVRIISMRGHHGQSFYSTRPPIHKDYVNRFLFLNWTGQSGFLRISNLKQDQ 120

QY 121 SYVFCVELDTRSSGRQOMOSIEGTKLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
Db 121 SYVFCVELDTRSSGRQOMOSIEGTKLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180

QY 181 TOGRRSDSMHISLETAAGVAVAVTVLGMILGLICLR-WRRRKQOQ 227
Db 173 TEGSGHSESWHLSDTAIRVALAVAVLKVITLGLCLLMMWRRRKGSR 220

RESULT 10
US-10-780-043-10
; Sequence 10, Application US/10780043

; Publication No. US20040137506A1
; GENERAL INFORMATION:
; APPLICANT: Bates, Elizabeth
; APPLICANT: Rounnier, Nathalie
; APPLICANT: Chalus, Lionel
; APPLICANT: Garione, Pierre
; TITLE OF INVENTION: MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHOD
; FILE REFERENCE: SF0977X
; CURRENT APPLICATION NUMBER: US/10/780,043
; CURRENT FILING DATE: 2004-02-17
; PRIOR APPLICATION NUMBER: US/09/869,388
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: IBM PC compatible
; SEQ ID NO 10
; LENGTH: 226
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-780-043-10

Query Match 61.2%; Score 973.5; DB 16; Length 226;
Best Local Similarity 82.5%; Pred. No. 5e-74;
Matches 188; Conservative 14; Mismatches 17; Indels 9; Gaps 2;

QY 1 MGRPLLLPPLPPLPAPFLOPGSGTSGSPSYLYGVTPPKHLASMGSGVEIPPSFYYPWE 60
Db 1 MGRPLLLPPLLLLOPAPFLOPGSGTSGSPSYLYGVTPPKHLASMGSGSVIPPSFYYPWE 60

QY 61 LATAPDVRIISMRGHHGQSFYSTRPPIHKDYVNRFLFLNWTGQSGFLRISNLKQDQ 120
Db 61 LATAPDVRIISMRGHHGQSFYSTRPPIHKDYVNRFLFLNWTGQSGFLRISNLKQDQ 120

QY 121 SYVFCVELDTRSSGRQOMOSIEGTKLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
Db 121 SYVFCVELDTRSSGRQOMOSIEGTKLSTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180

QY 181 TOGRRSDSMHISLETAAGVAVAVTVLGMILGLICLR-WRRRKQOQ 227
Db 173 TEGSGHSESWHLSDTAIRVALAVAVLKVITLGLCLLMMWRRRKGSR 220

RESULT 11
US-09-745-763-106
; Sequence 106, Application US/09745763
; Patent No. US20020065394A1
; GENERAL INFORMATION:
; APPLICANT: Jacobs, Kenneth
; McCoy, John M.
; Layallie, Edward R.
; Collins-Racie, Lisa A.
; Evans, Cheryl
; Merberg, David
; Treacy, Maurice
; Spaulding, Vikki
; TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
; NUMBER OF SEQUENCES: 219
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 Cambridgepark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/745,763
; FILING DATE: 18-Jun-2000
; CLASSIFICATION: <Unknown>

```

;
; ATTORNEY/AGENT INFORMATION:
;   NAME: Sprunger, Suzanne A.
;   REGISTRATION NUMBER: 41,323
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (617) 498-8284
;   TELEFAX: (617) 876-5851
;   INFORMATION FOR SEQ ID NO: 106:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH: 226 amino acids
;       TYPE: amino acid
;       STRANDEDNESS: <unknown>
;       TOPOLOGY: linear
;       MOLECULE TYPE: protein
;       SEQUENCE DESCRIPTION: SEQ ID NO: 106:
US-09-745-763-106

Query Match          60.8%; Score 967.5; DB 9; Length 226;
Best Local Similarity 82.0%; Pred. No. 1,6e-73;
Matches 187; Conservative 14; Mismatches 18; Indels 9; Gaps 2;

QY 1 MGRPLLLPLPLLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIIPFSFYPMW 60
DB 1 MGRPLLLPLLLLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIIPFSFYPMW 60
QY 61 LATAPDVATSWRRGHFHGQSFYSTRPPSIHKDYVRLFLNMTGQSGFLRISNLOKDO 120
DB 61 LATAPDVATSWRRGHFHGQSFYSTRPPSIHKDYVRLFLNMTGQSGFLRISNLOKDO 120
QY 121 SVYFCRVELDTRRSGRQLOQSIKGTKLITTOAVTT-----TTTWPSSSTTTIAGLRV 180
DB 121 SVYFCRVELDTRRSGRQLOQSIKGTKLITTOAVTT-----TTTWPSSSTTTIAGLRV 172
QY 181 TQGRKRSWSHISLETAVGAVAVAVVGLMILGICLLR--WRRRKGQ 227
DB 173 TESKHSBSWHLSDTAIRVALAVAVLKVTLIGLLCLLLWRRRKGSR 220

RESULT 12
US-10-262-445-128
; Sequence 128, Application US/10262445
; Publication No. US20040014058A1
; GENERAL INFORMATION:
;   APPLICANT: Alsebrook II, John
;   APPLICANT: Burgess, Catherine
;   APPLICANT: Catereron, Elina
;   APPLICANT: Chant, John
;   APPLICANT: Chaudhuri, Amitabha
;   APPLICANT: Edinger, Shlomit
;   APPLICANT: Gerlach, Valerie
;   APPLICANT: Glot, Loic
;   APPLICANT: Gorman, Linda
;   APPLICANT: Guo, Xiaojia
;   APPLICANT: Kekuda, Ramesh
;   APPLICANT: Mezes, Peter
;   APPLICANT: Millet, Isabelle
;   APPLICANT: Ooi, Chean Eng
;   APPLICANT: Paccurejan, Meera
;   APPLICANT: Rieger, Daniel
;   APPLICANT: Spytek, Kimberley
;   APPLICANT: Taupier Jr., Raymond J.
;   APPLICANT: Zethusen, Bryan
;   APPLICANT: Zhong, Haihong
;   APPLICANT: Zhong, Wei
;   TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS C
;   FILE REFERENCE: 21402-462D
;   CURRENT APPLICATION NUMBER: US/10/262,445
;   CURRENT FILING DATE: 2002-10-01
;   PRIOR APPLICATION NUMBER: 60/327,454
;   PRIOR FILING DATE: 2001-10-05
;   PRIOR APPLICATION NUMBER: 60/327,917
;   PRIOR FILING DATE: 2001-10-09
;   PRIOR APPLICATION NUMBER: 60/328,029
```

```

;
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/329,414
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/330,142
; PRIOR FILING DATE: 2001-10-17
; PRIOR APPLICATION NUMBER: 60/341,058
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: 60/343,629
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: 60/349,575
; PRIOR FILING DATE: 2001-10-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 133
; SOFTWARE: CuiSeqlist version 0.1
; SEQ ID NO 128
; LENGTH: 227
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-445-128

Query Match          60.2%; Score 958; DB 15; Length 227;
Best Local Similarity 80.8%; Pred. No. 1e-72;
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

QY 1 MGRPLLLPLPLLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIIPFSFYPMW 60
DB 1 MGRPLLLPLLLLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIIPFSFYPMW 60
QY 61 LATAPDVATSWRRGHFHGQSFYSTRPPSIHKDYVRLFLNMTGQSGFLRISNLOKDO 120
DB 61 LATAPDVATSWRRGHFHGQSFYSTRPPSIHKDYVRLFLNMTGQSGFLRISNLOKDO 120
QY 121 SVYFCRVELDTRRSGRQLOQSIKGTKLITTOAVTT-----TTTWPSSSTTTIAGLRV 180
DB 121 SVYFCRVELDTRRSGRQLOQSIKGTKLITTOAVTT-----TTTWPSSSTTTIAGLRV 172
QY 181 TQGRKRSWSHISLETAVGAVAVAVVGLMILGICLLR--WRRRKGQ 227
DB 173 TESKHSBSWHLSDTAIRVALAVAVLKVTLIGLLCLLLWRRRKGSR 221

RESULT 13
US-10-780-043-6
; Sequence 6, Application US/10780043
; Publication No. US20040137506A1
; GENERAL INFORMATION:
;   APPLICANT: Bates, Elizabeth
;   APPLICANT: Fournier, Nathalie
;   APPLICANT: Chaluis, Lionel
;   APPLICANT: Garrone, Pierre
;   TITLE OF INVENTION: MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHO
;   FILE REFERENCE: SP0977X
;   CURRENT APPLICATION NUMBER: US/10/780,043
;   CURRENT FILING DATE: 2004-02-17
;   PRIOR APPLICATION NUMBER: US/09/869,388
;   PRIOR FILING DATE: 2002-02-21
;   NUMBER OF SEQ ID NOS: 14
;   SOFTWARE: IBM PC compatible
;   SEQ ID NO 6
;   LENGTH: 227
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-780-043-6

Query Match          60.2%; Score 958; DB 16; Length 227;
Best Local Similarity 80.8%; Pred. No. 1e-72;
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

QY 1 MGRPLLLPLPLLPAPLQPSGSGSPSYLYGVTOPKHLASMGSGVEIIPFSFYPMW 60
```

Db 1 MGRPLLPPLLLLPALQPGSGTSGSPSYLYGVTPQKHLASMGSGVEIPSPFYPMW 60
QY 61 LATAPDVRIISMRGRGHFGSGFYSTRPSPSIHKDYVNRFLFWMTGQSGGFLRISNLQKQD 120
Db 61 LAIVPNVRISMRGRGHFGSGFYSTRPSPSIHKDYVNRFLFWMTGQSGGFLRISNLKREDQ 120
QY 121 SYVFCRVELDTRSSGRQOQOSIEGTKLSTTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
Db 121 SYVFCRVELDTRSSGRQOQOSIKGTKLTTTQAVTT-----TTWRPSSTTTIAGLRY 172
QY 181 TQGRKRSDSWHTSLETAAGVAVAVTVLGMILGICLLR--WRRKGGQ 227
Db 173 TESKGSSESWHLSLDTAIRVALAVAVLKVILGLCLLLMWRRRKGSR 221

RESULT 14
US-09-935-390A-21
Sequence 21, Application US/09935390A
Patent No. US20020076761A1
GENERAL INFORMATION:
APPLICANT: Escobedo, Jaime
Quintanilla, Hu
Garcia, Pablo
Williams, Lewis T.
Kothakota, Srinivas
TITLE OF INVENTION: Secreted Human Proteins
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: Chilton Corporation
STREET: 4560 Horton Street
CITY: Emeryville
STATE: CA
COUNTRY: USA
ZIP: 94608-2916
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/935,390A
FILING DATE: 22-Aug-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/988,671
FILING DATE: 1997-12-11
ATTORNEY/AGENT INFORMATION:
NAME: Jane E. R. Potter
REGISTRATION NUMBER: 33,332
REFERENCE/DOCKET NUMBER: 1369,002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 923-2718
TELEFAX: (510) 655-3542
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 291 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: No. US20020076761A1e
SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-935-390A-21

Query Match 60.2%; Score 958; DB 9; Length 291;
Best Local Similarity 80.8%; Pred. No. 1,4e-72;
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

QY 1 MGRPLLPPLLLLPALQPGSGTSGSPSYLYGVTPQKHLASMGSGVEIPSPFYPMW 60
Db 65 MGRPLLPPLLLLPALQPGSGTSGSPSYLYGVTPQKHLASMGSGVEIPSPFYPMW 124

QY 61 LATAPDVRIISMRGRGHFGSGFYSTRPSPSIHKDYVNRFLFWMTGQSGGFLRISNLQKQD 120
Db 125 LAIVPNVRISMRGRGHFGSGFYSTRPSPSIHKDYVNRFLFWMTGQSGGFLRISNLKREDQ 164
QY 121 SYVFCRVELDTRSSGRQOQOSIEGTKLSTTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
Db 185 SYVFCRVELDTRSSGRQOQOSIKGTKLTTTQAVTT-----TTWRPSSTTTIAGLRY 236
QY 181 TQGRKRSDSWHTSLETAAGVAVAVTVLGMILGICLLR--WRRKGGQ 227
Db 237 TESKGSSESWHLSLDTAIRVALAVAVLKVILGLCLLLMWRRRKGSR 285

RESULT 15
US-10-276-774-2380
Sequence 2380, Application US/10276774
Publication No. US20040053245A1
GENERAL INFORMATION:
APPLICANT: Hyseq, Inc.
APPLICANT: Yang, Y. Tom et al
TITLE OF INVENTION: No. US20040053245A1e1 Nucleic Acids and Polypeptides
FILE REFERENCE: 21272-030
CURRENT APPLICATION NUMBER: US/10/276,774
CURRENT FILING DATE: 2002-11-18
PRIOR APPLICATION NUMBER: 09/560,875
PRIOR FILING DATE: 2000-04-27
PRIOR APPLICATION NUMBER: 09/496,914
PRIOR FILING DATE: 2000-02-03
NUMBER OF SEQ ID NOS: 2700
SOFTWARE: Custom
SEQ ID NO 2380
LENGTH: 326
TYPE: PRT
ORGANISM: Homo sapiens
US-10-276-774-2380

Query Match 60.2%; Score 958; DB 15; Length 326;
Best Local Similarity 80.8%; Pred. No. 1,6e-72;
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

QY 1 MGRPLLPPLLLLPALQPGSGTSGSPSYLYGVTPQKHLASMGSGVEIPSPFYPMW 60
Db 100 MGRPLLPPLLLLPALQPGSGTSGSPSYLYGVTPQKHLASMGSGVEIPSPFYPMW 159
QY 61 LATAPDVRIISMRGRGHFGSGFYSTRPSPSIHKDYVNRFLFWMTGQSGGFLRISNLQKQD 120
Db 160 LAIVPNVRISMRGRGHFGSGFYSTRPSPSIHKDYVNRFLFWMTGQSGGFLRISNLKREDQ 219
QY 121 SYVFCRVELDTRSSGRQOQOSIEGTKLSTTQAVTTTQRPSSMTTWRLSSTTTTGLRV 180
Db 220 SYVFCRVELDTRSSGRQOQOSIKGTKLTTTQAVTT-----TTWRPSSTTTIAGLRY 271
QY 181 TQGRKRSDSWHTSLETAAGVAVAVTVLGMILGICLLR--WRRKGGQ 227
Db 272 TESKGSSESWHLSLDTAIRVALAVAVLKVILGLCLLLMWRRRKGSR 320

Search completed: June 1, 2005, 22:17:18
Job time: 144 secs